JP2023531113A - PDE4 INHIBITOR COMPOUNDS AND MEDICINE USES THEREOF - Google Patents
PDE4 INHIBITOR COMPOUNDS AND MEDICINE USES THEREOF Download PDFInfo
- Publication number
- JP2023531113A JP2023531113A JP2022551055A JP2022551055A JP2023531113A JP 2023531113 A JP2023531113 A JP 2023531113A JP 2022551055 A JP2022551055 A JP 2022551055A JP 2022551055 A JP2022551055 A JP 2022551055A JP 2023531113 A JP2023531113 A JP 2023531113A
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- methylsulfonyl
- ethoxy
- methoxypyridin
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 71
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title abstract description 6
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 46
- 239000012453 solvate Substances 0.000 claims abstract description 27
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims abstract description 10
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 23
- 150000002367 halogens Chemical group 0.000 claims description 23
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 20
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 18
- -1 C 1 -C 3 alkyl Chemical group 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 9
- JNFLHCQSQKTQDJ-JOCHJYFZSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=C(F)C=C4C)C=C3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=C(F)C=C4C)C=C3)NC2=O)CS(=O)(=O)C)=N1)C JNFLHCQSQKTQDJ-JOCHJYFZSA-N 0.000 claims description 8
- ZZJVBAQSDGTLQY-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC=C4)C=N3)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC=C4)C=N3)N(C2=O)C)CS(=O)(=O)C)=N1)C ZZJVBAQSDGTLQY-HXUWFJFHSA-N 0.000 claims description 8
- YZVNMMAOOJPPIG-HSZRJFAPSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=C(F)C=C3C)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=C(F)C=C3C)N(C2=O)C)CS(=O)(=O)C)=N1)C YZVNMMAOOJPPIG-HSZRJFAPSA-N 0.000 claims description 8
- SOSQUIAAPKKQGW-HSZRJFAPSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(N(C2=O)C)C=C(C=C3)C2=CC(C)=CC=C2F)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(N(C2=O)C)C=C(C=C3)C2=CC(C)=CC=C2F)CS(=O)(=O)C)=N1)C SOSQUIAAPKKQGW-HSZRJFAPSA-N 0.000 claims description 8
- VQVQJADUOSMZFN-JOCHJYFZSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(NC2=O)C=C(C=C3)C2=CC(C)=CC=C2F)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(NC2=O)C=C(C=C3)C2=CC(C)=CC=C2F)CS(=O)(=O)C)=N1)C VQVQJADUOSMZFN-JOCHJYFZSA-N 0.000 claims description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- YMONYXKJWBYVQT-HXUWFJFHSA-N O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC=CC=C3F)N(C2=O)C)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC=CC=C3F)N(C2=O)C)CS(=O)(=O)C)=N1 YMONYXKJWBYVQT-HXUWFJFHSA-N 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 150000002431 hydrogen Chemical group 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 125000003282 alkyl amino group Chemical group 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 6
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 6
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical group [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 229910052805 deuterium Inorganic materials 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 229910052722 tritium Inorganic materials 0.000 claims description 6
- IOCPFBRBIAKOKM-UHFFFAOYSA-N C(OC1=C(OC)C=CC(C(N2C3=C(C(=C(C=N3)C3=CC=CC=C3F)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC(C(N2C3=C(C(=C(C=N3)C3=CC=CC=C3F)C)NC2=O)CS(=O)(=O)C)=N1)C IOCPFBRBIAKOKM-UHFFFAOYSA-N 0.000 claims description 5
- IOCPFBRBIAKOKM-LJQANCHMSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=CC=C3F)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=CC=C3F)C)NC2=O)CS(=O)(=O)C)=N1)C IOCPFBRBIAKOKM-LJQANCHMSA-N 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 4
- VRRQTXFBGCWCKR-JOCHJYFZSA-N 3-[(1S)-1-(6-ethoxy-5-methoxypyridin-2-yl)-2-methylsulfonylethyl]-6-(2-ethylphenyl)-1-methylimidazo[4,5-b]pyridin-2-one Chemical compound O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC=CC=C3CC)N(C2=O)C)CS(=O)(=O)C)=N1 VRRQTXFBGCWCKR-JOCHJYFZSA-N 0.000 claims description 4
- QEYRIYRRUXLDHB-JOCHJYFZSA-N C(OC1=C(OC(C)C)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC=C4)C=N3)C)N(C2=O)CC(F)F)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC(C)C)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC=C4)C=N3)C)N(C2=O)CC(F)F)CS(=O)(=O)C)=N1)C QEYRIYRRUXLDHB-JOCHJYFZSA-N 0.000 claims description 4
- YDEGYNRCRRDUBA-JOCHJYFZSA-N C(OC1=C(OC(C)C)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=C(F)C=C3)C)N(C2=O)CC(F)F)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC(C)C)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=C(F)C=C3)C)N(C2=O)CC(F)F)CS(=O)(=O)C)=N1)C YDEGYNRCRRDUBA-JOCHJYFZSA-N 0.000 claims description 4
- DIPYMCBYVJJBCH-HSZRJFAPSA-N C(OC1=C(OC(C)C)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=CC=C3C)C)N(C2=O)CC(F)F)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC(C)C)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=CC=C3C)C)N(C2=O)CC(F)F)CS(=O)(=O)C)=N1)C DIPYMCBYVJJBCH-HSZRJFAPSA-N 0.000 claims description 4
- KJLXTPMUDWTFQZ-JOCHJYFZSA-N C(OC1=C(OC(C)C)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=CC=C3F)C)N(C2=O)CC(F)F)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC(C)C)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=CC=C3F)C)N(C2=O)CC(F)F)CS(=O)(=O)C)=N1)C KJLXTPMUDWTFQZ-JOCHJYFZSA-N 0.000 claims description 4
- ISTUAGOWKFVFEE-SFHVURJKSA-N C(OC1=C(OC(F)F)C=CC([C@@H](N2C3=C(C(=C(C=N3)C3=CC=CC=C3)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC(F)F)C=CC([C@@H](N2C3=C(C(=C(C=N3)C3=CC=CC=C3)C)NC2=O)CS(=O)(=O)C)=N1)C ISTUAGOWKFVFEE-SFHVURJKSA-N 0.000 claims description 4
- UPQKQIPECYUGBU-LJQANCHMSA-N C(OC1=C(OC(F)F)C=CC([C@H](N2C3=C(C(=C(C4=CC=C(F)C=C4)C=N3)C)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC(F)F)C=CC([C@H](N2C3=C(C(=C(C4=CC=C(F)C=C4)C=N3)C)N(C2=O)C)CS(=O)(=O)C)=N1)C UPQKQIPECYUGBU-LJQANCHMSA-N 0.000 claims description 4
- ISTUAGOWKFVFEE-GOSISDBHSA-N C(OC1=C(OC(F)F)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC=C4)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC(F)F)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC=C4)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C ISTUAGOWKFVFEE-GOSISDBHSA-N 0.000 claims description 4
- HCNOKOSATZNNAH-LJQANCHMSA-N C(OC1=C(OC(F)F)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC=C4C)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC(F)F)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC=C4C)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C HCNOKOSATZNNAH-LJQANCHMSA-N 0.000 claims description 4
- FMFYRMAJBUNEMX-GOSISDBHSA-N C(OC1=C(OC(F)F)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC=C4F)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC(F)F)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC=C4F)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C FMFYRMAJBUNEMX-GOSISDBHSA-N 0.000 claims description 4
- KPIKESPDMKOGRD-LJQANCHMSA-N C(OC1=C(OC(F)F)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=C(C=CC=C3)F)C)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC(F)F)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=C(C=CC=C3)F)C)N(C2=O)C)CS(=O)(=O)C)=N1)C KPIKESPDMKOGRD-LJQANCHMSA-N 0.000 claims description 4
- VCZFCKZLOYFEBL-GOSISDBHSA-N C(OC1=C(OC(F)F)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=C(F)C=C3)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC(F)F)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=C(F)C=C3)C)NC2=O)CS(=O)(=O)C)=N1)C VCZFCKZLOYFEBL-GOSISDBHSA-N 0.000 claims description 4
- FGMWWEORFJGUNN-LJQANCHMSA-N C(OC1=C(OC(F)F)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=CC=C3)C)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC(F)F)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=CC=C3)C)N(C2=O)C)CS(=O)(=O)C)=N1)C FGMWWEORFJGUNN-LJQANCHMSA-N 0.000 claims description 4
- KYDBONSKPKTESF-HXUWFJFHSA-N C(OC1=C(OC(F)F)C=CC([C@H](N2C3=NC=C(C4=CC=CC=C4C)C(C)=C3N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC(F)F)C=CC([C@H](N2C3=NC=C(C4=CC=CC=C4C)C(C)=C3N(C2=O)C)CS(=O)(=O)C)=N1)C KYDBONSKPKTESF-HXUWFJFHSA-N 0.000 claims description 4
- IROYDNBPWYKERE-NRFANRHFSA-N C(OC1=C(OC)C=CC([C@@H](N2C3=C(C(=C(C4=CC=CC=C4)C=N3)C)N(C2=O)CC)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@@H](N2C3=C(C(=C(C4=CC=CC=C4)C=N3)C)N(C2=O)CC)CS(=O)(=O)C)=N1)C IROYDNBPWYKERE-NRFANRHFSA-N 0.000 claims description 4
- TWHGNPSCWFDAPT-FQEVSTJZSA-N C(OC1=C(OC)C=CC([C@@H](N2C3=C(C(=C(C4=CC=CC=C4F)C=N3)C)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@@H](N2C3=C(C(=C(C4=CC=CC=C4F)C=N3)C)N(C2=O)C)CS(=O)(=O)C)=N1)C TWHGNPSCWFDAPT-FQEVSTJZSA-N 0.000 claims description 4
- QRBSMXJRNAJXGK-IBGZPJMESA-N C(OC1=C(OC)C=CC([C@@H](N2C3=C(C(=C(C4=CC=CC=C4OC)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@@H](N2C3=C(C(=C(C4=CC=CC=C4OC)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C QRBSMXJRNAJXGK-IBGZPJMESA-N 0.000 claims description 4
- RUICWHKKHVBRHN-SFHVURJKSA-N C(OC1=C(OC)C=CC([C@@H](N2C3=C(C(=C(C4=CC=CC=N4)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@@H](N2C3=C(C(=C(C4=CC=CC=N4)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C RUICWHKKHVBRHN-SFHVURJKSA-N 0.000 claims description 4
- YPCCDLZDIUTUKO-IBGZPJMESA-N C(OC1=C(OC)C=CC([C@@H](N2C3=C(C(=C(C=N3)C3=CC(F)=CC=C3F)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@@H](N2C3=C(C(=C(C=N3)C3=CC(F)=CC=C3F)C)NC2=O)CS(=O)(=O)C)=N1)C YPCCDLZDIUTUKO-IBGZPJMESA-N 0.000 claims description 4
- FDWDZQSNTJMACF-FQEVSTJZSA-N C(OC1=C(OC)C=CC([C@@H](N2C3=C(C(=C(C=N3)C3=CC=CC=C3C#N)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@@H](N2C3=C(C(=C(C=N3)C3=CC=CC=C3C#N)C)NC2=O)CS(=O)(=O)C)=N1)C FDWDZQSNTJMACF-FQEVSTJZSA-N 0.000 claims description 4
- YFCVHVOUYXHCHI-QFIPXVFZSA-N C(OC1=C(OC)C=CC([C@@H](N2C3=C(C=C(C=C3)C3=CC=CC=C3C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@@H](N2C3=C(C=C(C=C3)C3=CC=CC=C3C)NC2=O)CS(=O)(=O)C)=N1)C YFCVHVOUYXHCHI-QFIPXVFZSA-N 0.000 claims description 4
- PCCGPJAYUITYMK-JOCHJYFZSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=C(C)C=CC=C4)C=N3)C)N(C2=O)CC)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=C(C)C=CC=C4)C=N3)C)N(C2=O)CC)CS(=O)(=O)C)=N1)C PCCGPJAYUITYMK-JOCHJYFZSA-N 0.000 claims description 4
- JUJXKVLKYMHCER-GOSISDBHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=C(F)C=CC=C4OC)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=C(F)C=CC=C4OC)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C JUJXKVLKYMHCER-GOSISDBHSA-N 0.000 claims description 4
- DRSZRLSVKDDYLS-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC(C)=CC=C4F)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC(C)=CC=C4F)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C DRSZRLSVKDDYLS-HXUWFJFHSA-N 0.000 claims description 4
- RRHWRXUXRHCTLH-LJQANCHMSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC(F)=C(F)C=C4F)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC(F)=C(F)C=C4F)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C RRHWRXUXRHCTLH-LJQANCHMSA-N 0.000 claims description 4
- CUYYTVNCSMWNMB-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC(F)=CC=C4C)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC(F)=CC=C4C)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C CUYYTVNCSMWNMB-HXUWFJFHSA-N 0.000 claims description 4
- YPCCDLZDIUTUKO-LJQANCHMSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC(F)=CC=C4F)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC(F)=CC=C4F)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C YPCCDLZDIUTUKO-LJQANCHMSA-N 0.000 claims description 4
- XUMWQQJRHQVILL-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC(OC)=CC=C4F)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC(OC)=CC=C4F)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C XUMWQQJRHQVILL-HXUWFJFHSA-N 0.000 claims description 4
- GUOLLIIZFBUENR-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=C(C)C=C4C)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=C(C)C=C4C)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C GUOLLIIZFBUENR-OAQYLSRUSA-N 0.000 claims description 4
- FVYSEOGDQRKACK-LJQANCHMSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=C(F)C=C4OC)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=C(F)C=C4OC)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C FVYSEOGDQRKACK-LJQANCHMSA-N 0.000 claims description 4
- LHCRFRHKSRHCAW-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=C(OC)C=C4F)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=C(OC)C=C4F)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C LHCRFRHKSRHCAW-HXUWFJFHSA-N 0.000 claims description 4
- PZWXPCWTEZQNTF-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC(C)=C4C)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC(C)=C4C)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C PZWXPCWTEZQNTF-OAQYLSRUSA-N 0.000 claims description 4
- SAESFBYUKKAKTC-GOSISDBHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC(F)=C4F)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC(F)=C4F)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C SAESFBYUKKAKTC-GOSISDBHSA-N 0.000 claims description 4
- POOJMOFZWLBYSK-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC=C4)C=N3)C)N(C2=O)CC(F)(F)F)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC=C4)C=N3)C)N(C2=O)CC(F)(F)F)CS(=O)(=O)C)=N1)C POOJMOFZWLBYSK-HXUWFJFHSA-N 0.000 claims description 4
- KLKCYQJWGHXVMJ-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC=C4)C=N3)C)N(C2=O)CC(F)F)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC=C4)C=N3)C)N(C2=O)CC(F)F)CS(=O)(=O)C)=N1)C KLKCYQJWGHXVMJ-HXUWFJFHSA-N 0.000 claims description 4
- KTXJTQKAVXMXIE-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC=C4C)C=N3)C)N(C2=O)CC(F)(F)F)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC=C4C)C=N3)C)N(C2=O)CC(F)(F)F)CS(=O)(=O)C)=N1)C KTXJTQKAVXMXIE-OAQYLSRUSA-N 0.000 claims description 4
- OFFUZPRJXHZIHG-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC=C4C)C=N3)C)N(C2=O)CC(F)F)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC=C4C)C=N3)C)N(C2=O)CC(F)F)CS(=O)(=O)C)=N1)C OFFUZPRJXHZIHG-OAQYLSRUSA-N 0.000 claims description 4
- GPZCVNOZOJQIIB-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC=C4F)C=N3)C)N(C2=O)CC(F)(F)F)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC=C4F)C=N3)C)N(C2=O)CC(F)(F)F)CS(=O)(=O)C)=N1)C GPZCVNOZOJQIIB-HXUWFJFHSA-N 0.000 claims description 4
- QRBSMXJRNAJXGK-LJQANCHMSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC=C4OC)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC=C4OC)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C QRBSMXJRNAJXGK-LJQANCHMSA-N 0.000 claims description 4
- HIEATBHNHLWMAI-LJQANCHMSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC=N4)C=N3)C)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC=N4)C=N3)C)N(C2=O)C)CS(=O)(=O)C)=N1)C HIEATBHNHLWMAI-LJQANCHMSA-N 0.000 claims description 4
- CHSHRMHLGNWKHJ-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC=N4)C=N3)C)N(C2=O)CCOC)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC=N4)C=N3)C)N(C2=O)CCOC)CS(=O)(=O)C)=N1)C CHSHRMHLGNWKHJ-OAQYLSRUSA-N 0.000 claims description 4
- IHTNQXMWLVWFGY-CYBMUJFWSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)Br)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)Br)C)NC2=O)CS(=O)(=O)C)=N1)C IHTNQXMWLVWFGY-CYBMUJFWSA-N 0.000 claims description 4
- QCQBMMJTVLIICO-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=C(C=CC(C)=C3)C)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=C(C=CC(C)=C3)C)C)NC2=O)CS(=O)(=O)C)=N1)C QCQBMMJTVLIICO-OAQYLSRUSA-N 0.000 claims description 4
- RSOKNASNZMGQTR-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=C(C=CC=C3)F)C)N(C2=O)CC(F)F)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=C(C=CC=C3)F)C)N(C2=O)CC(F)F)CS(=O)(=O)C)=N1)C RSOKNASNZMGQTR-HXUWFJFHSA-N 0.000 claims description 4
- VXVVGULZPJXTBM-GOSISDBHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=C(F)C=CC=C3F)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=C(F)C=CC=C3F)C)NC2=O)CS(=O)(=O)C)=N1)C VXVVGULZPJXTBM-GOSISDBHSA-N 0.000 claims description 4
- ULPJUPYMJIJGGL-LJQANCHMSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC(F)=CC=C3OC)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC(F)=CC=C3OC)C)NC2=O)CS(=O)(=O)C)=N1)C ULPJUPYMJIJGGL-LJQANCHMSA-N 0.000 claims description 4
- GCOGWKLIBHARIQ-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=C(C)C=C3F)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=C(C)C=C3F)C)NC2=O)CS(=O)(=O)C)=N1)C GCOGWKLIBHARIQ-HXUWFJFHSA-N 0.000 claims description 4
- VPEDKANRBBORNV-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=C(F)C=C3)C)N(C2=O)CC(F)F)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=C(F)C=C3)C)N(C2=O)CC(F)F)CS(=O)(=O)C)=N1)C VPEDKANRBBORNV-HXUWFJFHSA-N 0.000 claims description 4
- SLIDARXTGISSNR-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=C(F)C=C3)C)N(C2=O)CC)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=C(F)C=C3)C)N(C2=O)CC)CS(=O)(=O)C)=N1)C SLIDARXTGISSNR-OAQYLSRUSA-N 0.000 claims description 4
- CPFVMTKCTKYZSG-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=C(F)C=C3C)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=C(F)C=C3C)C)NC2=O)CS(=O)(=O)C)=N1)C CPFVMTKCTKYZSG-HXUWFJFHSA-N 0.000 claims description 4
- NNRFRTFCRYFBCU-LJQANCHMSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=C(F)C=C3F)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=C(F)C=C3F)C)NC2=O)CS(=O)(=O)C)=N1)C NNRFRTFCRYFBCU-LJQANCHMSA-N 0.000 claims description 4
- GUFQOCNGGMJAAZ-LJQANCHMSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=CC(C)=C3F)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=CC(C)=C3F)C)NC2=O)CS(=O)(=O)C)=N1)C GUFQOCNGGMJAAZ-LJQANCHMSA-N 0.000 claims description 4
- BZIMTEUIVDEJOG-LJQANCHMSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=CC=C3)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=CC=C3)C)NC2=O)CS(=O)(=O)C)=N1)C BZIMTEUIVDEJOG-LJQANCHMSA-N 0.000 claims description 4
- FDWDZQSNTJMACF-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=CC=C3C#N)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=CC=C3C#N)C)NC2=O)CS(=O)(=O)C)=N1)C FDWDZQSNTJMACF-HXUWFJFHSA-N 0.000 claims description 4
- XBIKOSZUYKEBHZ-LJQANCHMSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=CC=C3C(F)(F)F)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=CC=C3C(F)(F)F)C)NC2=O)CS(=O)(=O)C)=N1)C XBIKOSZUYKEBHZ-LJQANCHMSA-N 0.000 claims description 4
- GBUMHYICBFBKRN-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=CC=C3CC)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=CC=C3CC)C)NC2=O)CS(=O)(=O)C)=N1)C GBUMHYICBFBKRN-OAQYLSRUSA-N 0.000 claims description 4
- RUICWHKKHVBRHN-GOSISDBHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=CC=N3)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=CC=CC=N3)C)NC2=O)CS(=O)(=O)C)=N1)C RUICWHKKHVBRHN-GOSISDBHSA-N 0.000 claims description 4
- ZGPFLKSWZZEKHC-GOSISDBHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C(F)(F)F)C=C3)N(C2=O)C2CC2)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C(F)(F)F)C=C3)N(C2=O)C2CC2)CS(=O)(=O)C)=N1)C ZGPFLKSWZZEKHC-GOSISDBHSA-N 0.000 claims description 4
- PCCSBWQXZOEQAH-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=C(C)C=CC=C4C)C=N3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=C(C)C=CC=C4C)C=N3)NC2=O)CS(=O)(=O)C)=N1)C PCCSBWQXZOEQAH-HXUWFJFHSA-N 0.000 claims description 4
- NDZOGDPJMBKUOM-LJQANCHMSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=C(C=C(C(F)=C4)F)F)C=N3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=C(C=C(C(F)=C4)F)F)C=N3)NC2=O)CS(=O)(=O)C)=N1)C NDZOGDPJMBKUOM-LJQANCHMSA-N 0.000 claims description 4
- NUHLMFWVHJPJJM-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=C(C=C(F)C=C4)OC)C=N3)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=C(C=C(F)C=C4)OC)C=N3)N(C2=O)C)CS(=O)(=O)C)=N1)C NUHLMFWVHJPJJM-HXUWFJFHSA-N 0.000 claims description 4
- WSVCQJKJBASEHJ-JOCHJYFZSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=C(C=C(OC)C=C4)F)C=C3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=C(C=C(OC)C=C4)F)C=C3)NC2=O)CS(=O)(=O)C)=N1)C WSVCQJKJBASEHJ-JOCHJYFZSA-N 0.000 claims description 4
- LDRIIWQSFSMFII-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=C(C=CC(F)=C4)OC)C=C3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=C(C=CC(F)=C4)OC)C=C3)NC2=O)CS(=O)(=O)C)=N1)C LDRIIWQSFSMFII-OAQYLSRUSA-N 0.000 claims description 4
- RHVZGGKYIWBDRG-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=C(F)C=CC=C4F)C=C3)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=C(F)C=CC=C4F)C=C3)N(C2=O)C)CS(=O)(=O)C)=N1)C RHVZGGKYIWBDRG-OAQYLSRUSA-N 0.000 claims description 4
- ZKOQWIRRVSHDTR-LJQANCHMSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=C(F)C=CC=C4F)C=N3)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=C(F)C=CC=C4F)C=N3)N(C2=O)C)CS(=O)(=O)C)=N1)C ZKOQWIRRVSHDTR-LJQANCHMSA-N 0.000 claims description 4
- RYOGLTHIIQFKDV-GOSISDBHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=C(F)C=CC=C4F)C=N3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=C(F)C=CC=C4F)C=N3)NC2=O)CS(=O)(=O)C)=N1)C RYOGLTHIIQFKDV-GOSISDBHSA-N 0.000 claims description 4
- FIKMXRBTIQVERF-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC(C)=CC=C4F)C=N3)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC(C)=CC=C4F)C=N3)N(C2=O)C)CS(=O)(=O)C)=N1)C FIKMXRBTIQVERF-OAQYLSRUSA-N 0.000 claims description 4
- PBBGLERWUXYZJM-JOCHJYFZSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC(F)=C(F)C=C4F)C=C3)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC(F)=C(F)C=C4F)C=C3)N(C2=O)C)CS(=O)(=O)C)=N1)C PBBGLERWUXYZJM-JOCHJYFZSA-N 0.000 claims description 4
- UHENRXFJQSFCIW-JOCHJYFZSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC(F)=CC=C4C)C=C3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC(F)=CC=C4C)C=C3)NC2=O)CS(=O)(=O)C)=N1)C UHENRXFJQSFCIW-JOCHJYFZSA-N 0.000 claims description 4
- ZFYMBTCZRJUWTQ-JOCHJYFZSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=C(C)C=C4C)C=N3)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=C(C)C=C4C)C=N3)N(C2=O)C)CS(=O)(=O)C)=N1)C ZFYMBTCZRJUWTQ-JOCHJYFZSA-N 0.000 claims description 4
- YHVJGDHHODNYEJ-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=C(C)C=C4C)C=N3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=C(C)C=C4C)C=N3)NC2=O)CS(=O)(=O)C)=N1)C YHVJGDHHODNYEJ-OAQYLSRUSA-N 0.000 claims description 4
- NKGVCKZJJSKYER-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=C(F)C=C4C)C=N3)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=C(F)C=C4C)C=N3)N(C2=O)C)CS(=O)(=O)C)=N1)C NKGVCKZJJSKYER-OAQYLSRUSA-N 0.000 claims description 4
- ULCCKLMEYOSDOF-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=C(F)C=C4C)C=N3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=C(F)C=C4C)C=N3)NC2=O)CS(=O)(=O)C)=N1)C ULCCKLMEYOSDOF-HXUWFJFHSA-N 0.000 claims description 4
- JOGRPXNGXPSGKR-JOCHJYFZSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=C(F)C=C4F)C=C3)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=C(F)C=C4F)C=C3)N(C2=O)C)CS(=O)(=O)C)=N1)C JOGRPXNGXPSGKR-JOCHJYFZSA-N 0.000 claims description 4
- ZSIPCYOTDZXIQY-LJQANCHMSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=C(F)C=C4OC)C=N3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=C(F)C=C4OC)C=N3)NC2=O)CS(=O)(=O)C)=N1)C ZSIPCYOTDZXIQY-LJQANCHMSA-N 0.000 claims description 4
- NOLTVKAMCYRFRN-XMMPIXPASA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC(C)=C4C)C=C3)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC(C)=C4C)C=C3)N(C2=O)C)CS(=O)(=O)C)=N1)C NOLTVKAMCYRFRN-XMMPIXPASA-N 0.000 claims description 4
- DHCUQNMKHBDEQV-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC(C)=C4C)C=N3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC(C)=C4C)C=N3)NC2=O)CS(=O)(=O)C)=N1)C DHCUQNMKHBDEQV-OAQYLSRUSA-N 0.000 claims description 4
- BYGYQCDXQBLCKS-HSZRJFAPSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC(F)=C4C)C=C3)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC(F)=C4C)C=C3)N(C2=O)C)CS(=O)(=O)C)=N1)C BYGYQCDXQBLCKS-HSZRJFAPSA-N 0.000 claims description 4
- MRWZJPVUUHCPTQ-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC(F)=C4C)C=N3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC(F)=C4C)C=N3)NC2=O)CS(=O)(=O)C)=N1)C MRWZJPVUUHCPTQ-HXUWFJFHSA-N 0.000 claims description 4
- BSZHCZOXUNBNAG-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC(F)=C4F)C=C3)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC(F)=C4F)C=C3)N(C2=O)C)CS(=O)(=O)C)=N1)C BSZHCZOXUNBNAG-OAQYLSRUSA-N 0.000 claims description 4
- DFXQORMXOYJEHT-LJQANCHMSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC(F)=C4F)C=N3)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC(F)=C4F)C=N3)N(C2=O)C)CS(=O)(=O)C)=N1)C DFXQORMXOYJEHT-LJQANCHMSA-N 0.000 claims description 4
- XBWSVLPOVOEIKY-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC(OC)=C4F)C=C3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC(OC)=C4F)C=C3)NC2=O)CS(=O)(=O)C)=N1)C XBWSVLPOVOEIKY-HXUWFJFHSA-N 0.000 claims description 4
- BSGJPPFKJRHGHQ-LJQANCHMSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC=C4C(F)(F)F)C=N3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC=C4C(F)(F)F)C=N3)NC2=O)CS(=O)(=O)C)=N1)C BSGJPPFKJRHGHQ-LJQANCHMSA-N 0.000 claims description 4
- BQKIICXGRWKHSW-HSZRJFAPSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC=C4C)C=C3)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC=C4C)C=C3)N(C2=O)C)CS(=O)(=O)C)=N1)C BQKIICXGRWKHSW-HSZRJFAPSA-N 0.000 claims description 4
- YFCVHVOUYXHCHI-JOCHJYFZSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC=C4C)C=C3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC=C4C)C=C3)NC2=O)CS(=O)(=O)C)=N1)C YFCVHVOUYXHCHI-JOCHJYFZSA-N 0.000 claims description 4
- RWXNBLYSYMLSEP-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC=C4CC)C=N3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC=C4CC)C=N3)NC2=O)CS(=O)(=O)C)=N1)C RWXNBLYSYMLSEP-OAQYLSRUSA-N 0.000 claims description 4
- VVSLSWOMHGILHA-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC=C4Cl)C=C3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC=C4Cl)C=C3)NC2=O)CS(=O)(=O)C)=N1)C VVSLSWOMHGILHA-OAQYLSRUSA-N 0.000 claims description 4
- HJEPJHNVGQNQJA-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC=C4OC)C=N3)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC=C4OC)C=N3)N(C2=O)C)CS(=O)(=O)C)=N1)C HJEPJHNVGQNQJA-HXUWFJFHSA-N 0.000 claims description 4
- PZMONGRUAKQCPA-LJQANCHMSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC=C4OC)C=N3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC=C4OC)C=N3)NC2=O)CS(=O)(=O)C)=N1)C PZMONGRUAKQCPA-LJQANCHMSA-N 0.000 claims description 4
- HKTBLGYBABAZTE-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC=N4)C=N3)N(C2=O)CC)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC=N4)C=N3)N(C2=O)CC)CS(=O)(=O)C)=N1)C HKTBLGYBABAZTE-HXUWFJFHSA-N 0.000 claims description 4
- FLTYSJYPKJHPDD-GOSISDBHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)Br)N(C2=O)CCS(=O)(=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)Br)N(C2=O)CCS(=O)(=O)C)CS(=O)(=O)C)=N1)C FLTYSJYPKJHPDD-GOSISDBHSA-N 0.000 claims description 4
- NPSBEZAKPDKBIH-LJQANCHMSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C)N(C2=O)C2CC2)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C)N(C2=O)C2CC2)CS(=O)(=O)C)=N1)C NPSBEZAKPDKBIH-LJQANCHMSA-N 0.000 claims description 4
- CVOJHIGHVDGAKG-JOCHJYFZSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=C(C)C=CC=C3C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=C(C)C=CC=C3C)NC2=O)CS(=O)(=O)C)=N1)C CVOJHIGHVDGAKG-JOCHJYFZSA-N 0.000 claims description 4
- NAOCHPYUAQXUMV-HSZRJFAPSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=C(C=C(C)C=C3)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=C(C=C(C)C=C3)C)NC2=O)CS(=O)(=O)C)=N1)C NAOCHPYUAQXUMV-HSZRJFAPSA-N 0.000 claims description 4
- CBYYZTIYDQLXTM-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=C(F)C=CC=C3F)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=C(F)C=CC=C3F)NC2=O)CS(=O)(=O)C)=N1)C CBYYZTIYDQLXTM-HXUWFJFHSA-N 0.000 claims description 4
- BTPJJAUIJNMDTK-XMMPIXPASA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC(C)=CC=C3C)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC(C)=CC=C3C)N(C2=O)C)CS(=O)(=O)C)=N1)C BTPJJAUIJNMDTK-XMMPIXPASA-N 0.000 claims description 4
- VXJPLPCQVMRFSN-HSZRJFAPSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC(C)=CC=C3C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC(C)=CC=C3C)NC2=O)CS(=O)(=O)C)=N1)C VXJPLPCQVMRFSN-HSZRJFAPSA-N 0.000 claims description 4
- QQJWYWVXZRJDQH-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC(F)=C(F)C=C3F)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC(F)=C(F)C=C3F)NC2=O)CS(=O)(=O)C)=N1)C QQJWYWVXZRJDQH-OAQYLSRUSA-N 0.000 claims description 4
- HUZNOJMMMPWWIW-HSZRJFAPSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC(F)=CC=C3C)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC(F)=CC=C3C)N(C2=O)C)CS(=O)(=O)C)=N1)C HUZNOJMMMPWWIW-HSZRJFAPSA-N 0.000 claims description 4
- UJQCEEPYTCQIHS-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC(F)=CC=C3F)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC(F)=CC=C3F)NC2=O)CS(=O)(=O)C)=N1)C UJQCEEPYTCQIHS-OAQYLSRUSA-N 0.000 claims description 4
- XRXQXWLPGVHGAK-JOCHJYFZSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC(F)=CC=C3OC)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC(F)=CC=C3OC)N(C2=O)C)CS(=O)(=O)C)=N1)C XRXQXWLPGVHGAK-JOCHJYFZSA-N 0.000 claims description 4
- DUHBAFVYRZQZBO-JOCHJYFZSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC(OC)=CC=C3F)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC(OC)=CC=C3F)NC2=O)CS(=O)(=O)C)=N1)C DUHBAFVYRZQZBO-JOCHJYFZSA-N 0.000 claims description 4
- BULRJJITHKMCNB-XMMPIXPASA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=C(C)C=C3C)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=C(C)C=C3C)N(C2=O)C)CS(=O)(=O)C)=N1)C BULRJJITHKMCNB-XMMPIXPASA-N 0.000 claims description 4
- ASZZGTWWBGMREM-HSZRJFAPSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=C(C)C=C3F)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=C(C)C=C3F)N(C2=O)C)CS(=O)(=O)C)=N1)C ASZZGTWWBGMREM-HSZRJFAPSA-N 0.000 claims description 4
- DEJWIXPQTUQHTO-JOCHJYFZSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=C(C)C=C3F)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=C(C)C=C3F)NC2=O)CS(=O)(=O)C)=N1)C DEJWIXPQTUQHTO-JOCHJYFZSA-N 0.000 claims description 4
- KRFNBORIVODOKR-JOCHJYFZSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=C(F)C=C3OC)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=C(F)C=C3OC)N(C2=O)C)CS(=O)(=O)C)=N1)C KRFNBORIVODOKR-JOCHJYFZSA-N 0.000 claims description 4
- MLLXUPWNIHTJLC-HSZRJFAPSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=C(OC)C=C3F)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=C(OC)C=C3F)N(C2=O)C)CS(=O)(=O)C)=N1)C MLLXUPWNIHTJLC-HSZRJFAPSA-N 0.000 claims description 4
- BDWWAFAIXZVLKV-HSZRJFAPSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=CC(C)=C3C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=CC(C)=C3C)NC2=O)CS(=O)(=O)C)=N1)C BDWWAFAIXZVLKV-HSZRJFAPSA-N 0.000 claims description 4
- QOOZNUNRWGWMMW-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=CC(C)=C3F)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=CC(C)=C3F)NC2=O)CS(=O)(=O)C)=N1)C QOOZNUNRWGWMMW-OAQYLSRUSA-N 0.000 claims description 4
- AGOQVSJJTZAXPQ-JOCHJYFZSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=CC(F)=C3C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=CC(F)=C3C)NC2=O)CS(=O)(=O)C)=N1)C AGOQVSJJTZAXPQ-JOCHJYFZSA-N 0.000 claims description 4
- WCLFSXOVOBOKMK-XMMPIXPASA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=CC=C3C3CC3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=CC=C3C3CC3)NC2=O)CS(=O)(=O)C)=N1)C WCLFSXOVOBOKMK-XMMPIXPASA-N 0.000 claims description 4
- LIFQLXZUYAJPJM-XMMPIXPASA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=CC=C3CC)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=CC=C3CC)N(C2=O)C)CS(=O)(=O)C)=N1)C LIFQLXZUYAJPJM-XMMPIXPASA-N 0.000 claims description 4
- LPYIMSLPRTVJRX-HSZRJFAPSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=CC=C3CC)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=CC=C3CC)NC2=O)CS(=O)(=O)C)=N1)C LPYIMSLPRTVJRX-HSZRJFAPSA-N 0.000 claims description 4
- IZPFDLGXWXYOEO-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=NC=CC=C3)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=NC=CC=C3)N(C2=O)C)CS(=O)(=O)C)=N1)C IZPFDLGXWXYOEO-OAQYLSRUSA-N 0.000 claims description 4
- FUELGAUIMQAIFN-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC(C)=CC=C3C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC(C)=CC=C3C)NC2=O)CS(=O)(=O)C)=N1)C FUELGAUIMQAIFN-OAQYLSRUSA-N 0.000 claims description 4
- IFPMVKWCRUJREU-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC(F)=C(F)C=C3F)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC(F)=C(F)C=C3F)N(C2=O)C)CS(=O)(=O)C)=N1)C IFPMVKWCRUJREU-HXUWFJFHSA-N 0.000 claims description 4
- USHFRDRHOATZNL-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC(F)=CC=C3F)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC(F)=CC=C3F)N(C2=O)C)CS(=O)(=O)C)=N1)C USHFRDRHOATZNL-HXUWFJFHSA-N 0.000 claims description 4
- URTSVICFCFHDGY-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC(F)=CC=C3OC)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC(F)=CC=C3OC)N(C2=O)C)CS(=O)(=O)C)=N1)C URTSVICFCFHDGY-HXUWFJFHSA-N 0.000 claims description 4
- GLNICQVHQAJBMP-LJQANCHMSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC(F)=CC=C3OC)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC(F)=CC=C3OC)NC2=O)CS(=O)(=O)C)=N1)C GLNICQVHQAJBMP-LJQANCHMSA-N 0.000 claims description 4
- GOCSWXDURRDXQP-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC=C(C)C=C3F)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC=C(C)C=C3F)N(C2=O)C)CS(=O)(=O)C)=N1)C GOCSWXDURRDXQP-OAQYLSRUSA-N 0.000 claims description 4
- CZVPMNPPUWRVEH-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC=C(C)C=C3F)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC=C(C)C=C3F)NC2=O)CS(=O)(=O)C)=N1)C CZVPMNPPUWRVEH-HXUWFJFHSA-N 0.000 claims description 4
- XGOHKQAXGIBRKL-LJQANCHMSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC=C(F)C=C3F)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC=C(F)C=C3F)NC2=O)CS(=O)(=O)C)=N1)C XGOHKQAXGIBRKL-LJQANCHMSA-N 0.000 claims description 4
- WMJGFDGVRBNUJJ-JOCHJYFZSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC=CC(C)=C3C)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC=CC(C)=C3C)N(C2=O)C)CS(=O)(=O)C)=N1)C WMJGFDGVRBNUJJ-JOCHJYFZSA-N 0.000 claims description 4
- HQHJXNKKHLYSBF-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC=CC(F)=C3C)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC=CC(F)=C3C)N(C2=O)C)CS(=O)(=O)C)=N1)C HQHJXNKKHLYSBF-OAQYLSRUSA-N 0.000 claims description 4
- VYRKBTCTEDIWBP-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC=CC=C3C(F)(F)F)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC=CC=C3C(F)(F)F)N(C2=O)C)CS(=O)(=O)C)=N1)C VYRKBTCTEDIWBP-HXUWFJFHSA-N 0.000 claims description 4
- XOKWOTJIGHLQJR-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC=CC=C3C)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC=CC=C3C)N(C2=O)C)CS(=O)(=O)C)=N1)C XOKWOTJIGHLQJR-OAQYLSRUSA-N 0.000 claims description 4
- NGHRBHDTPWWUJP-JOCHJYFZSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC=CC=C3C3CC3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC=CC=C3C3CC3)NC2=O)CS(=O)(=O)C)=N1)C NGHRBHDTPWWUJP-JOCHJYFZSA-N 0.000 claims description 4
- SKYGXDWQAJXDCO-LJQANCHMSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC=CC=C3F)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC=CC=C3F)NC2=O)CS(=O)(=O)C)=N1)C SKYGXDWQAJXDCO-LJQANCHMSA-N 0.000 claims description 4
- YMZMDUBBOZIOTH-JOCHJYFZSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(N(C2=O)C)C=C(C2=CC(F)=CC=C2F)C=C3)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(N(C2=O)C)C=C(C2=CC(F)=CC=C2F)C=C3)CS(=O)(=O)C)=N1)C YMZMDUBBOZIOTH-JOCHJYFZSA-N 0.000 claims description 4
- GAPBYPIQBIFIKB-HSZRJFAPSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(N(C2=O)C)C=C(C=C3)C2=CC(OC)=CC=C2F)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(N(C2=O)C)C=C(C=C3)C2=CC(OC)=CC=C2F)CS(=O)(=O)C)=N1)C GAPBYPIQBIFIKB-HSZRJFAPSA-N 0.000 claims description 4
- WDDGPZAYNAWWIN-JOCHJYFZSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(N(C2=O)C)C=C(C=C3)C2=CC=CC(C)=C2F)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(N(C2=O)C)C=C(C=C3)C2=CC=CC(C)=C2F)CS(=O)(=O)C)=N1)C WDDGPZAYNAWWIN-JOCHJYFZSA-N 0.000 claims description 4
- VLPFQADNFLZUMD-JOCHJYFZSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(N(C2=O)C)C=C(C=N3)C2=CC(C)=CC=C2C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(N(C2=O)C)C=C(C=N3)C2=CC(C)=CC=C2C)CS(=O)(=O)C)=N1)C VLPFQADNFLZUMD-JOCHJYFZSA-N 0.000 claims description 4
- RGXWJURNLVWHTN-XMMPIXPASA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(N(C2=O)C2CC2)C=C(C=C3)C2=CC=CC=C2F)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(N(C2=O)C2CC2)C=C(C=C3)C2=CC=CC=C2F)CS(=O)(=O)C)=N1)C RGXWJURNLVWHTN-XMMPIXPASA-N 0.000 claims description 4
- SIGDMKAQVAHJJS-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(N(C2=O)CCOC)C=C(C2=CC=CC=N2)C=N3)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(N(C2=O)CCOC)C=C(C2=CC=CC=N2)C=N3)CS(=O)(=O)C)=N1)C SIGDMKAQVAHJJS-OAQYLSRUSA-N 0.000 claims description 4
- ITOQERDNUPBSJF-HSZRJFAPSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(N(C2=O)CCOC)C=C(C=C3)C2=CC=CC=N2)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(N(C2=O)CCOC)C=C(C=C3)C2=CC=CC=N2)CS(=O)(=O)C)=N1)C ITOQERDNUPBSJF-HSZRJFAPSA-N 0.000 claims description 4
- KYSPTDMLCHFYIK-LJQANCHMSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(NC2=O)C=C(C2=CC(F)=CC=C2F)C=N3)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(NC2=O)C=C(C2=CC(F)=CC=C2F)C=N3)CS(=O)(=O)C)=N1)C KYSPTDMLCHFYIK-LJQANCHMSA-N 0.000 claims description 4
- IHNFMFDWOATDTR-GOSISDBHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(NC2=O)C=C(C2=CC=CC=N2)C=N3)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(NC2=O)C=C(C2=CC=CC=N2)C=N3)CS(=O)(=O)C)=N1)C IHNFMFDWOATDTR-GOSISDBHSA-N 0.000 claims description 4
- WGUPIKKKVNDLNK-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(NC2=O)C=C(C=N3)C2=CC(C)=CC=C2F)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(NC2=O)C=C(C=N3)C2=CC(C)=CC=C2F)CS(=O)(=O)C)=N1)C WGUPIKKKVNDLNK-HXUWFJFHSA-N 0.000 claims description 4
- ZQDWHOVZLGYJBK-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=NC=C(C4=CC=C(F)C=C4)C=C3N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=NC=C(C4=CC=C(F)C=C4)C=C3N(C2=O)C)CS(=O)(=O)C)=N1)C ZQDWHOVZLGYJBK-HXUWFJFHSA-N 0.000 claims description 4
- MCVIYERXWBFLPX-LJQANCHMSA-N C(OC1=C(OC)C=CC([C@H](N2C3=NC=C(C4=CC=CC=N4)C=C3N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=NC=C(C4=CC=CC=N4)C=C3N(C2=O)C)CS(=O)(=O)C)=N1)C MCVIYERXWBFLPX-LJQANCHMSA-N 0.000 claims description 4
- LGISIENWYJKHLG-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=NC=C(C=C3N(C2=O)C)C2=CC(F)=CC=C2C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=NC=C(C=C3N(C2=O)C)C2=CC(F)=CC=C2C)CS(=O)(=O)C)=N1)C LGISIENWYJKHLG-OAQYLSRUSA-N 0.000 claims description 4
- SJDQAQUDMDSITO-QGZVFWFLSA-N C1=C(C(=NC(=C1)[C@H](N1C(=O)C2=C(NC(=O)C)C=CC=C2C1)CS(=O)(=O)C)OCC)OC Chemical compound C1=C(C(=NC(=C1)[C@H](N1C(=O)C2=C(NC(=O)C)C=CC=C2C1)CS(=O)(=O)C)OCC)OC SJDQAQUDMDSITO-QGZVFWFLSA-N 0.000 claims description 4
- ZXDGMEODEOXOLQ-LJQANCHMSA-N CCOC(N=C([C@@H](CS(C)(=O)=O)N(C(C(N1)=C2)=NC=C2C(C=C2)=CC=C2F)C1=O)C=C1)=C1OC Chemical compound CCOC(N=C([C@@H](CS(C)(=O)=O)N(C(C(N1)=C2)=NC=C2C(C=C2)=CC=C2F)C1=O)C=C1)=C1OC ZXDGMEODEOXOLQ-LJQANCHMSA-N 0.000 claims description 4
- JLVGOLQZVYBBGU-GOSISDBHSA-N CCOC(N=C([C@@H](CS(C)(=O)=O)N(C(C(N1)=C2)=NC=C2C(C=CC=C2F)=C2F)C1=O)C=C1)=C1OC Chemical compound CCOC(N=C([C@@H](CS(C)(=O)=O)N(C(C(N1)=C2)=NC=C2C(C=CC=C2F)=C2F)C1=O)C=C1)=C1OC JLVGOLQZVYBBGU-GOSISDBHSA-N 0.000 claims description 4
- ZPBMSCIIEAOOLA-GOSISDBHSA-N CCOC(N=C([C@@H](CS(C)(=O)=O)N(C(C(N1)=C2C)=NC=C2C(C=CC=C2OC)=C2F)C1=O)C=C1)=C1OC Chemical compound CCOC(N=C([C@@H](CS(C)(=O)=O)N(C(C(N1)=C2C)=NC=C2C(C=CC=C2OC)=C2F)C1=O)C=C1)=C1OC ZPBMSCIIEAOOLA-GOSISDBHSA-N 0.000 claims description 4
- TWHGNPSCWFDAPT-HXUWFJFHSA-N CCOC(N=C([C@@H](CS(C)(=O)=O)N(C(C(N1C)=C2C)=NC=C2C(C=CC=C2)=C2F)C1=O)C=C1)=C1OC Chemical compound CCOC(N=C([C@@H](CS(C)(=O)=O)N(C(C(N1C)=C2C)=NC=C2C(C=CC=C2)=C2F)C1=O)C=C1)=C1OC TWHGNPSCWFDAPT-HXUWFJFHSA-N 0.000 claims description 4
- IOCPFBRBIAKOKM-IBGZPJMESA-N CCOC(N=C([C@H](CS(C)(=O)=O)N(C(C(N1)=C2C)=NC=C2C(C=CC=C2)=C2F)C1=O)C=C1)=C1OC Chemical compound CCOC(N=C([C@H](CS(C)(=O)=O)N(C(C(N1)=C2C)=NC=C2C(C=CC=C2)=C2F)C1=O)C=C1)=C1OC IOCPFBRBIAKOKM-IBGZPJMESA-N 0.000 claims description 4
- VLCIAXWKNPJNGD-UHFFFAOYSA-N O(C)C1=CC=C(C(N2C(=O)C=3C(=CSC=3N(=O)=O)C2=O)CS(=O)(=O)C)N=C1OCC Chemical compound O(C)C1=CC=C(C(N2C(=O)C=3C(=CSC=3N(=O)=O)C2=O)CS(=O)(=O)C)N=C1OCC VLCIAXWKNPJNGD-UHFFFAOYSA-N 0.000 claims description 4
- SLIDARXTGISSNR-NRFANRHFSA-N O(CC)C1=C(OC)C=CC([C@@H](N2C3=C(C(=C(C4=CC=C(F)C=C4)C=N3)C)N(C2=O)CC)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC([C@@H](N2C3=C(C(=C(C4=CC=C(F)C=C4)C=N3)C)N(C2=O)CC)CS(=O)(=O)C)=N1 SLIDARXTGISSNR-NRFANRHFSA-N 0.000 claims description 4
- POOJMOFZWLBYSK-FQEVSTJZSA-N O(CC)C1=C(OC)C=CC([C@@H](N2C3=C(C(=C(C4=CC=CC=C4)C=N3)C)N(C2=O)CC(F)(F)F)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC([C@@H](N2C3=C(C(=C(C4=CC=CC=C4)C=N3)C)N(C2=O)CC(F)(F)F)CS(=O)(=O)C)=N1 POOJMOFZWLBYSK-FQEVSTJZSA-N 0.000 claims description 4
- BZIMTEUIVDEJOG-IBGZPJMESA-N O(CC)C1=C(OC)C=CC([C@@H](N2C3=C(C(=C(C=N3)C3=CC=CC=C3)C)NC2=O)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC([C@@H](N2C3=C(C(=C(C=N3)C3=CC=CC=C3)C)NC2=O)CS(=O)(=O)C)=N1 BZIMTEUIVDEJOG-IBGZPJMESA-N 0.000 claims description 4
- GPZCVNOZOJQIIB-FQEVSTJZSA-N O(CC)C1=C(OC)C=CC([C@@H](N2C3=C(C(=C(C=N3)C3=CC=CC=C3F)C)N(C2=O)CC(F)(F)F)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC([C@@H](N2C3=C(C(=C(C=N3)C3=CC=CC=C3F)C)N(C2=O)CC(F)(F)F)CS(=O)(=O)C)=N1 GPZCVNOZOJQIIB-FQEVSTJZSA-N 0.000 claims description 4
- KYSPTDMLCHFYIK-IBGZPJMESA-N O(CC)C1=C(OC)C=CC([C@@H](N2C3=C(C=C(C=N3)C3=CC(F)=CC=C3F)NC2=O)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC([C@@H](N2C3=C(C=C(C=N3)C3=CC(F)=CC=C3F)NC2=O)CS(=O)(=O)C)=N1 KYSPTDMLCHFYIK-IBGZPJMESA-N 0.000 claims description 4
- MMVUALBXOLWSHD-IBGZPJMESA-N O(CC)C1=C(OC)C=CC([C@@H](N2C3=NC=C(C4=CC=C(F)C=C4)C(=C3NC2=O)C)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC([C@@H](N2C3=NC=C(C4=CC=C(F)C=C4)C(=C3NC2=O)C)CS(=O)(=O)C)=N1 MMVUALBXOLWSHD-IBGZPJMESA-N 0.000 claims description 4
- MMVUALBXOLWSHD-LJQANCHMSA-N O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=C(F)C=C4)C=N3)C)NC2=O)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=C(F)C=C4)C=N3)C)NC2=O)CS(=O)(=O)C)=N1 MMVUALBXOLWSHD-LJQANCHMSA-N 0.000 claims description 4
- QBOSHGHGRNPJDE-JOCHJYFZSA-N O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC=C4C(C)C)C=N3)C)NC2=O)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C(=C(C4=CC=CC=C4C(C)C)C=N3)C)NC2=O)CS(=O)(=O)C)=N1 QBOSHGHGRNPJDE-JOCHJYFZSA-N 0.000 claims description 4
- VGSROAVKCDURSC-HXUWFJFHSA-N O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=C(C)C=CC=C3C)C)NC2=O)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=C(C)C=CC=C3C)C)NC2=O)CS(=O)(=O)C)=N1 VGSROAVKCDURSC-HXUWFJFHSA-N 0.000 claims description 4
- BWVULPSUQWTKGI-OAHLLOKOSA-N O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C=C(Br)C=C3)NC2=O)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C=C(Br)C=C3)NC2=O)CS(=O)(=O)C)=N1 BWVULPSUQWTKGI-OAHLLOKOSA-N 0.000 claims description 4
- HIKJUTZCSUCVSA-OAQYLSRUSA-N O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=C(F)C=CC=C3OC)N(C2=O)C)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=C(F)C=CC=C3OC)N(C2=O)C)CS(=O)(=O)C)=N1 HIKJUTZCSUCVSA-OAQYLSRUSA-N 0.000 claims description 4
- UWLFFMTYQOAZQE-HXUWFJFHSA-N O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=C(F)C=CC=C3OC)NC2=O)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=C(F)C=CC=C3OC)NC2=O)CS(=O)(=O)C)=N1 UWLFFMTYQOAZQE-HXUWFJFHSA-N 0.000 claims description 4
- OSUTYRZULCWTDY-OAQYLSRUSA-N O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=C(F)C=C3F)NC2=O)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=C(F)C=C3F)NC2=O)CS(=O)(=O)C)=N1 OSUTYRZULCWTDY-OAQYLSRUSA-N 0.000 claims description 4
- AJSDNDOSRVKCNA-OAQYLSRUSA-N O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=C(F)C=C3OC)NC2=O)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=C(F)C=C3OC)NC2=O)CS(=O)(=O)C)=N1 AJSDNDOSRVKCNA-OAQYLSRUSA-N 0.000 claims description 4
- PAPHAPAVAOVTOY-HXUWFJFHSA-N O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=CC(F)=C3F)NC2=O)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=CC(F)=C3F)NC2=O)CS(=O)(=O)C)=N1 PAPHAPAVAOVTOY-HXUWFJFHSA-N 0.000 claims description 4
- LNXURQHGDAJDRE-HXUWFJFHSA-N O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=C(C=C(C=C3)F)F)N(C2=O)C)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=C(C=C(C=C3)F)F)N(C2=O)C)CS(=O)(=O)C)=N1 LNXURQHGDAJDRE-HXUWFJFHSA-N 0.000 claims description 4
- IGHLIEPCBGMENE-GOSISDBHSA-N O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=C(F)C=CC=C3OC)NC2=O)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=C(F)C=CC=C3OC)NC2=O)CS(=O)(=O)C)=N1 IGHLIEPCBGMENE-GOSISDBHSA-N 0.000 claims description 4
- YNXRLXOBJLNBTH-LJQANCHMSA-N O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC=CC=C3)NC2=O)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC=CC=C3)NC2=O)CS(=O)(=O)C)=N1 YNXRLXOBJLNBTH-LJQANCHMSA-N 0.000 claims description 4
- SAMXOUUSZZLPKG-HXUWFJFHSA-N O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC=CC=C3C)NC2=O)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C=C(C=N3)C3=CC=CC=C3C)NC2=O)CS(=O)(=O)C)=N1 SAMXOUUSZZLPKG-HXUWFJFHSA-N 0.000 claims description 4
- UJKNUFQSVXUNLO-OAQYLSRUSA-N O(CC)C1=C(OC)C=CC([C@H](N2C3=NC=C(C=C3N(C2=O)C)C2=C(C)C=CC=C2C)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC([C@H](N2C3=NC=C(C=C3N(C2=O)C)C2=C(C)C=CC=C2C)CS(=O)(=O)C)=N1 UJKNUFQSVXUNLO-OAQYLSRUSA-N 0.000 claims description 4
- WIKKZTDZHCZSAB-HXUWFJFHSA-N O(CC)C1=C(OC)C=CC([C@H](N2C3=NC=C(C=C3NC2=O)C2=CC(F)=CC=C2C)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC([C@H](N2C3=NC=C(C=C3NC2=O)C2=CC(F)=CC=C2C)CS(=O)(=O)C)=N1 WIKKZTDZHCZSAB-HXUWFJFHSA-N 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- XOQGAISDBZCHJD-UHFFFAOYSA-N C1=C(C(=NC(=C1)C(N1C(=O)C=2C(=CSC=2NC(=O)C)C1=O)CS(=O)(=O)C)OCC)OC Chemical compound C1=C(C(=NC(=C1)C(N1C(=O)C=2C(=CSC=2NC(=O)C)C1=O)CS(=O)(=O)C)OCC)OC XOQGAISDBZCHJD-UHFFFAOYSA-N 0.000 claims description 3
- VTRRMUDARYRSCK-KRWDZBQOSA-N C1=C(C(=NC(=C1)[C@@H](N1C(=O)C2=C(NC(=O)CC)C=CC=C2C1)CS(=O)(=O)C)OCC)OC Chemical compound C1=C(C(=NC(=C1)[C@@H](N1C(=O)C2=C(NC(=O)CC)C=CC=C2C1)CS(=O)(=O)C)OCC)OC VTRRMUDARYRSCK-KRWDZBQOSA-N 0.000 claims description 3
- VLCIAXWKNPJNGD-LLVKDONJSA-N C1=C(C(=NC(=C1)[C@H](N1C(=O)C=2C(=CSC=2N(=O)=O)C1=O)CS(=O)(=O)C)OCC)OC Chemical compound C1=C(C(=NC(=C1)[C@H](N1C(=O)C=2C(=CSC=2N(=O)=O)C1=O)CS(=O)(=O)C)OCC)OC VLCIAXWKNPJNGD-LLVKDONJSA-N 0.000 claims description 3
- NKMJQNTWKWNVPU-MRXNPFEDSA-N C1=C(C(=NC(=C1)[C@H](N1C(=O)C=2C(=CSC=2NC(=O)CN(CC)CC)C1=O)CS(=O)(=O)C)OCC)OC Chemical compound C1=C(C(=NC(=C1)[C@H](N1C(=O)C=2C(=CSC=2NC(=O)CN(CC)CC)C1=O)CS(=O)(=O)C)OCC)OC NKMJQNTWKWNVPU-MRXNPFEDSA-N 0.000 claims description 3
- XOQGAISDBZCHJD-ZDUSSCGKSA-N C1=C(C(=NC([C@@H](N2C(=O)C=3C(=CSC=3NC(=O)C)C2=O)CS(=O)(=O)C)=C1)OCC)OC Chemical compound C1=C(C(=NC([C@@H](N2C(=O)C=3C(=CSC=3NC(=O)C)C2=O)CS(=O)(=O)C)=C1)OCC)OC XOQGAISDBZCHJD-ZDUSSCGKSA-N 0.000 claims description 3
- VTRRMUDARYRSCK-QGZVFWFLSA-N C1=C(C(=NC([C@H](N2C(=O)C3=C(C=CC=C3C2)NC(=O)CC)CS(=O)(=O)C)=C1)OCC)OC Chemical compound C1=C(C(=NC([C@H](N2C(=O)C3=C(C=CC=C3C2)NC(=O)CC)CS(=O)(=O)C)=C1)OCC)OC VTRRMUDARYRSCK-QGZVFWFLSA-N 0.000 claims description 3
- HVHSQSICXQXXTH-GOSISDBHSA-N C1=C([C@H](N2C(=O)C3=C(C=CC=C3C2)NC(=O)C2CC2)CS(=O)(=O)C)N=C(C(=C1)OC)OCC Chemical compound C1=C([C@H](N2C(=O)C3=C(C=CC=C3C2)NC(=O)C2CC2)CS(=O)(=O)C)N=C(C(=C1)OC)OCC HVHSQSICXQXXTH-GOSISDBHSA-N 0.000 claims description 3
- SJDQAQUDMDSITO-KRWDZBQOSA-N C1=CC(=C(N=C1[C@@H](N1C(=O)C2=C(C=CC=C2C1)NC(=O)C)CS(=O)(=O)C)OCC)OC Chemical compound C1=CC(=C(N=C1[C@@H](N1C(=O)C2=C(C=CC=C2C1)NC(=O)C)CS(=O)(=O)C)OCC)OC SJDQAQUDMDSITO-KRWDZBQOSA-N 0.000 claims description 3
- MFNSQHUFGRYQAY-QGZVFWFLSA-N C1=CC(=C(N=C1[C@H](N1C(=O)C=2C(=CSC=2NC(=O)CN2CCCCC2)C1=O)CS(=O)(=O)C)OCC)OC Chemical compound C1=CC(=C(N=C1[C@H](N1C(=O)C=2C(=CSC=2NC(=O)CN2CCCCC2)C1=O)CS(=O)(=O)C)OCC)OC MFNSQHUFGRYQAY-QGZVFWFLSA-N 0.000 claims description 3
- YRKDAIRRSMDRKT-CQSZACIVSA-N CCOC(N=C([C@@H](CS(C)(=O)=O)N(C(C1=CSC(NC(CN(C)C)=O)=C11)=O)C1=O)C=C1)=C1OC Chemical compound CCOC(N=C([C@@H](CS(C)(=O)=O)N(C(C1=CSC(NC(CN(C)C)=O)=C11)=O)C1=O)C=C1)=C1OC YRKDAIRRSMDRKT-CQSZACIVSA-N 0.000 claims description 3
- XGZLEFQDZNVZPJ-MRXNPFEDSA-N CCOC(N=C([C@@H](CS(C)(=O)=O)N(C(C1=CSC(NC(CN2CCCC2)=O)=C11)=O)C1=O)C=C1)=C1OC Chemical compound CCOC(N=C([C@@H](CS(C)(=O)=O)N(C(C1=CSC(NC(CN2CCCC2)=O)=C11)=O)C1=O)C=C1)=C1OC XGZLEFQDZNVZPJ-MRXNPFEDSA-N 0.000 claims description 3
- IGUMJGSLDUAXPQ-QRWMCTBCSA-N CCON(C([C@@H](CS(C)(=O)=O)N(C(C=CC(C(OCC(F)(F)F)=O)=C1)=C1N1)C1=O)C=C1)C=C1OC Chemical compound CCON(C([C@@H](CS(C)(=O)=O)N(C(C=CC(C(OCC(F)(F)F)=O)=C1)=C1N1)C1=O)C=C1)C=C1OC IGUMJGSLDUAXPQ-QRWMCTBCSA-N 0.000 claims description 3
- LMZBFTGTQSGYAY-JFGZAKSSSA-N CCON(C([C@@H](CS(C)(=O)=O)N(C(C=CC=C1C2=C(C)C=CC=C2)=C1N1)C1=O)C=C1)C=C1OC Chemical compound CCON(C([C@@H](CS(C)(=O)=O)N(C(C=CC=C1C2=C(C)C=CC=C2)=C1N1)C1=O)C=C1)C=C1OC LMZBFTGTQSGYAY-JFGZAKSSSA-N 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- HVHSQSICXQXXTH-SFHVURJKSA-N O(C)C1=CC=C([C@@H](N2C(=O)C3=C(C=CC=C3C2)NC(=O)C2CC2)CS(=O)(=O)C)N=C1OCC Chemical compound O(C)C1=CC=C([C@@H](N2C(=O)C3=C(C=CC=C3C2)NC(=O)C2CC2)CS(=O)(=O)C)N=C1OCC HVHSQSICXQXXTH-SFHVURJKSA-N 0.000 claims description 3
- SLXQKSVCUNRJFX-LLVKDONJSA-N O(C)C1=CC=C([C@H](N2C(=O)C=3C(=CSC=3N)C2=O)CS(=O)(=O)C)N=C1OCC Chemical compound O(C)C1=CC=C([C@H](N2C(=O)C=3C(=CSC=3N)C2=O)CS(=O)(=O)C)N=C1OCC SLXQKSVCUNRJFX-LLVKDONJSA-N 0.000 claims description 3
- ZBZZCFOQIIJGSO-CQSZACIVSA-N O(C)C1=CC=C([C@H](N2C(=O)C=3C(=CSC=3NC(=O)C3CC3)C2=O)CS(=O)(=O)C)N=C1OCC Chemical compound O(C)C1=CC=C([C@H](N2C(=O)C=3C(=CSC=3NC(=O)C3CC3)C2=O)CS(=O)(=O)C)N=C1OCC ZBZZCFOQIIJGSO-CQSZACIVSA-N 0.000 claims description 3
- YNEPHVSPXYHZEZ-CYBMUJFWSA-N O(C)C1=CC=C([C@H](N2C(=O)C=3C(=CSC=3NC(=O)CC)C2=O)CS(=O)(=O)C)N=C1OCC Chemical compound O(C)C1=CC=C([C@H](N2C(=O)C=3C(=CSC=3NC(=O)CC)C2=O)CS(=O)(=O)C)N=C1OCC YNEPHVSPXYHZEZ-CYBMUJFWSA-N 0.000 claims description 3
- GWIQJNRXTAQDOS-MRXNPFEDSA-N O(C)C1=CC=C([C@H](N2C(=O)C=3C(=CSC=3NC(=O)CN3CCOCC3)C2=O)CS(=O)(=O)C)N=C1OCC Chemical compound O(C)C1=CC=C([C@H](N2C(=O)C=3C(=CSC=3NC(=O)CN3CCOCC3)C2=O)CS(=O)(=O)C)N=C1OCC GWIQJNRXTAQDOS-MRXNPFEDSA-N 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- XOQGAISDBZCHJD-CYBMUJFWSA-N CCOC(N=C([C@@H](CS(C)(=O)=O)N(C(C1=CSC(NC(C)=O)=C11)=O)C1=O)C=C1)=C1OC Chemical compound CCOC(N=C([C@@H](CS(C)(=O)=O)N(C(C1=CSC(NC(C)=O)=C11)=O)C1=O)C=C1)=C1OC XOQGAISDBZCHJD-CYBMUJFWSA-N 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 2
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 10
- 201000011510 cancer Diseases 0.000 abstract description 7
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 229940127557 pharmaceutical product Drugs 0.000 abstract 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 234
- 238000000034 method Methods 0.000 description 231
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 107
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 54
- 235000002639 sodium chloride Nutrition 0.000 description 37
- 238000006243 chemical reaction Methods 0.000 description 26
- 239000000243 solution Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 15
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 11
- 125000000217 alkyl group Chemical group 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 125000006413 ring segment Chemical group 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229910001873 dinitrogen Inorganic materials 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- BWPYXAMXSVYLRL-MRVPVSSYSA-N (1S)-1-(6-ethoxy-5-methoxypyridin-2-yl)-2-methylsulfonylethanamine Chemical compound C(C)OC1=C(C=CC(=N1)[C@@H](CS(=O)(=O)C)N)OC BWPYXAMXSVYLRL-MRVPVSSYSA-N 0.000 description 2
- QCSLIRFWJPOENV-UHFFFAOYSA-N (2-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1F QCSLIRFWJPOENV-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- BWPYXAMXSVYLRL-UHFFFAOYSA-N 1-(6-ethoxy-5-methoxypyridin-2-yl)-2-methylsulfonylethanamine Chemical compound C(C)OC1=C(C=CC(=N1)C(CS(=O)(=O)C)N)OC BWPYXAMXSVYLRL-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- XEUHDTJWPVEFDQ-HXUWFJFHSA-N 3-[(1S)-1-(6-ethoxy-5-methoxypyridin-2-yl)-2-methylsulfonylethyl]-7-phenyl-1H-benzimidazol-2-one Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=CC=C3)C3=CC=CC=C3)NC2=O)CS(=O)(=O)C)=N1)C XEUHDTJWPVEFDQ-HXUWFJFHSA-N 0.000 description 2
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 2
- VJPPLCNBDLZIFG-ZDUSSCGKSA-N 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide Chemical compound C(C#CC)(=O)N[C@@H]1CN(CCC1)C1=C2C(=C(NC2=C(C=C1F)C(=O)N)C)C VJPPLCNBDLZIFG-ZDUSSCGKSA-N 0.000 description 2
- BLJOCKNDWUTFEN-UHFFFAOYSA-N 5-bromo-2-chloro-4-methyl-3-nitropyridine Chemical compound CC1=C(Br)C=NC(Cl)=C1[N+]([O-])=O BLJOCKNDWUTFEN-UHFFFAOYSA-N 0.000 description 2
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VXVVGULZPJXTBM-SFHVURJKSA-N C(OC1=C(OC)C=CC([C@@H](N2C3=C(C(=C(C4=C(F)C=CC=C4F)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@@H](N2C3=C(C(=C(C4=C(F)C=CC=C4F)C=N3)C)NC2=O)CS(=O)(=O)C)=N1)C VXVVGULZPJXTBM-SFHVURJKSA-N 0.000 description 2
- YZQGWWIGLBAOLA-NRFANRHFSA-N C(OC1=C(OC)C=CC([C@@H](N2C3=C(C=C(C4=CC=CC=C4F)C=C3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@@H](N2C3=C(C=C(C4=CC=CC=C4F)C=C3)NC2=O)CS(=O)(=O)C)=N1)C YZQGWWIGLBAOLA-NRFANRHFSA-N 0.000 description 2
- QBGPAHADQUPCQR-NRFANRHFSA-N C(OC1=C(OC)C=CC([C@@H](N2C3=C(C=C(C4=CC=CC=C4OC)C=C3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@@H](N2C3=C(C=C(C4=CC=CC=C4OC)C=C3)NC2=O)CS(=O)(=O)C)=N1)C QBGPAHADQUPCQR-NRFANRHFSA-N 0.000 description 2
- SEBNNEOYMFRMNK-NRFANRHFSA-N C(OC1=C(OC)C=CC([C@@H](N2C3=C(NC2=O)C=C(C2=CC=C(F)C=C2)C=C3)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@@H](N2C3=C(NC2=O)C=C(C2=CC=C(F)C=C2)C=C3)CS(=O)(=O)C)=N1)C SEBNNEOYMFRMNK-NRFANRHFSA-N 0.000 description 2
- BAUZZZVMYKSYPC-XMMPIXPASA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=C3)C3=CC=CC=C3C(C)C)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=C3)C3=CC=CC=C3C(C)C)C)NC2=O)CS(=O)(=O)C)=N1)C BAUZZZVMYKSYPC-XMMPIXPASA-N 0.000 description 2
- SHVRRVTWISSKLN-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=CC=C3)C3=C(C)C=CC=C3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=CC=C3)C3=C(C)C=CC=C3)NC2=O)CS(=O)(=O)C)=N1)C SHVRRVTWISSKLN-OAQYLSRUSA-N 0.000 description 2
- DTDYHRLXGPWISP-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=CC=C3)C3=C(F)C=CC=C3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=CC=C3)C3=C(F)C=CC=C3)NC2=O)CS(=O)(=O)C)=N1)C DTDYHRLXGPWISP-HXUWFJFHSA-N 0.000 description 2
- HTHACDWVDWIOKE-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=CC=C3)C3=C(OC)C=CC=C3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=CC=C3)C3=C(OC)C=CC=C3)NC2=O)CS(=O)(=O)C)=N1)C HTHACDWVDWIOKE-HXUWFJFHSA-N 0.000 description 2
- XUWBHHVWCOTXGX-GOSISDBHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C(=O)OC(C)C)C=C3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C(=O)OC(C)C)C=C3)NC2=O)CS(=O)(=O)C)=N1)C XUWBHHVWCOTXGX-GOSISDBHSA-N 0.000 description 2
- SEBNNEOYMFRMNK-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=C(F)C=C4)C=C3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=C(F)C=C4)C=C3)NC2=O)CS(=O)(=O)C)=N1)C SEBNNEOYMFRMNK-OAQYLSRUSA-N 0.000 description 2
- QYOUUEJOKGVNLL-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC=C4)C=C3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC=C4)C=C3)NC2=O)CS(=O)(=O)C)=N1)C QYOUUEJOKGVNLL-OAQYLSRUSA-N 0.000 description 2
- XQDVZRQFKBDCRW-JOCHJYFZSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC=C4OCC)C=C3)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC=C4OCC)C=C3)NC2=O)CS(=O)(=O)C)=N1)C XQDVZRQFKBDCRW-JOCHJYFZSA-N 0.000 description 2
- GSXHSDGCTDYEMD-JOCHJYFZSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC=N4)C=C3)N(C2=O)CC)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C4=CC=CC=N4)C=C3)N(C2=O)CC)CS(=O)(=O)C)=N1)C GSXHSDGCTDYEMD-JOCHJYFZSA-N 0.000 description 2
- UZLBRYWMTWOHON-MRXNPFEDSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C(=O)OCC(F)(F)F)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C(=O)OCC(F)(F)F)NC2=O)CS(=O)(=O)C)=N1)C UZLBRYWMTWOHON-MRXNPFEDSA-N 0.000 description 2
- DMAGTECJXQTQRC-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=C(C=CC=C3)C(F)(F)F)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=C(C=CC=C3)C(F)(F)F)NC2=O)CS(=O)(=O)C)=N1)C DMAGTECJXQTQRC-OAQYLSRUSA-N 0.000 description 2
- FYESDHQNROZHKJ-JOCHJYFZSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=C(F)C=C3)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=C(F)C=C3)N(C2=O)C)CS(=O)(=O)C)=N1)C FYESDHQNROZHKJ-JOCHJYFZSA-N 0.000 description 2
- CIBRLAMYIMHXQJ-JOCHJYFZSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=CC=C3F)N(C2=O)C)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=CC=C3F)N(C2=O)C)CS(=O)(=O)C)=N1)C CIBRLAMYIMHXQJ-JOCHJYFZSA-N 0.000 description 2
- YZQGWWIGLBAOLA-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=CC=C3F)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=CC=C3F)NC2=O)CS(=O)(=O)C)=N1)C YZQGWWIGLBAOLA-OAQYLSRUSA-N 0.000 description 2
- QBGPAHADQUPCQR-OAQYLSRUSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=CC=C3OC)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=CC=C3OC)NC2=O)CS(=O)(=O)C)=N1)C QBGPAHADQUPCQR-OAQYLSRUSA-N 0.000 description 2
- CCOBHQPDDLUGDH-JOCHJYFZSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(N(C2=O)C)C=C(C2=CC=CC=C2)C=C3)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(N(C2=O)C)C=C(C2=CC=CC=C2)C=C3)CS(=O)(=O)C)=N1)C CCOBHQPDDLUGDH-JOCHJYFZSA-N 0.000 description 2
- VJEXUKDQVNVAOT-QGZVFWFLSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(NC2=O)C=C(C=C3)C(=O)OCC)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(NC2=O)C=C(C=C3)C(=O)OCC)CS(=O)(=O)C)=N1)C VJEXUKDQVNVAOT-QGZVFWFLSA-N 0.000 description 2
- AYKXELUINCBMHP-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(NC2=O)C=C(C=C3)C2=CC=CC=N2)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(NC2=O)C=C(C=C3)C2=CC=CC=N2)CS(=O)(=O)C)=N1)C AYKXELUINCBMHP-HXUWFJFHSA-N 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- SAESFBYUKKAKTC-SFHVURJKSA-N O(CC)C1=C(OC)C=CC([C@@H](N2C3=C(C(=C(C=N3)C3=CC=CC(F)=C3F)C)NC2=O)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC([C@@H](N2C3=C(C(=C(C=N3)C3=CC=CC(F)=C3F)C)NC2=O)CS(=O)(=O)C)=N1 SAESFBYUKKAKTC-SFHVURJKSA-N 0.000 description 2
- FYESDHQNROZHKJ-QFIPXVFZSA-N O(CC)C1=C(OC)C=CC([C@@H](N2C3=C(C=C(C4=CC=C(F)C=C4)C=C3)N(C2=O)C)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC([C@@H](N2C3=C(C=C(C4=CC=C(F)C=C4)C=C3)N(C2=O)C)CS(=O)(=O)C)=N1 FYESDHQNROZHKJ-QFIPXVFZSA-N 0.000 description 2
- XQDVZRQFKBDCRW-QFIPXVFZSA-N O(CC)C1=C(OC)C=CC([C@@H](N2C3=C(C=C(C=C3)C3=CC=CC=C3OCC)NC2=O)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC([C@@H](N2C3=C(C=C(C=C3)C3=CC=CC=C3OCC)NC2=O)CS(=O)(=O)C)=N1 XQDVZRQFKBDCRW-QFIPXVFZSA-N 0.000 description 2
- FSKGQEHJCKHJPH-OAQYLSRUSA-N O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C(=CC=C3)CC3=CC=CC=C3F)NC2=O)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C(=CC=C3)CC3=CC=CC=C3F)NC2=O)CS(=O)(=O)C)=N1 FSKGQEHJCKHJPH-OAQYLSRUSA-N 0.000 description 2
- GPBNLNWUNNSEEF-JOCHJYFZSA-N O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=CC=C3C(F)(F)F)N(C2=O)C)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC([C@H](N2C3=C(C=C(C=C3)C3=CC=CC=C3C(F)(F)F)N(C2=O)C)CS(=O)(=O)C)=N1 GPBNLNWUNNSEEF-JOCHJYFZSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 210000005091 airway smooth muscle Anatomy 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- QCXJEYYXVJIFCE-UHFFFAOYSA-N para-acetamidobenzoic acid Natural products CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- FEOHYDSNGHIXOM-WLDMJGECSA-N (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)-2-methyloxane-2,4,5-triol Chemical compound CC1(O)[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO FEOHYDSNGHIXOM-WLDMJGECSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- SKNUPXIXICTRJE-UHFFFAOYSA-N 1-butyl-4-chlorobenzene Chemical compound CCCCC1=CC=C(Cl)C=C1 SKNUPXIXICTRJE-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- MCSJGXLZPITMIH-UHFFFAOYSA-N 2-aminobutane-1,1,1-triol Chemical compound CCC(N)C(O)(O)O MCSJGXLZPITMIH-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- QVUNLLWWQKILLR-UHFFFAOYSA-N 2-nitrothiophene-3,4-dicarboxylic acid Chemical compound OC(=O)C1=CSC([N+]([O-])=O)=C1C(O)=O QVUNLLWWQKILLR-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- YGYGASJNJTYNOL-CQSZACIVSA-N 3-[(4r)-2,2-dimethyl-1,1-dioxothian-4-yl]-5-(4-fluorophenyl)-1h-indole-7-carboxamide Chemical compound C1CS(=O)(=O)C(C)(C)C[C@@H]1C1=CNC2=C(C(N)=O)C=C(C=3C=CC(F)=CC=3)C=C12 YGYGASJNJTYNOL-CQSZACIVSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- IGSYEZFZPOZFNC-UHFFFAOYSA-N 4-O-alpha-D-Galactopyranuronosyl-D-galacturonic acid Natural products OC1C(O)C(O)OC(C(O)=O)C1OC1C(O)C(O)C(O)C(C(O)=O)O1 IGSYEZFZPOZFNC-UHFFFAOYSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- XYLLPTJEAUKCAF-UHFFFAOYSA-N 4-nitrothieno[3,4-c]furan-1,3-dione Chemical compound O=C1OC(=O)C2=C([N+](=O)[O-])SC=C21 XYLLPTJEAUKCAF-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZDVWISISGMXFTP-HXUWFJFHSA-N C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=C(C(F)=CC=C3)C)C)NC2=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](N2C3=C(C(=C(C=N3)C3=C(C(F)=CC=C3)C)C)NC2=O)CS(=O)(=O)C)=N1)C ZDVWISISGMXFTP-HXUWFJFHSA-N 0.000 description 1
- WEMTURJXWJFLBA-CYBMUJFWSA-N C(OC1=C(OC)C=CC([C@H](NC2=C(C(=C(C=N2)Br)C)N(=O)=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](NC2=C(C(=C(C=N2)Br)C)N(=O)=O)CS(=O)(=O)C)=N1)C WEMTURJXWJFLBA-CYBMUJFWSA-N 0.000 description 1
- XMHDQANTYBYBGR-LJQANCHMSA-N C(OC1=C(OC)C=CC([C@H](NC2=C(C(=C(C=N2)C2=CC=CC=C2F)C)N(=O)=O)CS(=O)(=O)C)=N1)C Chemical compound C(OC1=C(OC)C=CC([C@H](NC2=C(C(=C(C=N2)C2=CC=CC=C2F)C)N(=O)=O)CS(=O)(=O)C)=N1)C XMHDQANTYBYBGR-LJQANCHMSA-N 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- WEMTURJXWJFLBA-UHFFFAOYSA-N CCOC(N=C(C(CS(C)(=O)=O)NC(C([N+]([O-])=O)=C1C)=NC=C1Br)C=C1)=C1OC Chemical compound CCOC(N=C(C(CS(C)(=O)=O)NC(C([N+]([O-])=O)=C1C)=NC=C1Br)C=C1)=C1OC WEMTURJXWJFLBA-UHFFFAOYSA-N 0.000 description 1
- BHVNDLZDYZHMPG-OAHLLOKOSA-N CCOC(N=C([C@@H](CS(C)(=O)=O)N(CC1=CC=CC(N)=C11)C1=O)C=C1)=C1OC Chemical compound CCOC(N=C([C@@H](CS(C)(=O)=O)N(CC1=CC=CC(N)=C11)C1=O)C=C1)=C1OC BHVNDLZDYZHMPG-OAHLLOKOSA-N 0.000 description 1
- XJZRLHPJXDQISA-LJQANCHMSA-N CCOC1=C(OC)C=CC([C@H](NC2=C(C(=C(C=N2)C2=CC=CC=C2F)C)N)CS(=O)(=O)C)=N1 Chemical compound CCOC1=C(OC)C=CC([C@H](NC2=C(C(=C(C=N2)C2=CC=CC=C2F)C)N)CS(=O)(=O)C)=N1 XJZRLHPJXDQISA-LJQANCHMSA-N 0.000 description 1
- XATALZZHUUMFRT-UHFFFAOYSA-N CCON(C(C(CS(C)(=O)=O)NC(C([N+]([O-])=O)=C1C)=NC=C1C(C=CC=C1)=C1F)C=C1)C=C1OC Chemical compound CCON(C(C(CS(C)(=O)=O)NC(C([N+]([O-])=O)=C1C)=NC=C1C(C=CC=C1)=C1F)C=C1)C=C1OC XATALZZHUUMFRT-UHFFFAOYSA-N 0.000 description 1
- XATALZZHUUMFRT-VQCQRNETSA-N CCON(C([C@@H](CS(C)(=O)=O)NC(C([N+]([O-])=O)=C1C)=NC=C1C(C=CC=C1)=C1F)C=C1)C=C1OC Chemical compound CCON(C([C@@H](CS(C)(=O)=O)NC(C([N+]([O-])=O)=C1C)=NC=C1C(C=CC=C1)=C1F)C=C1)C=C1OC XATALZZHUUMFRT-VQCQRNETSA-N 0.000 description 1
- 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 102000015689 E-Selectin Human genes 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000243251 Hydra Species 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- FTGUEYJWRJZRFP-OAHLLOKOSA-N O(C)C1=CC=C([C@H](N2C(=O)C3=C(N(=O)=O)C=CC=C3C2)CS(=O)(=O)C)N=C1OCC Chemical compound O(C)C1=CC=C([C@H](N2C(=O)C3=C(N(=O)=O)C=CC=C3C2)CS(=O)(=O)C)N=C1OCC FTGUEYJWRJZRFP-OAHLLOKOSA-N 0.000 description 1
- XJZRLHPJXDQISA-UHFFFAOYSA-N O(CC)C1=C(OC)C=CC(C(NC2=C(C(=C(C=N2)C2=CC=CC=C2F)C)N)CS(=O)(=O)C)=N1 Chemical compound O(CC)C1=C(OC)C=CC(C(NC2=C(C(=C(C=N2)C2=CC=CC=C2F)C)N)CS(=O)(=O)C)=N1 XJZRLHPJXDQISA-UHFFFAOYSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 229910020008 S(O) Chemical group 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010053879 Sepsis syndrome Diseases 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 150000001454 anthracenes Chemical class 0.000 description 1
- IMOZEMNVLZVGJZ-QGZVFWFLSA-N apremilast Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-QGZVFWFLSA-N 0.000 description 1
- 229960001164 apremilast Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 150000004074 biphenyls Chemical class 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000003262 carboxylic acid ester group Chemical group [H]C([H])([*:2])OC(=O)C([H])([H])[*:1] 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000006041 cell recruitment Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- MCMSJVMUSBZUCN-YYDJUVGSSA-N chembl285913 Chemical compound C1=2C=C(OC)C(OC)=CC=2CCN(C(N2C)=O)C1=C\C2=N/C1=C(C)C=C(C)C=C1C MCMSJVMUSBZUCN-YYDJUVGSSA-N 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 201000004990 juvenile ankylosing spondylitis Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- SJJJFLXTGHEZJB-UHFFFAOYSA-N methyl 2-(bromomethyl)-6-nitrobenzoate Chemical compound COC(=O)C1=C(CBr)C=CC=C1[N+]([O-])=O SJJJFLXTGHEZJB-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- OCIDXARMXNJACB-UHFFFAOYSA-N n'-phenylethane-1,2-diamine Chemical compound NCCNC1=CC=CC=C1 OCIDXARMXNJACB-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940116353 sebacic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- XQTUSPVIMZCNPC-UHFFFAOYSA-N thieno[3,4-c]furan-1,3-dione Chemical compound S1C=C2C(=O)OC(=O)C2=C1 XQTUSPVIMZCNPC-UHFFFAOYSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229950004127 trequinsin Drugs 0.000 description 1
- 125000002827 triflate group Chemical class FC(S(=O)(=O)O*)(F)F 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
【要約】PDE4阻害剤化合物、その異性体、溶媒和物、重水素化誘導体または薬学的に許容される塩である。該化合物、異性体、溶媒和物、重水素化誘導体およびそれらの薬学的に許容される塩を含む医薬品、ならびに自己免疫疾患や癌のようなPDE4の阻害に関する疾患のための医薬品の製造におけるそれらの使用を含む。【化1】TIFF2023531113000259.tif66165SUMMARY A PDE4 inhibitor compound, its isomers, solvates, deuterated derivatives or pharmaceutically acceptable salts. Pharmaceutical products containing said compounds, isomers, solvates, deuterated derivatives and pharmaceutically acceptable salts thereof and in the manufacture of pharmaceutical products for diseases related to inhibition of PDE4 such as autoimmune diseases and cancer including the use of [Formula 1] TIFF2023531113000259.tif66165
Description
本出願は、2020年2月24日に中国専利局で出願された出願番号が202010114076.2(発明の名称:PDE4阻害剤化合物及びその医薬用途)である中国特許出願、2020年7月28日に中国専利局で出願された出願番号が202010748673.0(発明の名称:PDE4阻害剤化合物及びその医薬用途)である中国特許出願、および2020年8月28日に中国専利局で出願された出願番号が202010881875.2(発明の名称:PDE4阻害剤化合物及びその医薬用途)である中国特許出願に基づく優先権を主張し、それらの全ての開示は、参照として本願に組み込まれる。 This application is a Chinese patent application with application number 202010114076.2 (title of invention: PDE4 inhibitor compound and its medicinal use) filed in China Patent Office on February 24, 2020, a Chinese patent application with application number 202010748673.0 (title of invention: PDE4 inhibitor compound and its medicinal use) filed at China Patent Office on July 28, 2020, and 202 It claims priority from a Chinese patent application with application number 202010881875.2 (Title of Invention: PDE4 Inhibitor Compounds and Medical Uses Thereof) filed with the Chinese Patent Office on Aug. 28, 2000, the entire disclosures of which are incorporated herein by reference.
本発明は、PDE4阻害剤化合物、その異性体、溶媒和物、重水素化誘導体、または該化合物の薬学的に許容される塩、および該化合物またはその塩を活性成分として含む医薬品、ならびに自己免疫疾患や癌のようなPDE4関連疾患の治療薬の製造におけるその使用に関する。 The present invention relates to PDE4 inhibitor compounds, their isomers, solvates, deuterated derivatives, or pharmaceutically acceptable salts of said compounds, and medicaments containing said compounds or salts thereof as active ingredients, and their use in the manufacture of medicaments for the treatment of PDE4-related diseases, such as autoimmune diseases and cancer.
腫瘍壊死因子(TNFα)は、主に単核性食細胞(mononuclear phagocyte)が免疫刺激物に応答する際に放出されるサイトカインである。TNFαは、細胞の分化、リクルート、増殖、およびタンパク質分解などの多くのポロセスを促進することができる。低レベルでは、TNFαは感染物、腫瘍、組織損傷を防止する保護作用がある。TNFαの放出が多すぎると、例えば、哺乳動物やヒトにTNFαを投与した場合、炎症、発熱、心血管作用、出血、血液凝固、および急性感染やショック状態に類似した急性反応を引き起こしたり悪化させたりするなどの疾患を引き起こすこともある。動物体や成人の体内で過剰または制御できないTNFαは、長期にわたり、エンドトキシン血症および/または毒素性ショック症候群、悪液質、成人呼吸窮迫症候群、癌(例えば、固形腫瘍や血液系腫瘍)、心臓疾患(例えばうっ血性心不全)、ウイルス感染症、遺伝性疾患、炎症性疾患、アレルギー性疾患または自己免疫疾患を患っている。 Tumor necrosis factor (TNFα) is a cytokine released primarily by mononuclear phagocytic cells in response to immune stimuli. TNFα can promote many processes such as cell differentiation, recruitment, proliferation, and protein degradation. At low levels, TNFα is protective against infections, tumors, and tissue damage. Too much TNFα release can also cause diseases such as inflammation, fever, cardiovascular effects, hemorrhage, blood clotting, and acute reactions that mimic acute infections and shock conditions, for example, when TNFα is administered to mammals and humans. Excessive or unregulated TNFα in animals and adults has long been associated with endotoxemia and/or toxic shock syndrome, cachexia, adult respiratory distress syndrome, cancer (e.g. solid tumors and hematologic tumors), heart disease (e.g. congestive heart failure), viral infections, genetic diseases, inflammatory diseases, allergic diseases or autoimmune diseases.
癌は特に破壊的な疾患である。血液中のTNFαのレベルの上昇は、癌に罹患するリスクや癌が拡散するリスクがあることを示唆する。一般的に、癌細胞は、健康な生体の循環系で生存できない。その理由の一つは、血管内壁が癌細胞の外部浸透の障壁になることである。研究により、内皮細胞上のELAM-1は、結腸癌細胞のサイトカインで処理された内皮への接着促進を媒介することが明らかになった。 Cancer is a particularly devastating disease. Elevated levels of TNFα in the blood indicate a risk of contracting or spreading cancer. Generally, cancer cells cannot survive in the circulatory system of healthy organisms. One of the reasons is that the inner wall of blood vessels becomes a barrier for cancer cells to permeate to the outside. Studies have shown that ELAM-1 on endothelial cells mediates enhanced adhesion of colon cancer cells to cytokine-treated endothelium.
環状アデノシン一リン酸(cAMP)は多くの疾患や病症で機能する。炎症時に、白血球中のcAMP濃度の上昇は、白血球の活性化を抑制し、その後、TNFαおよびNF-κBなどの炎症調節因子を放出する。また、cAMPのレベルの向上は、気道平滑筋の弛緩にもつながる。 Cyclic adenosine monophosphate (cAMP) functions in many diseases and conditions. During inflammation, elevated cAMP concentrations in leukocytes suppress leukocyte activation, which subsequently releases inflammatory regulators such as TNFα and NF-κB. Increased levels of cAMP also lead to relaxation of airway smooth muscle.
cAMP不活化の主な細胞メカニズムは、環状ヌクレオチドホスポジエステラーゼ(PDE)と呼ばれるアイソザイムファミリーがcAMPを破壊したことに起因する。なお、PDEファミリーには、11個のメンバーが知られている。これまで、PDE4酵素の阻害は、炎症メディエーターの放出抑制および気道平滑筋の弛緩に特に有効であることが実証されているため、PDE4酵素はすでに注目されている医薬品標的の1つになっている。遺伝子コードによって、PDE-4ファミリーは4つのサブタイプ(PDE-4A、B、C、D)に分けることができる。その中で、PDE-4A、PDE-4BおよびPDE-4Dは、炎症細胞(例えばB細胞、T細胞および好中球など)における発現がPDE-4Cより強い。PDE4酵素を阻害すると、cAMPのレベルを上昇させ、それによってTNFαのレベルを調節し、疾患を治療する目的を達成する。 The primary cellular mechanism of cAMP inactivation is attributed to the destruction of cAMP by a family of isoenzymes called cyclic nucleotide phospositases (PDEs). In addition, 11 members are known in the PDE family. To date, inhibition of PDE4 enzymes has been demonstrated to be particularly effective in inhibiting the release of inflammatory mediators and relaxing airway smooth muscle, making PDE4 enzymes already one of the hottest drug targets. According to the genetic code, the PDE-4 family can be divided into four subtypes (PDE-4A, B, C, D). Among them, PDE-4A, PDE-4B and PDE-4D are more strongly expressed in inflammatory cells such as B cells, T cells and neutrophils than PDE-4C. Inhibiting the PDE4 enzyme will increase the level of cAMP, thereby regulating the level of TNFα, with the goal of treating disease.
PDE4酵素を阻害し、cAMPのレベルを上昇させることにより、TNFαのレベルを調節し、例えば、敗血症性ショック、敗血症、エンドトキシンショック、出血性ショック、敗血症症候群、虚血再灌流障害、ミコバクテリウムマラリア感染、髄膜炎、乾癬、うっ血性心不全、線維性疾患、悪液質、移植拒絶、腫瘍、自己免疫異常系疾患、AIDS日和見感染、関節リウマチ、リウマチ性脊椎炎、骨関節炎、その他の炎症性疾患、クローン病、潰瘍性大腸炎、多発性硬化症、全身性エリテマトーデス、アトピー性皮膚炎、らい性結節性紅斑、放射線障害、高濃度酸素による肺損傷などの炎症、感染性疾患、免疫性疾患またはその他の悪性疾患を治療する。 By inhibiting the PDE4 enzyme and increasing the level of cAMP, it modulates the level of TNFα, e.g., septic shock, sepsis, endotoxin shock, hemorrhagic shock, sepsis syndrome, ischemia-reperfusion injury, mycobacterial malaria infection, meningitis, psoriasis, congestive heart failure, fibrotic disease, cachexia, transplant rejection, tumors, autoimmune disorders, AIDS opportunistic infections, rheumatoid arthritis, rheumatoid spine. inflammation, osteoarthritis, other inflammatory diseases, Crohn's disease, ulcerative colitis, multiple sclerosis, systemic lupus erythematosus, atopic dermatitis, erythema nodosum leprosy, radiation injury, high oxygen lung injury, infectious diseases, immune diseases or other malignant diseases.
本発明の一局面は、式(I)で表される構造を有する化合物、およびその異性体、溶媒和物、重水素化誘導体または薬学的に許容される塩を提供することを目的とする。 One aspect of the present invention aims to provide compounds having the structure represented by Formula (I), and isomers, solvates, deuterated derivatives or pharmaceutically acceptable salts thereof.
ただし、
X1は、NまたはCHから選択され;
X2、X3、X4のうちの1つはNから選択され、その他はCHであり;
Xは、O、-N(R6)、-CH(R6)-から選択され;
Rは水素、C1-C3アルキル、C3-C6シクロアルキルから選択され、Rはハロゲンで置換されていてもよく;
R1、R2、R3は、それぞれ独立して、水素、ハロゲン、ヒドロキシル、-CN、-NH2、C1-C6アルキル、C1-6アルコキシ、C1-C6アルキルアミノ、C2-6アルケニル、C3-6シクロアルケニル、3-6員ヘテロシクロアルケニル、C3-C6シクロアルキル、3-6員ヘテロシクロアルキル、フェニル、5-6員ヘテロアリール、-COOR8からなる群から選択され、これらの基は、ハロゲン、C1-C6アルキル、ハロゲン化されていてもよいC1-C6アルキル、C3-C6シクロアルキル、ハロゲン化されていてもよいC3-C6シクロアルキルで置換されていてもよく;
R4、R5は、それぞれ独立して、C1-C6アルキル、C3-C6シクロアルキルからなる群から選択され、R4、R5は、重水素、トリチウム又はハロゲンで置換されていてもよく;
R6は、H、ハロゲン、ヒドロキシル、-CN、-NH2、-COOH、R7-L1-からなる群から選択され、またはC1-6アルキル、C1-C6ヘテロアルキル、C3-C6シクロアルキル、3-6員ヘテロシクロアルキル、フェニル、5-6員ヘテロアリール、-COOR9、-SO2R10、-SO2NHR11、-NHCONHR12からなる群から選択され、これらの基は、ハロゲン、C1-C6アルキル、ハロゲン化されていてもよいC1-C6アルキル、C3-C6シクロアルキル、ハロゲン化されていてもよいC3-C6シクロアルキルで置換されていてもよく;
R7は、C3-C6シクロアルキル、3-6員ヘテロシクロアルキル、3-6員ヘテロシクロアルケニル、フェニル、5-6員ヘテロアリール、-COOR8からなる群から選択され、R7は、ハロゲン、C1-C6アルキル、C3-C6シクロアルキルで置換されていてもよく;
L1は、-CH2-、-CH2CH2-、O、S、NHからなる群から選択され;
R8、R9、R10、R11、R12は、C1-C6アルキル、ハロゲン化C1-C6アルキル、C3-C6シクロアルキルである。
however,
X 1 is selected from N or CH;
one of X 2 , X 3 , X 4 is selected from N and the others are CH;
X is selected from O, -N(R 6 ), -CH(R 6 )-;
R is selected from hydrogen, C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl, R is optionally substituted with halogen;
R 1 、R 2 、R 3は、それぞれ独立して、水素、ハロゲン、ヒドロキシル、-CN、-NH 2 、C1-C6アルキル、C1-6アルコキシ、C1-C6アルキルアミノ、C2-6アルケニル、C3-6シクロアルケニル、3-6員ヘテロシクロアルケニル、C3-C6シクロアルキル、3-6員ヘテロシクロアルキル、フェニル、5-6員ヘテロアリール、-COOR 8からなる群から選択され、これらの基は、ハロゲン、C1-C6アルキル、ハロゲン化されていてもよいC1-C6アルキル、C3-C6シクロアルキル、ハロゲン化されていてもよいC3-C6シクロアルキルで置換されていてもよく;
R 4 and R 5 are each independently selected from the group consisting of C1-C6 alkyl and C3-C6 cycloalkyl, and R 4 and R 5 are optionally substituted with deuterium, tritium or halogen;
R 6は、H、ハロゲン、ヒドロキシル、-CN、-NH 2 、-COOH、R 7 -L 1 -からなる群から選択され、またはC1-6アルキル、C1-C6ヘテロアルキル、C3-C6シクロアルキル、3-6員ヘテロシクロアルキル、フェニル、5-6員ヘテロアリール、-COOR 9 、-SO 2 R 10 、-SO 2 NHR 11 、-NHCONHR 12からなる群から選択され、これらの基は、ハロゲン、C1-C6アルキル、ハロゲン化されていてもよいC1-C6アルキル、C3-C6シクロアルキル、ハロゲン化されていてもよいC3-C6シクロアルキルで置換されていてもよく;
R 7 is selected from the group consisting of C3-C6 cycloalkyl, 3-6 membered heterocycloalkyl, 3-6 membered heterocycloalkenyl, phenyl, 5-6 membered heteroaryl, —COOR 8 , R 7 is optionally substituted with halogen, C1-C6 alkyl, C3-C6 cycloalkyl;
L 1 is selected from the group consisting of -CH 2 -, -CH 2 CH 2 -, O, S, NH;
R 8 , R 9 , R 10 , R 11 , R 12 are C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C6 cycloalkyl.
好ましくは、式(I)で表される構造を有する化合物、およびその異性体、溶媒和物、重水素化誘導体または薬学的に許容される塩であり、ここで、Xは、 Preferred are compounds having the structure represented by formula (I), and isomers, solvates, deuterated derivatives or pharmaceutically acceptable salts thereof, wherein X is
からなる群から選択される。 selected from the group consisting of
好ましくは、式(I)で表される構造を有する化合物、およびその異性体、溶媒和物、重水素化誘導体または薬学的に許容される塩であり、ここで、R1、R2、R3は、それぞれ独立して、 Preferred are compounds having the structure represented by formula (I), and isomers, solvates, deuterated derivatives or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 are each independently:
からなる群から選択され、
これらの基は、ハロゲン、-OH、-NH2、-CN、C1-C6アルキル、ハロゲン化されていてもよいC1-C6アルキル、C3-C6シクロアルキル、ハロゲン化されていてもよいC3-C6シクロアルキルで置換されていてもよい。
is selected from the group consisting of
These groups may be substituted with halogen, —OH, —NH 2 , —CN, C1-C6 alkyl, optionally halogenated C1-C6 alkyl, C3-C6 cycloalkyl, optionally halogenated C3-C6 cycloalkyl.
好ましくは、式(I)で表される構造を有する化合物、およびその異性体、溶媒和物、重水素化誘導体または薬学的に許容される塩であり、ここで、前記化合物は、以下の構造を含む。
3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-エチルフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-イソプロピルフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-メトキシフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-メトキシフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(2-(トリフルオロメチル)フェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-2-(3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-2-オキソ-2,3-ジヒドロ-1H-イミダゾ[4,5-b]ピリジン-6-イル)ベンゾニトリル;
(R)-2-(3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-2-オキソ-2,3-ジヒドロ-1H-イミダゾ[4,5-b]ピリジン-6-イル)ベンゾニトリル;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1,7-ジメチル-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-(2-メトキシエチル)-7-メチル-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-1,7-ジメチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-1,7-ジメチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,6-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)(S)-6-(2,6-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,3-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-6-(2,3-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-ジメチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,5-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,4-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,4,5-トリフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-6-(2,5-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,4-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,5-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,3-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,6-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(4-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(5-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-5-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-3-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-4-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-5-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-3-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-4-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(5-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(4-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(6-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-エチル-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-エチル-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-エチル-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-エチル-7-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1-(2,2,2-トリフルオロエチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1-(2,2,2-トリフルオロエチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1-(2,2,2-トリフルオロエチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1-(2,2,2-トリフルオロエチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(o-メチルフェニル)-1-(2,2,2-トリフルオロエチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-1,7-ジメチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1,7-ジメチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-1,7-ジメチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1,7-ジメチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-イソプロポキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-イソプロポキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-イソプロポキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-イソプロポキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-ブロモ-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル) -6-フェニル-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-エチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-エチルフェニル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-メトキシフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-メトキシフェニル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-(トリフルオロメチル)フェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-(トリフルオロメチル)フェニル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-シクロプロピルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,6-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,6-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,3-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,3-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,5-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,5-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,4-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,4-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,4,5-トリフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,4,5-トリフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-6-(2,5-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,4-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,4-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,5-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,5-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,3-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,3-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,6-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,6-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(4-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(4-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(5-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(5-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(3-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(3-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-5-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-5-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-4-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-4-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(5-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(5-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(4-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(4-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(6-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(ピリジン-2-イル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-エチル-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-(2-メトキシエチル)-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-5-ブロモ-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-フェニル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-フェニル-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロフェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(R)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(4-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(R)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(4-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-5-(4-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(R)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-5-(4-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(o-メチルフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(o-メチルフェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(R)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(o-メチルフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-クロロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-メトキシフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-メトキシフェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(R)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-メトキシフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-(トリフルオロメチル)フェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-(トリフルオロメチル)フェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-シクロプロピルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-イソプロピルフェニル)-4-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-エチルフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-エチルフェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,3-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,3-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,6-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,6-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,4-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,4-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,4,5-トリフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,4,5-トリフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,5-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,5-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,4-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,4-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,5-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,5-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,3-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,3-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,6-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(4-フルオロ-2-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(4-フルオロ-2-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(5-フルオロ-2-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(5-フルオロ-2-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(3-フルオロ-2-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(3-フルオロ-2-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル--1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-5-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-5-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-3-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-3-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-4-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-4-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-5-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-5-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-3-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-4-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-4-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(5-フルオロ-2-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(5-フルオロ-2-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(4-フルオロ-2-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(4-フルオロ-2-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(6-フルオロ-2-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(6-フルオロ-2-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-エトキシフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(R)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-エトキシフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(ピリジン-2-イル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(R)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(ピリジン-2-イル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-5-(ピリジン-2-イル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-エチル-5-(ピリジン-2-イル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-(2-メトキシエチル)-5-(ピリジン-2-イル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(4-フルオロ-2-メチルフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(4-フルオロ-2-メチルフェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロ-5-メチルフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロ-5-メチルフェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4-(2-メトキシフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4-(o-メチルフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4-(2-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4-フェニル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4-(2-フルオロベンジル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-3-シクロプロピル-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-3-シクロプロピル-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-ブロモ-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-(2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-3-シクロプロピル-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(トリフルオロメチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-エチル1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-2-オキソ-2,3-ジヒドロ-1H-ベンゾ[d]イミダゾール-5-カルボキシレート;
(S)-イソプロピル1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-2-オキソ-2,3-ジヒドロ-1H-ベンゾ[d]イミダゾール-5-カルボキシレート;および
(S)-2,2,2-トリフルオロエチル1-(1-(1-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-2-オキソ-2,3-ジヒドロ-1H-ベンゾ[d]イミダゾール-5-カルボキシレート。
Preferred are compounds having the structure represented by Formula (I), and isomers, solvates, deuterated derivatives or pharmaceutically acceptable salts thereof, wherein said compounds include the structures:
3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(o-methylphenyl)-1H-imidazo[4,5b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(o-methylphenyl)-1H-imidazo[4,5b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-ethylphenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-isopropylphenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-methoxyphenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-methoxyphenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(2-(trifluoromethyl)phenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-2-(3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)benzonitrile;
(R)-2-(3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)benzonitrile;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1,7-dimethyl-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-(2-methoxyethyl)-7-methyl-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-1,7-dimethyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-1,7-dimethyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,6-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)(S)-6-(2,6-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,3-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-6-(2,3-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-dimethyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,5-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,4-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,4,5-trifluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-6-(2,5-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,4-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,5-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,3-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,6-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(4-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(5-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-5-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-3-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-4-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-5-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-3-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-4-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(5-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(4-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(6-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-ethyl-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-ethyl-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-ethyl-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-ethyl-7-methyl-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(o-methylphenyl)-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-1,7-dimethyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1,7-dimethyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-1,7-dimethyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1,7-dimethyl-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-isopropoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-isopropoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-isopropoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-isopropoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-phenyl-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-ethylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-ethylphenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-methoxyphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-methoxyphenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-(trifluoromethyl)phenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-(trifluoromethyl)phenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-cyclopropylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,6-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,6-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,3-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,3-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,5-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,5-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,4-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,4-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,4,5-trifluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,4,5-trifluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-6-(2,5-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,4-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,4-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,5-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,5-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,3-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,3-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,6-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,6-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(4-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(4-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(5-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(5-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(3-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(3-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-5-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-5-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-4-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-4-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(5-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(5-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(4-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(4-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(6-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(pyridin-2-yl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-ethyl-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-(2-methoxyethyl)-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-5-bromo-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-phenyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-phenyl-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluorophenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(R)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(4-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one;
(R)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(4-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-5-(4-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one;
(R)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-5-(4-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(o-methylphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(o-methylphenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(R)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(o-methylphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-chlorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-methoxyphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-methoxyphenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(R)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-methoxyphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-(trifluoromethyl)phenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-cyclopropylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-isopropylphenyl)-4-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-ethylphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-ethylphenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,3-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,3-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,6-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,6-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,4-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,4-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,4,5-trifluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,4,5-trifluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,5-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,5-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,4-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,4-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,5-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,5-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,3-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,3-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,6-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(4-fluoro-2-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(4-fluoro-2-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(5-fluoro-2-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(5-fluoro-2-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(3-fluoro-2-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(3-fluoro-2-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl--1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-5-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-5-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-3-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-3-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-4-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-4-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-5-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-5-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-3-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-4-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-4-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(5-fluoro-2-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(5-fluoro-2-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(4-fluoro-2-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(4-fluoro-2-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(6-fluoro-2-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(6-fluoro-2-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-ethoxyphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(R)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-ethoxyphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(pyridin-2-yl)-1H-benzo[d]imidazol-2(3H)-one;
(R)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(pyridin-2-yl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-5-(pyridin-2-yl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-ethyl-5-(pyridin-2-yl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-(2-methoxyethyl)-5-(pyridin-2-yl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(4-fluoro-2-methylphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(4-fluoro-2-methylphenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluoro-5-methylphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluoro-5-methylphenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4-(2-methoxyphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4-(o-methylphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4-(2-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4-phenyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4-(2-fluorobenzyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-3-cyclopropyl-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-3-cyclopropyl-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-bromo-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-(2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-3-cyclopropyl-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(trifluoromethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-ethyl 1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate;
(S)-isopropyl 1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate; and (S)-2,2,2-trifluoroethyl 1-(1-(1-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-2 - oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate.
本発明の他の一局面は、式(II)で表される構造を有する化合物、およびその異性体、溶媒和物、重水素化誘導体または薬学的に許容される塩を提供することを目的とする。 Another aspect of the present invention aims to provide compounds having the structure represented by formula (II), and isomers, solvates, deuterated derivatives or pharmaceutically acceptable salts thereof.
ただし、
Y1は、NまたはCHから選択され;
Y2、Y3、Y4のうちの1つはNから選択され、その他はCHであり;
R13は、C1-C3アルキル、C1-C6シクロアルキルからなる群から選択され、R13はハロゲンで置換されていてもよく;
R14、R15、R16は、それぞれ独立して、水素、ハロゲン、ヒドロキシル、CN、-NO2、-NH2、C1-C6アルキル、C1-C6アルコキシ、C1-C6アルキルアミノ、C1-C6アルキルアミド、C3-C6シクロアルキルアミド、C2-C6アルケニル、C3-C6シクロアルケニル、3-6員ヘテロシクロアルケニル、C3-C6シクロアルキル、3-6員ヘテロシクリル、フェニル、5-6員ヘテロアリールからなる群から選択され、これらの基は、ハロゲン、C3-C6シクロアルキル、C1-C8アルコキシ、C3-C8シクロアルコキシ、3-12員ヘテロシクリル、C1-C8アルキルアミノ、ジ(C1-C8アルキル)置換アミノ、フェニル、5-6員ヘテロアリールで置換されていてもよく;
R17、R18は、それぞれ独立して、C1-C6アルキル、C3-C6シクロアルキルからなる群から選択され、R17、R18は、重水素、トリチウム又はハロゲンで置換されていてもよい。
however,
Y 1 is selected from N or CH;
one of Y 2 , Y 3 , Y 4 is selected from N and the others are CH;
R 13 is selected from the group consisting of C1-C3 alkyl, C1-C6 cycloalkyl, and R 13 is optionally substituted with halogen;
R 14 、R 15 、R 16は、それぞれ独立して、水素、ハロゲン、ヒドロキシル、CN、-NO 2 、-NH 2 、C1-C6アルキル、C1-C6アルコキシ、C1-C6アルキルアミノ、C1-C6アルキルアミド、C3-C6シクロアルキルアミド、C2-C6アルケニル、C3-C6シクロアルケニル、3-6員ヘテロシクロアルケニル、C3-C6シクロアルキル、3-6員ヘテロシクリル、フェニル、5-6員ヘテロアリールからなる群から選択され、これらの基は、ハロゲン、C3-C6シクロアルキル、C1-C8アルコキシ、C3-C8シクロアルコキシ、3-12員ヘテロシクリル、C1-C8アルキルアミノ、ジ(C1-C8アルキル)置換アミノ、フェニル、5-6員ヘテロアリールで置換されていてもよく;
R 17 and R 18 are each independently selected from the group consisting of C1-C6 alkyl and C3-C6 cycloalkyl, and R 17 and R 18 are optionally substituted with deuterium, tritium or halogen.
好ましくは、式(II)で表される構造を有する化合物、およびその異性体、溶媒和物、重水素化誘導体または薬学的に許容される塩であり、ここで、前記化合物は、以下の構造を含む。
(S)-N-(2-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-オキソイソインドリン-4-イル)アセトアミド;
(R)-N-(2-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-オキソイソインドリン-4-イル)アセトアミド;
(S)-N-(2-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-オキソイソインドリン-4-イル)シクロプロパンカルボキサミド;
(R)-N-(2-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-オキソイソインドリン-4-イル)シクロプロパンカルボキサミド;
(S)-N-(2-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-オキソイソインドリン-4-イル)プロピオンアミド;または
(R)-N-(2-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-オキソイソインドリン-4-イル)プロピオンアミド。
Preferred are compounds having the structure represented by Formula (II), and isomers, solvates, deuterated derivatives or pharmaceutically acceptable salts thereof, wherein said compounds include the structures:
(S)-N-(2-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-oxoisoindolin-4-yl)acetamide;
(R)-N-(2-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-oxoisoindolin-4-yl)acetamide;
(S)-N-(2-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-oxoisoindolin-4-yl)cyclopropanecarboxamide;
(R)-N-(2-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-oxoisoindolin-4-yl)cyclopropanecarboxamide;
(S)-N-(2-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-oxoisoindolin-4-yl)propionamide; or (R)-N-(2-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-oxoisoindolin-4-yl)propionamide.
本発明の他の一局面は、式(III)で表される構造を有する化合物、およびその異性体、溶媒和物、重水素化誘導体、ならびにそれらの薬学的に許容される塩を提供することを目的とする。 Another aspect of the present invention aims to provide compounds having the structure represented by Formula (III), and isomers, solvates, deuterated derivatives thereof, and pharmaceutically acceptable salts thereof.
ただし、
R19は、C1-C3アルキル、C3-C6シクロアルキルからなる群から選択され、R19はハロゲンで置換されていてもよく;
R20、R21は、水素、ハロゲン、C1-C8アルキル、C1-C8アルコキシ、ヒドロキシル、シアノ、ニトロ、-NHC(O)R26、-NHSO2R26または-NR24R25からなる群からそれぞれ選択され;
R22、R23は、それぞれ独立して、C1-C6アルキルからなる群から選択され、R22、R23は、重水素、トリチウム又はハロゲンで置換されていてもよく;
R24、R25は、水素、C1-C8アルキル、C6-C12アリール、C(O)R26、SO2R26からなる群からそれぞれ選択され、或いは、R24、R25は、それらが結合されたNとともに4-8員環または-CH2CH2ZCH2CH2-を形成し;
Zは、O、S、NR26からなる群から選択され;
R26は、水素、C1-C6アルキル、C3-C6シクロアルキル、C1-C8アルキルアミノであり、R26は、ハロゲン、C1-C8アルコキシ、C3-C8シクロアルコキシ、3-12員ヘテロシクリル、C1-C8アルキルアミノ、ジ(C1-C8アルキル)置換アミノで置換されていてもよい。
however,
R 19 is selected from the group consisting of C1-C3 alkyl, C3-C6 cycloalkyl, and R 19 is optionally substituted with halogen;
R 20 , R 21 are each selected from the group consisting of hydrogen, halogen, C1-C8 alkyl, C1-C8 alkoxy, hydroxyl, cyano, nitro, —NHC(O)R 26 , —NHSO 2 R 26 or —NR 24 R 25 ;
R 22 , R 23 are each independently selected from the group consisting of C1-C6 alkyl, and R 22 , R 23 are optionally substituted with deuterium, tritium or halogen;
R 24 , R 25 are each selected from the group consisting of hydrogen, C1-C8 alkyl, C6-C12 aryl, C(O)R 26 , SO 2 R 26 , or R 24 , R 25 together with the N to which they are attached form a 4-8 membered ring or -CH 2 CH 2 ZCH 2 CH 2 -;
Z is selected from the group consisting of O, S, NR26 ;
R 26 is hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C8 alkylamino, and R 26 is optionally substituted with halogen, C1-C8 alkoxy, C3-C8 cycloalkoxy, 3-12 membered heterocyclyl, C1-C8 alkylamino, di(C1-C8 alkyl)-substituted amino.
好ましくは、式(III)で表される構造を有する化合物、およびその異性体、溶媒和物、重水素化誘導体または薬学的に許容される塩であり、ここで、前記化合物は、以下の構造を含むが、これらに限定されない。
5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-ニトロ-4H-チエノ[3,4-c]ピロール-4,6(5H)-ジオン;
(S)-5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-ニトロ-4H-チエノ[3,4-c]ピロール-4,6(5H)-ジオン;
(S)-1-アミノ-5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4H-チエノ[3,4-c]ピロール-4,6(5H)-ジオン;
N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)アセトアミド;
(S)-N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)アセトアミド;
(R)-N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)アセトアミド;
(S)-N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)プロピオンアミド;
(S)-N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)シクロプロパンカルボキサミド;
(S)-2-(ジメチルアミノ)-N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)アセトアミド;
(S)-2-(ジエチルアミノ)-N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)アセトアミド;
(S)-N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)-2-(ピペリジン-1-イル)アセトアミド;
(S)-N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)-2-(ピロリジン-1-イル)アセトアミド;または
(S)-N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)-2-モルホリノアセトアミド。
Preferred are compounds having the structure represented by formula (III), and isomers, solvates, deuterated derivatives or pharmaceutically acceptable salts thereof, wherein said compounds include, but are not limited to the following structures:
5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-nitro-4H-thieno[3,4-c]pyrrole-4,6(5H)-dione;
(S)-5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-nitro-4H-thieno[3,4-c]pyrrole-4,6(5H)-dione;
(S)-1-amino-5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4H-thieno[3,4-c]pyrrole-4,6(5H)-dione;
N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)acetamide;
(S)-N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)acetamide;
(R)-N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)acetamide;
(S)-N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)propionamide;
(S)-N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)cyclopropanecarboxamide;
(S)-2-(dimethylamino)-N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)acetamide;
(S)-2-(diethylamino)-N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)acetamide;
(S)-N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)-2-(piperidin-1-yl)acetamide;
(S)-N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)-2-(pyrrolidin-1-yl)acetamide; or (S)-N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)- 2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)-2-morpholinoacetamide.
専門用語
「アルキル」という用語は、分子鎖に1~12個の炭素原子を有する直鎖または分岐鎖のアルキル基を意味し、アルキルの例として、メチル(Me)、エチル(Et)、n-プロピル、イソプロピル、ブチル、イソブチル、sec-ブチル、tert-ブチル(t-Bu)、ペンチル、イソペンチル、tert-ペンチル、ヘキシル、イソヘキシル、および当業者や本文による教示により上記の例のいずれかに相当すると考えられるものなどが挙げられる。
Terminology The term "alkyl" means a straight or branched chain alkyl group having from 1 to 12 carbon atoms in the molecular chain, examples of alkyl being methyl (Me), ethyl (Et), n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl (t-Bu), pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and any of the above examples that would be considered equivalent by those skilled in the art or by teaching in the text. mentioned.
「アルコキシ」という用語は、酸素原子に結合している上記のように定義されたアルキル基を意味する。アルコキシ基は、酸素原子を介して母体構造に結合している。 The term "alkoxy" means an alkyl group as defined above attached to an oxygen atom. Alkoxy groups are attached to the parent structure through an oxygen atom.
「アルケニル」という用語は、少なくとも2つの炭素原子と少なくとも1つの炭素-炭素二重結合からなる上記のように定義されたアルキル基を意味し、例えばビニル、1-プロペニル、2-プロペニルなどがある。好ましくはC2-10アルケニル、より好ましくはC2-6アルケニル、最も好ましくはC2-4アルケニル、もっと好ましくはビニルである。アルケニル基は置換されていても置換されていなくてもよい。アルケニル基は置換されている場合、置換基が、それぞれ独立して、アルキル、アルコキシ、アルキルアミノ、ハロゲン、ヒドロキシル、シクロアルキル、ヘテロシクロアルキル、ヘテロシクロアルコキシからなる群から選択される1つ以上の基であることが好ましい。 The term "alkenyl" means an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, and includes, for example, vinyl, 1-propenyl, 2-propenyl, and the like. Preferably C2-10 alkenyl, more preferably C2-6 alkenyl, most preferably C2-4 alkenyl, more preferably vinyl. Alkenyl groups can be substituted or unsubstituted. When the alkenyl group is substituted, it is preferred that each substituent is independently one or more groups selected from the group consisting of alkyl, alkoxy, alkylamino, halogen, hydroxyl, cycloalkyl, heterocycloalkyl, heterocycloalkoxy.
「アミノ」という用語は、-NH2基、或いはモノまたはジ-アルキルアミノ基を意味する。 The term "amino" means a -NH2 group, or a mono- or di-alkylamino group.
「シクロアルキル」という用語は、環に当たり3~12個の炭素原子を有する、飽和および部分飽和の、単環式、縮合多環式、架橋多環式、またはスピロ多環式の炭素環を意味する。シクロアルキルの例示的な例としては、 The term "cycloalkyl" means saturated and partially saturated monocyclic, fused-polycyclic, bridged-polycyclic, or spiro-polycyclic carbocyclic rings having from 3 to 12 carbon atoms per ring. Illustrative examples of cycloalkyl are:
を適切に結合したものが挙げられる。 properly combined.
「ヘテロアリール」という用語は、単環式、縮合二環式または縮合多環式の芳香族複素環(環構造は、炭素原子と、窒素、酸素および硫黄からなる群から選択される4個までのヘテロ原子とから選択される環原子を有する)を指し、各複素環は3~12個の環原子を有する。ヘテロアリールの例示的な例としては、 The term "heteroaryl" refers to a monocyclic, fused bicyclic or fused polycyclic aromatic heterocycle (the ring structure has ring atoms selected from carbon atoms and up to 4 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur), each heterocycle having from 3 to 12 ring atoms. Illustrative examples of heteroaryl are:
を適切に結合したものが挙げられる。 properly combined.
「アリール」という用語は、窒素、酸素、硫黄などのヘテロ原子を含まず、C5-C20を含む単環式、縮合二環式または縮合多環式の芳香環を意味する。典型的な芳香環としては、ベンゼンに由来する残基、置換ベンゼン、ナフタレン、アントラセン、ビフェニルなどが挙げられるが、これらに限定されない。 The term "aryl" means a monocyclic, fused bicyclic or fused polycyclic aromatic ring containing C5-C20 without heteroatoms such as nitrogen, oxygen or sulfur. Typical aromatic rings include, but are not limited to, residues derived from benzene, substituted benzenes, naphthalenes, anthracenes, biphenyls, and the like.
「ヘテロシクリル」という用語は、飽和または部分不飽和の単環式または多環式の環状炭化水素置換基を意味する。該ヘテロシクロアルキルは3~20個の環原子を含み、そのうち、1つ以上の環原子が窒素、酸素、またはS(O)m(mは0~2の整数)から選択されるヘテロ原子であり、残りの環原子が炭素である。好ましくは、3~12個の環原子を含み、そのうち、1~4個のヘテロ原子を含み、より好ましくは、ヘテロシクロアルキル環は、3~10個の環原子を含み、更に好ましくは、ヘテロシクロアルキル環は、5~6個の環原子を含む。単環式のヘテロシクロアルキルの例は、ピロリジニル基、ピペリジニル基、モルホリニル基、テトラヒドロフラニル基などを含むが、これらに限定されない。多環式ヘテロシクロアルキルには、スピロ環、縮合環、架橋環のヘテロシクロアルキルが含まれる。ヘテロ環は置換されていてもよく、置換されていなくてもよく、置換されている場合、置換基は、アルキル基、ハロゲン化アルキル基、アルコキシ基、アルキルアミノ基、ハロゲン、水酸基、アミノ基、オキソ基、アルキルアミノ基、シクロアルキル基、ヘテロシクロアルキル基、ヘテロシクロアルコキシ基、ヒドロキシアルキル基、カルボキシル基、又はカルボン酸エステル基からなる群から独立に選択される1つ以上の基であることが好ましい。 The term "heterocyclyl" means a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent. The heterocycloalkyl contains 3 to 20 ring atoms, of which one or more ring atoms are heteroatoms selected from nitrogen, oxygen, or S(O)m, where m is an integer from 0 to 2, and the remaining ring atoms are carbon. Preferably, the heterocycloalkyl ring contains 3 to 12 ring atoms, of which 1 to 4 heteroatoms, more preferably the heterocycloalkyl ring contains 3 to 10 ring atoms, and still more preferably the heterocycloalkyl ring contains 5 to 6 ring atoms. Examples of monocyclic heterocycloalkyl include, but are not limited to, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydrofuranyl, and the like. Polycyclic heterocycloalkyls include spiro-, fused-, and bridged-ring heterocycloalkyls. The heterocycle may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more groups independently selected from the group consisting of an alkyl group, a halogenated alkyl group, an alkoxy group, an alkylamino group, a halogen, a hydroxyl group, an amino group, an oxo group, an alkylamino group, a cycloalkyl group, a heterocycloalkyl group, a heterocycloalkoxy group, a hydroxyalkyl group, a carboxyl group, or a carboxylic acid ester group.
「ハロゲン」という用語は、塩素、フッ素、臭素、またはヨウ素を意味する。「ハロゲン化」という用語は、塩素化、フッ素化、臭素化、またはヨウ素化を意味する。「ハロアルキル」という用語は、1つ以上のハロゲン原子で置換された上記で定義されたアルキル基を意味する。「ハロゲン化アルキル基」という用語は、1つ以上のハロゲン原子で置換された上記のように定義されたアルキル基を意味する。 The term "halogen" means chlorine, fluorine, bromine or iodine. The term "halogenated" means chlorinated, fluorinated, brominated, or iodinated. The term "haloalkyl" means an alkyl group as defined above substituted with one or more halogen atoms. The term "halogenated alkyl group" means an alkyl group, as defined above, substituted with one or more halogen atoms.
「薬学的に許容される担体、希釈剤または賦形剤」としては、限定されないが、アメリカ食品医薬品局によってヒトまたは動物への使用が承認された、アジュバント、担体、賦形剤、流動促進剤、甘味料、希釈剤、防腐剤、染料/着色剤、増味剤、界面活性剤、湿潤剤、分散剤、懸濁剤、安定剤、等張剤、溶剤または乳化剤などの医薬組成物の調製に対して副作用がないものが挙げられる。 "Pharmaceutically acceptable carriers, diluents or excipients" include, but are not limited to, adjuvants, carriers, excipients, glidants, sweeteners, diluents, preservatives, dyes/colorants, flavoring agents, surfactants, wetting agents, dispersing agents, suspending agents, stabilizers, isotonic agents, solvents or emulsifiers that are approved for human or animal use by the U.S. Food and Drug Administration and have no adverse effects on the preparation of pharmaceutical compositions.
「薬学的に許容される塩」には、「薬学的に許容される酸付加塩」及び「薬学的に許容される塩基付加塩」が含まれる。 "Pharmaceutically acceptable salts" include "pharmaceutically acceptable acid addition salts" and "pharmaceutically acceptable base addition salts."
「薬学的に許容される酸付加塩」とは、遊離塩基の生物学的有効性及び特性を保持する塩を意味し、上記の酸付加塩は、無機酸または有機酸からなり、生物学的面または他の面で好ましいものである。上記の無機酸としては、例えば、塩酸、臭化水素酸、硫酸、硝酸、リン酸などが挙げられるが、これらに限定されない。上記の有機酸としては、例えば、酢酸、2,2-ジクロロ酢酸、アジピン酸、アルギン酸、アスコルビン酸、アスパラギン酸、ベンゼンスルホン酸、安息香酸、4-アセトアミノ安息香酸、カンファー酸、カンファー-10-スルホン酸、デカン酸、カプロン酸、オクタン酸、炭酸、桂皮酸、クエン酸、シクロヘキシルスルファミン酸、ドデシル硫酸、エタン-1,2-ジスルホン酸、エタンスルホン酸、2-ヒドロキシエタンスルホン酸、ギ酸、フマル酸、粘液酸、ゲンチジン酸、グルコヘプトン酸、グルコン酸、グルクロン酸、グルタミン酸、グルタル酸、2-オキソグルタル酸、グリセロリン酸、グリコール酸、馬尿酸、イソ酪酸、乳酸、ジガラクツロン酸、ラウリン酸、マレイン酸、リンゴ酸、マロン酸、扁桃酸、メタンスルホン酸、粘液酸、ナフタレン-1,5-ジスルホン酸、ナフタレン-2-スルホン酸、1-ヒドロキシ-2-ナフトエ酸、ニコチン酸、オレイン酸、オロチン酸、シュウ酸、パルミチン酸、パモ酸、プロピオン酸、ピログルタミン酸、ピルビン酸、サリチル酸、4-アミノサリチル酸、セバシン酸、ステアリン酸、コハク酸、酒石酸、チオシアン酸、p-トルエンスルホン酸、トリフルオロ酢酸、ウンデセン酸などが挙げられるが、これらに限定されない。 "Pharmaceutically acceptable acid addition salt" means a salt that retains the biological effectiveness and properties of the free base, said acid addition salts consisting of inorganic or organic acids, which are biologically or otherwise preferred. Examples of the inorganic acid include, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Examples of the above organic acids include acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetaminobenzoic acid, camphoric acid, camphor-10-sulfonic acid, decanoic acid, caproic acid, octanoic acid, carbonic acid, cinnamic acid, citric acid, cyclohexylsulfamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethyl Tansulfonic acid, formic acid, fumaric acid, mucic acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxoglutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic acid, digalacturonic acid, lauric acid, maleic acid, malic acid, malonic acid, tonsillic acid, methanesulfonic acid, mucic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid acids, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, undecenoic acid, and the like.
「薬学的に許容される塩基付加塩」とは、遊離酸の生物学的有効性および特性を保持する塩を意味し、上記の塩基付加塩は、生物学的面または他の面で好ましいものである。これらの塩は、遊離酸に無機塩基又は有機塩基を添加することにより調製される。無機塩基由来の塩としては、ナトリウム、カリウム、リチウム、アンモニウム、カルシウム、マグネシウム、鉄、亜鉛、銅、マンガン、アルミニウムの塩などが挙げられるが、これらに限定されない。好ましい無機塩は、アンモニウム塩、ナトリウム塩、カリウム塩、カルシウム塩及びマグネシウム塩である。有機塩基由来の塩としては、第1級アミン、第2級アミン及び第3級アミンの塩、天然置換アミンを含む置換アミン、シクロアミン及び塩基性イオン交換樹脂の塩を含み、例えば、アンモニア、イソプロピルアミン、トリメチルアミン、ジエチルアミン、トリエチルアミン、トリプロピルアミン、ジエタノールアミン、エタノールアミン、ジメチルアミノエタノール、2-ジメチルエタノール、2-ジエチルアミノエタノール、ジシクロヘキシルアミン、リジン、アルギニン、ヒスチジン、カフェイン、プロカイン、ヒドラバミン(hydrabamine)、コリン、ベタイン、ベンジルアミン、フェニルエチレンジアミン、エチレンジアミン、グルコサミン、メチルグルコサミン、テオブロミン、トリエタノールアミン、アミノブタントリオール、プリン、ピペラジン、ピペリジン、N-エチルピペリジン、およびポリアミン樹脂などが挙げられるが、これらに限定されない。特に好ましい有機塩基は、イソプロピルアミン、ジエチルアミン、エタノールアミン、トリメチルアミン、ジシクロヘキシルアミン、コリン及びカフェインである。 "Pharmaceutically acceptable base addition salt" means a salt that retains the biological effectiveness and properties of the free acid, and base addition salts described above are biologically or otherwise preferred. These salts are prepared by adding an inorganic or organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts, and the like. Preferred inorganic salts are ammonium, sodium, potassium, calcium and magnesium salts. Salts derived from organic bases include salts of primary, secondary and tertiary amines, substituted amines including naturally substituted amines, cycloamines and salts of basic ion exchange resins such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, dimethylaminoethanol, 2-dimethylethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydra. Hydrabamine, choline, betaine, benzylamine, phenylethylenediamine, ethylenediamine, glucosamine, methylglucosamine, theobromine, triethanolamine, aminobutanetriol, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like. Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine.
「医薬組成物」とは、本発明の化合物と、当該技術分野で一般的に許容される媒体とからなる製剤を指し、前記媒体は、哺乳動物(ヒトなど)に生物活性化合物を送達するための媒体を指す。このような媒体は、すべての薬学的に許容される担体、希釈剤または賦形剤を含む。 A "pharmaceutical composition" refers to a formulation comprising a compound of the present invention and a vehicle generally accepted in the art, said vehicle being a vehicle for delivery of a biologically active compound to a mammal (such as a human). Such vehicles include all pharmaceutically acceptable carriers, diluents or excipients.
第2の局面では、本発明は、式(I)、式(II)又は式(III)で表される構造を有する化合物、およびその異性体、重水素化誘導体の製造方法を提供する。詳細については、実施例の記載の通りである。 In a second aspect, the present invention provides a method for producing a compound having a structure represented by formula (I), formula (II) or formula (III), and isomers and deuterated derivatives thereof. Details are as described in Examples.
本発明で提供される実施形態では、本発明の化合物は、例えば塩基性基を含む場合、酸と塩を形成することができ、当業者に周知の方法により、非環式ヌクレオシド誘導体誘導体、異性体の塩を調製することができる。 In embodiments provided by the present invention, compounds of the present invention can form salts with acids, e.g., if they contain basic groups, and salts of acyclic nucleoside derivatives, isomers can be prepared by methods well known to those skilled in the art.
一般的な塩には、有機酸塩、無機酸塩などがある。通常、より一般的に使われる有機酸塩としては、クエン酸塩、フマル酸塩、シュウ酸塩、リンゴ酸塩、乳酸塩、スルホン酸塩(例えば、カンファースルホン酸塩、p‐トルエンスルホン酸塩、メタンスルホン酸塩など)など;無機酸塩としては、ハロゲン化水素酸塩、硫酸塩、リン酸塩、硝酸塩などが挙げられる。例えば、メタンスルホン酸、トリフルオロメタンスルホン酸などの低級アルキルスルホン酸と、メタンスルホン酸塩またはトリフルオロメタンスルホン酸塩を形成することができる。ベンゼンスルホン酸やp‐トルエンスルホン酸などのアリールスルホン酸と、p‐トルエンスルホン酸塩やベンゼンスルホン酸塩を形成することができる。酢酸、フマル酸、酒石酸、シュウ酸、マレイン酸、リンゴ酸、コハク酸またはクエン酸などの有機カルボン酸と、対応する塩を形成することができる。グルタミン酸またはアスパラギン酸などのアミノ酸と、グルタミン酸塩またはアスパラギン酸塩を形成することができる。ハロゲン化水素酸(フッ化水素酸、臭化水素酸、ヨウ化水素酸、塩素酸)、硝酸、炭酸、硫酸またはリン酸などの無機酸と、対応する塩を形成することができる。 Common salts include organic acid salts, inorganic acid salts, and the like. Generally, more commonly used organic acid salts include citrate, fumarate, oxalate, malate, lactate, sulfonate (e.g., camphorsulfonate, p-toluenesulfonate, methanesulfonate, etc.); inorganic acid salts include hydrohalide, sulfate, phosphate, nitrate, and the like. For example, lower alkyl sulfonic acids such as methanesulfonic acid, trifluoromethanesulfonic acid, and the like can form methanesulfonates or trifluoromethanesulfonates. Arylsulfonic acids such as benzenesulfonic acid and p-toluenesulfonic acid can form p-toluenesulfonates and benzenesulfonates. Corresponding salts can be formed with organic carboxylic acids such as acetic acid, fumaric acid, tartaric acid, oxalic acid, maleic acid, malic acid, succinic acid or citric acid. Glutamate or aspartate can be formed with amino acids such as glutamate or aspartate. Corresponding salts can be formed with inorganic acids such as hydrohalic acids (hydrofluoric, hydrobromic, hydroiodic, chloric), nitric acid, carbonic acid, sulfuric acid or phosphoric acid.
第3の局面では、本発明は、本発明の式(I)で表される構造を有する化合物、式(II)で表される構造を有する化合物、または式(III)で表される構造を有する化合物、異性体、溶媒和物、重水素化誘導体またはそれらの薬学的に許容される塩あるいは溶媒和物を活性成分として利用する医薬品を提供する。上記の医薬品には、1つ以上の薬学的に許容される担体がさらに含まれてもよく、この担体には、薬学分野における通常の希釈剤、賦形剤、充填剤、結合剤、湿潤剤、崩壊剤、吸収促進剤、界面活性剤、吸着担体、潤滑剤などを含み、必要に応じて着香剤、甘味料などを添加してもよい。本発明の医薬品は、錠剤、粉剤、顆粒剤、カプセル、経口液及び注射剤などの様々な形態にすることができ、上記の各剤形の医薬品は薬学分野における常法に従って調製することができる。 In a third aspect, the present invention provides a medicament utilizing, as an active ingredient, a compound having a structure represented by formula (I), a compound having a structure represented by formula (II), or a compound having a structure represented by formula (III), an isomer, a solvate, a deuterated derivative, or a pharmaceutically acceptable salt or solvate thereof. The above-mentioned medicament may further contain one or more pharmaceutically acceptable carriers, which include usual diluents, excipients, fillers, binders, wetting agents, disintegrants, absorption enhancers, surfactants, adsorption carriers, lubricants and the like in the pharmaceutical field, and if necessary, flavoring agents, sweeteners and the like may be added. The medicament of the present invention can be in various forms such as tablets, powders, granules, capsules, oral solutions and injections, and the medicaments in each of the above dosage forms can be prepared according to conventional methods in the pharmaceutical field.
第4の局面では、本発明は、治療を必要とする被験者に本発明の化合物の少なくとも1つを治療有効量で投与することを含む、式(I)で表される構造を有する化合物、式(II)で表される構造を有する化合物、または式(III)で表される構造を有する化合物、異性体、溶媒和物、重水素化誘導体またはそれらの薬学的に許容される塩によってPDE4を抑制する方法を提供する。 In a fourth aspect, the present invention provides a method of inhibiting PDE4 by a compound having the structure represented by Formula (I), the compound having the structure represented by Formula (II), or the compound having the structure represented by Formula (III), isomer, solvate, deuterated derivative or pharmaceutically acceptable salt thereof, comprising administering to a subject in need of treatment a therapeutically effective amount of at least one of the compounds of the invention.
1つの好ましい実施形態は、炎症および自己免疫性疾患の治療における医薬品の使用である。本発明のこの目的は、炎症性及び自己免疫性疾患、または全身性エリテマトーデス(SLE)、ループス腎炎、皮膚ループス、クローン病、潰瘍性大腸炎、1型糖尿病、乾癬、関節リウマチ、全身型若年性特発性関節炎(systemic-onset juvenile idiopathic arthritis)、強直性脊椎炎、または多発性硬化症などを含む。 One preferred embodiment is the use of the medicament in treating inflammation and autoimmune diseases. This object of the invention includes inflammatory and autoimmune diseases, or systemic lupus erythematosus (SLE), lupus nephritis, cutaneous lupus, Crohn's disease, ulcerative colitis, type 1 diabetes, psoriasis, rheumatoid arthritis, systemic-onset juvenile idiopathic arthritis, ankylosing spondylitis, or multiple sclerosis.
以下の実施例は本発明の実施可能性を説明するものであり、当業者は、従来技術の教示に基づいて、対応する技術的特徴を修正または置換することが依然として本発明の保護範囲内であることを理解すべきである。 The following examples illustrate the feasibility of the present invention, and those skilled in the art should understand that modifying or replacing the corresponding technical features based on the teachings of the prior art still falls within the protection scope of the present invention.
実施例1. 3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 1. 3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
工程1:5-ブロモ-N-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4-メチル-3-ニトロピリジン-2-アミン
室温で、30.0gの5-ブロモ-2-クロロ-4-メチル-3-ニトロピリジン、29.4gの1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチルアミン(WO2018157779に開示された方法を参照して合成する)および30gのジイソプロピルアミンを、N,N-ジメチルホルムアミド150.0mLに溶解し、窒素保護下、120℃で2時間反応させ、混合物に水1000mLを添加し、酢酸エチル(250mL×3)で抽出した。有機相を合わせ、飽和食塩水(100mL×3)で洗浄し、無水硫酸ナトリウムで乾燥させ、濾過し、減圧下で濃縮し、残留物をカラムクロマトグラフィーにより精製して、目的化合物36.8gを得た。
ESI MS m/z:489.04[M+1]+
Step 1: 5-bromo-N-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4-methyl-3-nitropyridin-2-amine At room temperature, 30.0 g of 5-bromo-2-chloro-4-methyl-3-nitropyridine, 29.4 g of 1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethylamine ( WO2018157779) and 30 g of diisopropylamine were dissolved in 150.0 mL of N,N-dimethylformamide, reacted at 120° C. for 2 hours under nitrogen protection, 1000 mL of water was added to the mixture, and extracted with ethyl acetate (250 mL×3). The organic phases were combined, washed with saturated brine (100 mL×3), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by column chromatography to obtain 36.8 g of the target compound.
ESI MS m/z: 489.04 [M+1] +
工程2:N-(1-(1-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロフェニル)-4-メチル-3-ニトロピリジン-2-アミン Step 2: N-(1-(1-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluorophenyl)-4-methyl-3-nitropyridin-2-amine
室温で、24.1gの工程2の生成物および10.40gのo-フルオロフェニルボロン酸を、ジオキサン300mLと水100mLに溶解し、窒素ガス保護下で20gの炭酸カリウムおよび4gの[1,1’-ビス(ジフェニルホスフィノ)フェロセン]ジクロロパラジウムのジクロロメタン複合体を加え、窒素ガス保護下で反応混合物を80℃に加熱し、反応を14時間撹拌した。反応終了後、室温まで冷却し、反応混合物に水600mLを添加し、酢酸エチル(300mL×3)で抽出した。有機相を合わせ、無水硫酸ナトリウムで乾燥させ、濾過して乾燥剤を除去し、減圧下で濃縮し、残留物をカラムクロマトグラフィーにより精製して、目的化合物16.4gを得た。
ESI MS m/z:505.15[M+1]+
At room temperature, 24.1 g of the product of step 2 and 10.40 g of o-fluorophenylboronic acid were dissolved in 300 mL of dioxane and 100 mL of water, 20 g of potassium carbonate and 4 g of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium complex in dichloromethane were added under nitrogen gas protection, the reaction mixture was heated to 80° C. under nitrogen gas protection, and the reaction was stirred for 14 hours. After completion of the reaction, the reaction mixture was cooled to room temperature, added with 600 mL of water, and extracted with ethyl acetate (300 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered to remove the drying agent, concentrated under reduced pressure, and the residue was purified by column chromatography to obtain 16.4 g of the desired compound.
ESI MS m/z: 505.15 [M+1] +
工程3:N2-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロフェニル)-4-メチルピリジン-2,3-ジアミン Step 3: N2-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluorophenyl)-4-methylpyridine-2,3-diamine
室温で、工程3の生成物12.0gおよび塩化アンモニウム13gにエタノール(200mL)を添加し、0℃で亜鉛粉末15gを20バッチに分けて添加し、反応混合物を0℃で撹拌しながら16時間反応させた。反応終了後、反応混合物を濾過して亜鉛粉末を除去し、濾液を減圧下で濃縮して残留物を得た。残留物をジクロロメタン300mLに溶解させ、懸濁液を濾過して不溶物を除去し、濾液を減圧下で濃縮して化合物8.7gを得た。
ESI MS m/z:475.17[M+1]+
Ethanol (200 mL) was added to 12.0 g of the product of step 3 and 13 g of ammonium chloride at room temperature, 15 g of zinc powder was added in 20 batches at 0° C., and the reaction mixture was allowed to react at 0° C. for 16 hours with stirring. After completion of the reaction, the reaction mixture was filtered to remove zinc powder, and the filtrate was concentrated under reduced pressure to obtain a residue. The residue was dissolved in 300 mL of dichloromethane, the suspension was filtered to remove insoluble matter, and the filtrate was concentrated under reduced pressure to give 8.7 g of compound.
ESI MS m/z: 475.17 [M+1] +
工程4:3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン
室温で、4.65g工程3の生成物および10gトリエチルアミンを、テトラヒドロフラン50.0mLに溶解し、0℃に冷却し、トリホスゲン1.17gおよびテトラヒドロフラン10.0mLの溶液を上記反応液に滴下した完了後、窒素ガス保護下で反応混合物を0℃で撹拌しながら2時間反応させた。反応終了後、反応混合物に水100mLを添加し、酢酸エチル(20mL×3)で抽出した。有機相を合わせ、無水硫酸ナトリウムで乾燥させ、濾過し、減圧下で濃縮し、残留物をカラムクロマトグラフィーにより精製して、目的化合物を得た。
ESI MS m/z:501.15[M+1]+
Step 4: 3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one At room temperature, 4.65 g of the product of step 3 and 10 g triethylamine are dissolved in 50.0 mL of tetrahydrofuran, cooled to 0° C. and triphosgene 1. After a solution of 17 g and 10.0 mL of tetrahydrofuran was added dropwise to the above reaction solution, the reaction mixture was reacted for 2 hours while stirring at 0° C. under nitrogen gas protection. After completion of the reaction, 100 mL of water was added to the reaction mixture and extracted with ethyl acetate (20 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by column chromatography to obtain the desired compound.
ESI MS m/z: 501.15 [M+1] +
実施例2. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 2. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
工程1、 (S)-5-ブロモ-N-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4-メチル-3-ニトロピリジン-2-アミン Step 1, (S)-5-bromo-N-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4-methyl-3-nitropyridin-2-amine
(S)-1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチルアミン(1.43g,5.23mmol)(ラセミ体からSFCによる分割によって製造する)を、10mLのN,N-ジメチルホルムアミドに溶解し、(5-ブロモ-2-クロロ-4-メチル-3-ニトロピリジン)(1.93g,8.16mmol)、トリエチルアミン3mLを加え、窒素保護下で、100℃に加熱し、16時間反応させた。室温まで冷却し、水でクエンチし、酢酸エチル(50mL*3)で抽出し、有機相を合わせ、飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥させ、濾過して濃縮し、カラムクロマトグラフィーにより精製して、溶出液を濃縮して、目的化合物1.3gを得た。 (S)-1-(6-Ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethylamine (1.43 g, 5.23 mmol) (prepared from racemate by SFC resolution) was dissolved in 10 mL of N,N-dimethylformamide, (5-bromo-2-chloro-4-methyl-3-nitropyridine) (1.93 g, 8.16 mmol), 3 mL of triethylamine was added, and nitrogen was added. Heated to 100° C. under protection and allowed to react for 16 hours. Cool to room temperature, quench with water, extract with ethyl acetate (50 mL*3), combine the organic phases, wash with saturated brine, dry over anhydrous sodium sulfate, filter and concentrate, purify by column chromatography, concentrate the eluate to obtain 1.3 g of the target compound.
工程2. (S)-N-(1-(1-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロフェニル)-4-メチル-3-ニトロピリジン-2-アミン Step 2. (S)-N-(1-(1-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluorophenyl)-4-methyl-3-nitropyridin-2-amine
工程1の生成物(121mg,0.25mmol)を8mLの混合溶媒(1,4-ジオキサン:水=3:1)に溶解し、(2-フルオロフェニル)ボロン酸(52mg,0.37mmol)、(dppf)PdCl2(110mmg)、炭酸カリウム(102mg,0.74mmol)を加え、系を真空吸引により排気し、窒素保護下で、85℃で8時間還流させた。室温まで冷却し、水でクエンチし、珪藻土で吸引濾過し、酢酸エチル(50mL*3)で抽出し、有機相を合わせ、飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥させ、濾過し、濃縮して乾燥させ、目的化合物1.3gを得た。 The product of step 1 (121 mg, 0.25 mmol) was dissolved in 8 mL of mixed solvent (1,4-dioxane:water=3:1), (2-fluorophenyl)boronic acid (52 mg, 0.37 mmol), (dppf)PdCl2 (110 mmg), potassium carbonate (102 mg, 0.74 mmol) were added, the system was evacuated by vacuum suction and refluxed at 85° C. for 8 hours under nitrogen protection. Cool to room temperature, quench with water, suction filter over diatomaceous earth, extract with ethyl acetate (50 mL*3), combine the organic phases, wash with saturated brine, dry over anhydrous sodium sulfate, filter and concentrate to dryness to obtain 1.3 g of the target compound.
工程3. (S)-N2-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロフェニル)-4-メチルピリジン-2,3-ジアミン Step 3. (S)—N 2 -(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluorophenyl)-4-methylpyridine-2,3-diamine
室温で、工程2の生成物1.2gおよび塩化アンモニウム2.3gにエタノール(200mL)を加え、0℃で亜鉛粉末2.8gを20バッチに分けて添加し、反応混合物を0℃で撹拌しながら、4時間反応させた。反応終了後、反応混合物を濾過して亜鉛粉末を除去し、濾液を減圧下で濃縮して残留物を得た。残留物をジクロロメタン300mLに溶解させ、炭酸ナトリウム水溶液で2回洗浄し、酢酸エチル層を無水硫酸ナトリウムで乾燥させ、濾過し、減圧下で濃縮し、化合物0.8gを得た。
ESI MS m/z:475.17[M+1]+
Ethanol (200 mL) was added to 1.2 g of the product of step 2 and 2.3 g of ammonium chloride at room temperature, 2.8 g of zinc powder was added in 20 batches at 0° C., and the reaction mixture was allowed to react at 0° C. with stirring for 4 hours. After completion of the reaction, the reaction mixture was filtered to remove zinc powder, and the filtrate was concentrated under reduced pressure to obtain a residue. The residue was dissolved in 300 mL of dichloromethane, washed twice with aqueous sodium carbonate solution, the ethyl acetate layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give 0.8 g of compound.
ESI MS m/z: 475.17 [M+1] +
工程4:(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン
室温で、0.6gの工程3の生成物および0.8gのトリエチルアミンを、テトラヒドロフラン50.0mLに溶解し、0℃に冷却し、トリホスゲン0.3gおよびテトラヒドロフラン10.0mLの溶液を、上記の反応液に滴下した後、窒素ガス保護下で反応混合物を0℃で撹拌しながら2時間反応させた。反応終了後、反応混合物に飽和炭酸ナトリウム水溶液20mLを添加し、酢酸エチル100mLで抽出し、2M炭酸ナトリウム水溶液で2回洗浄し、酢酸エチル層を無水硫酸ナトリウムで乾燥させ、濾過し、減圧下で濃縮し、化合物0.4gを得た。
1HNMR(400MHz,DMSO-D6)δ11.52(s,1H),7.75(s,1H),7.50-7.46(m,1H),7.39-7.29(m,3H),7.26-7.24(d,1H),6.85-6.83(d,1H),6.09-6.05(q,1H),4.58(m,1H),4.35-4.30(q,1H),4.28-4.17(m,2H),3.75(s,3H),3.08(s,3H),2.14(s,3H),1.23-1.18(q,3H).
ESI MS m/z:501.15[M+1]+
Step 4: (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one At room temperature, 0.6 g of the product of step 3 and 0.8 g of triethylamine are dissolved in 50.0 mL of tetrahydrofuran and cooled to 0°C. , 0.3 g of triphosgene and 10.0 mL of tetrahydrofuran were added dropwise to the above reaction solution, and the reaction mixture was allowed to react for 2 hours while stirring at 0° C. under nitrogen gas protection. After completion of the reaction, the reaction mixture was added with 20 mL of saturated aqueous sodium carbonate solution, extracted with 100 mL of ethyl acetate, washed twice with 2M aqueous sodium carbonate solution, the ethyl acetate layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain 0.4 g of compound.
1 HNMR(400MHz,DMSO-D6)δ11.52(s,1H),7.75(s,1H),7.50-7.46(m,1H),7.39-7.29(m,3H),7.26-7.24(d,1H),6.85-6.83(d,1H),6.09-6.05(q,1H),4.58(m,1H),4.35-4.30(q,1H),4.28-4.17(m,2H),3.75(s,3H),3.08(s,3H),2.14(s,3H),1.23-1.18(q,3H).
ESI MS m/z: 501.15 [M+1] +
実施例3. (R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 3. (R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.50(s,1H),7.75(s,1H),7.50-7.46(m,1H),7.39-7.29(m,3H),7.26-7.24(d,1H),6.85-6.83(d,1H),6.09-6.05(q,1H),4.65-4.59(q,1H),4.34-4.30(q,1H),4.27-4.19(m,2H),3.75(s,3H),3.08(s,3H),2.14(s,3H),1.28-1.20(m,3H).
ESI MS m/z:501.15[M+1]+
Synthesized by referring to the method of Example 2.
1 HNMR(400MHz,DMSO-D6)δ11.50(s,1H),7.75(s,1H),7.50-7.46(m,1H),7.39-7.29(m,3H),7.26-7.24(d,1H),6.85-6.83(d,1H),6.09-6.05(q,1H),4.65-4.59(q,1H),4.34-4.30(q,1H),4.27-4.19(m,2H),3.75(s,3H),3.08(s,3H),2.14(s,3H),1.28-1.20(m,3H).
ESI MS m/z: 501.15 [M+1] +
実施例4. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 4. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.47(s,1H),7.76(s1H),7.48-7.37(m,5H),7.25-7.23(d,1H),6.82-6.79(d,1H),4.65-4.59(q,1H),4.34-4.22(m,3H),3.75(s,3H),3.07(s,3H),2.24(s,3H),1.28-1.24(m,3H).
ESI MS m/z:483.16[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.47 (s, 1H), 7.76 (s1H), 7.48-7.37 (m, 5H), 7.25-7.23 (d, 1H), 6.82-6.79 (d, 1H), 4.65-4.59 (q, 1H), 4.34-4.22 (m, 3H) , 3.75(s, 3H), 3.07(s, 3H), 2.24(s, 3H), 1.28-1.24(m, 3H).
ESI MS m/z: 483.16 [M+1] +
実施例5. (R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 5. (R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.47(s,1H),7.76(s1H),7.48-7.37(m,5H),7.25-7.23(d,1H),6.82-6.79(d,1H),4.65-4.59(q,1H),4.34-4.22(m,3H),3.75(s,3H),3.07(s,3H),2.24(s,3H),1.28-1.24(m,3H).
ESI MS m/z:483.16[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.47 (s, 1H), 7.76 (s1H), 7.48-7.37 (m, 5H), 7.25-7.23 (d, 1H), 6.82-6.79 (d, 1H), 4.65-4.59 (q, 1H), 4.34-4.22 (m, 3H) , 3.75(s, 3H), 3.07(s, 3H), 2.24(s, 3H), 1.28-1.24(m, 3H).
ESI MS m/z: 483.16 [M+1] +
実施例6. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 6. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:501.15[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 501.15 [M+1] +
実施例7. (R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 7. (R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:501.15[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 501.15 [M+1] +
実施例8. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5b]ピリジン-2(3H)-オン Example 8. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(o-methylphenyl)-1H-imidazo[4,5b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.44(s,1H),7.63-7.62(d,1H),7.33-7.24(m,4H),7.13-7.11(q,1H),6.89-6.86-(t,3H),6.09-6.04(m,1H),4.68-4.60(m,1H),4.34-4.29(q,1H),4.23-4.16(m,2H),4.06-4.01(q,1H),3.07(d,3H),2.02-2.00(t,6H),1.22-1.16(m,3H).
ESI MS m/z:497.18[M+1]+
Synthesized by referring to the method of Example 2.
1 HNMR(400MHz,DMSO-D6)δ11.44(s,1H),7.63-7.62(d,1H),7.33-7.24(m,4H),7.13-7.11(q,1H),6.89-6.86-(t,3H),6.09-6.04(m,1H),4.68-4.60(m,1H),4.34-4.29(q,1H),4.23-4.16(m,2H),4.06-4.01(q,1H),3.07(d,3H),2.02-2.00(t,6H),1.22-1.16(m,3H).
ESI MS m/z: 497.18 [M+1] +
実施例9. (R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5b]ピリジン-2(3H)-オン Example 9. (R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(o-methylphenyl)-1H-imidazo[4,5b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.44(s,1H),7.63-7.62(d,1H),7.32-7.24(m,4H),7.13-7.11(q,1H),6.89-6.86-(t,3H),6.09-6.04(m,1H),4.68-4.60(m,1H),4.34-4.29(q,1H),4.23-4.16(m,2H),4.06-4.01(q,1H),3.06(d,3H),2.02-2.00(m,6H),1.22-1.16(m,3H).
ESI MS m/z:497.18[M+1]+
Synthesized by referring to the method of Example 2.
1 HNMR(400MHz,DMSO-D6)δ11.44(s,1H),7.63-7.62(d,1H),7.32-7.24(m,4H),7.13-7.11(q,1H),6.89-6.86-(t,3H),6.09-6.04(m,1H),4.68-4.60(m,1H),4.34-4.29(q,1H),4.23-4.16(m,2H),4.06-4.01(q,1H),3.06(d,3H),2.02-2.00(m,6H),1.22-1.16(m,3H).
ESI MS m/z: 497.18 [M+1] +
実施例10. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-エチルフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 10. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-ethylphenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.43(s,1H),7.64-7.63(d,1H),7.37-7.33(m,2H),7.28-7.23(m,2H),7.09-7.07(d,1H),6.92-6.88(t,1H),6.09-6.04(m,1H),4.66-4.63(q,1H),4.33-4.29(t,1H),4.22-4.18(m,2H),3.75(s,3H),3.06(s,3H),2.49-1.99(m,2H),2.05(s,3H),1.28-1.16(m,3H),1.00-0.94(m,3H).
ESI MS m/z:511.19[M+1]+
Synthesized by referring to the method of Example 2.
1 HNMR(400MHz,DMSO-D6)δ11.43(s,1H),7.64-7.63(d,1H),7.37-7.33(m,2H),7.28-7.23(m,2H),7.09-7.07(d,1H),6.92-6.88(t,1H),6.09-6.04(m,1H),4.66-4.63(q,1H),4.33-4.29(t,1H),4.22-4.18(m,2H),3.75(s,3H),3.06(s,3H),2.49-1.99(m,2H),2.05(s,3H),1.28-1.16(m,3H),1.00-0.94(m,3H).
ESI MS m/z: 511.19 [M+1] +
実施例11. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-イソプロピルフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 11. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-isopropylphenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:525.218[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 525.218 [M+1] +
実施例12. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-メトキシフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 12. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-methoxyphenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.39(s,1H),7.63(s,1H),7.42-7.38(m,1H),7.26-7.24(d,1H),7.15-7.10(m,2H),7.04-7.00(m,1H),6.84-6.82(d, 1H),6.08-6.04(q,1H),4.63-4.60(t,1H),4.33-4.21(m,3H),3.75-3.73(d,6H),3.08(s,3H),2.05(s,3H),1.25-1.21(t,3H).
ESI MS m/z:513.17[M+1]+
Synthesized by referring to the method of Example 2.
1 HNMR(400MHz,DMSO-D6)δ11.39(s,1H),7.63(s,1H),7.42-7.38(m,1H),7.26-7.24(d,1H),7.15-7.10(m,2H),7.04-7.00(m,1H),6.84-6.82(d, 1H),6.08-6.04(q,1H),4.63-4.60(t,1H),4.33-4.21(m,3H),3.75-3.73(d,6H),3.08(s,3H),2.05(s,3H),1.25-1.21(t,3H).
ESI MS m/z: 513.17 [M+1] +
実施例13. (R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-メトキシフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 13. (R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-methoxyphenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.39(s,1H),7.63(s,1H),7.42-7.38(m,1H),7.26-7.24(d,1H),7.15-7.10(m,2H),7.04-7.00(m,1H),6.84-6.82(d,1H),6.08-6.04(q,1H),4.66-4.59(q,1H),4.34-4.21(m,3H),3.75-3.73(d,6H),3.08(s,3H),2.05(s,3H),1.25-1.21(t,3H).
ESI MS m/z:513.17[M+1]+
Synthesized by referring to the method of Example 2.
1 HNMR(400MHz,DMSO-D6)δ11.39(s,1H),7.63(s,1H),7.42-7.38(m,1H),7.26-7.24(d,1H),7.15-7.10(m,2H),7.04-7.00(m,1H),6.84-6.82(d,1H),6.08-6.04(q,1H),4.66-4.59(q,1H),4.34-4.21(m,3H),3.75-3.73(d,6H),3.08(s,3H),2.05(s,3H),1.25-1.21(t,3H).
ESI MS m/z: 513.17 [M+1] +
実施例14. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(2-(トリフルオロメチル)フェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 14. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(2-(trifluoromethyl)phenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:551.15[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 551.15 [M+1] +
実施例15. (S)-2-(3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-2-オキソ-2,3-ジヒドロ-1H-イミダゾ[4,5-b]ピリジン-6-イル)ベンゾニトリル Example 15. (S)-2-(3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)benzonitrile
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.36(s,1H),7.89-7.86(m,1H),7.79-7.77(d,1H),7.47-7.43(m,1H),7.23-7.21(d,1H),6.87-6.86(d,1H),6.77-6.75(d,1H),6.04-6.01(q,1H),4.62-4.55(q,1H),4.30-4.20(m,2H),3.74(s,2H),3.02(s,3H),2.52-2.50(m,3H),2.32(s,3H),1.24-1.21(t,3H).
ESI MS m/z:508.16[M+1]+
Synthesized by referring to the method of Example 2.
1 HNMR(400MHz,DMSO-D6)δ11.36(s,1H),7.89-7.86(m,1H),7.79-7.77(d,1H),7.47-7.43(m,1H),7.23-7.21(d,1H),6.87-6.86(d,1H),6.77-6.75(d,1H),6.04-6.01(q,1H),4.62-4.55(q,1H),4.30-4.20(m,2H),3.74(s,2H),3.02(s,3H),2.52-2.50(m,3H),2.32(s,3H),1.24-1.21(t,3H).
ESI MS m/z: 508.16 [M+1] +
実施例16. (R)-2-(3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-2-オキソ-2,3-ジヒドロ-1H-イミダゾ[4,5-b]ピリジン-6-イル)ベンゾニトリル Example 16. (R)-2-(3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)benzonitrile
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.36(s,1H),7.89-7.86(m,1H),7.79-7.77(d,1H),7.46-7.43(m,1H),7.23-7.21(d,1H),6.87-6.86(d,1H),6.77-6.75 (d,1H),6.04-6.01(q,1H),4.62-4.55(q,1H),4.30-4.20(m,2H),3.74(s,2H),3.02(s,3H),2.51-2.50(m,3H),2.32(s,3H),1.24-1.21(t,3H).
ESI MS m/z:508.16[M+1]+
Synthesized by referring to the method of Example 2.
1 HNMR(400MHz,DMSO-D6)δ11.36(s,1H),7.89-7.86(m,1H),7.79-7.77(d,1H),7.46-7.43(m,1H),7.23-7.21(d,1H),6.87-6.86(d,1H),6.77-6.75 (d,1H),6.04-6.01(q,1H),4.62-4.55(q,1H),4.30-4.20(m,2H),3.74(s,2H),3.02(s,3H),2.51-2.50(m,3H),2.32(s,3H),1.24-1.21(t,3H).
ESI MS m/z: 508.16 [M+1] +
実施例17. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 17. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:484.16[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 484.16 [M+1] +
実施例18. (R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 18. (R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:484.16[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 484.16 [M+1] +
実施例19. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1,7-ジメチル-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 19. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1,7-dimethyl-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例17の化合物100mgを1mlのN,N-ジメチルホルムアミドに溶解し、ヨードメタン100mg、トリエチルアミン0.1mLを加え、窒素保護下で、0℃に加熱し、16時間反応させた。室温まで冷却し、水でクエンチし、酢酸エチル(10mL*3)で抽出し、有機相を合わせ、飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥させ、濾過し、濃縮し、カラムクロマトグラフィーにより精製し、溶出液を濃縮して、目的化合物53mgを得た。
ESI MS m/z:498.17[M+1]+
100 mg of the compound of Example 17 was dissolved in 1 ml of N,N-dimethylformamide, 100 mg of iodomethane and 0.1 mL of triethylamine were added, and the mixture was heated to 0° C. under nitrogen protection and reacted for 16 hours. Cool to room temperature, quench with water, extract with ethyl acetate (10 mL*3), combine the organic phases, wash with saturated brine, dry over anhydrous sodium sulfate, filter, concentrate, purify by column chromatography, concentrate the eluate to obtain 53 mg of the target compound.
ESI MS m/z: 498.17 [M+1] +
実施例20. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-(2-メトキシエチル)-7-メチル-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 20. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-(2-methoxyethyl)-7-methyl-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:542.208[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 542.208 [M+1] +
実施例21. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-1,7-ジメチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 21. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-1,7-dimethyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:519.14[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 519.14 [M+1] +
実施例22. (R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-1,7-ジメチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 22. (R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-1,7-dimethyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:515.17[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 515.17 [M+1] +
実施例23. (S)-6-(2,6-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 23. (S)-6-(2,6-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.38(s,1H),7.79-7.77(d,1H),7.73- 7.68(m,1H),7.23-7.21(d,1H),6.87-6.86(t,1H),6.77-6.74(t,1H),6.04-6.01(q,1H),4.61-4.55(q,1H),4.30-4.19(m,3H),4.15-4.13(q,1H),3.74(s,3H),3.03(s,3H),2.32(s,3H),1.24-1.20(t,3H).
ESI MS m/z:519.14[M+1]+
Synthesized by referring to the method of Example 2.
1 HNMR(400MHz,DMSO-D6)δ11.38(s,1H),7.79-7.77(d,1H),7.73- 7.68(m,1H),7.23-7.21(d,1H),6.87-6.86(t,1H),6.77-6.74(t,1H),6.04-6.01(q,1H),4.61-4.55(q,1H),4.30-4.19(m,3H),4.15-4.13(q,1H),3.74(s,3H),3.03(s,3H),2.32(s,3H),1.24-1.20(t,3H).
ESI MS m/z: 519.14 [M+1] +
実施例24. (R)(S)-6-(2,6-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 24. (R)(S)-6-(2,6-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:519.14[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 519.14 [M+1] +
実施例25. (S)-6-(2,3-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 25. (S)-6-(2,3-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.38(s,1H),7.78(s,1H),7.74-7.67(m,1H),7.23-7.21(d,1H),6.87-6.86(t,1H),6.77-6.74(q,1H),6.04-6.01(q,1H),4.64-4.55(q,1H),4.30-4.18(m,3H),4.15-4.13(q,1H),3.74(s,3H),3.03(s,3H),2.33(s ,3H),1.24-1.20(t,3H).
ESI MS m/z:519.14[M+1]+
Synthesized by referring to the method of Example 2.
1 HNMR(400MHz,DMSO-D6)δ11.38(s,1H),7.78(s,1H),7.74-7.67(m,1H),7.23-7.21(d,1H),6.87-6.86(t,1H),6.77-6.74(q,1H),6.04-6.01(q,1H),4.64-4.55(q,1H),4.30-4.18(m,3H),4.15-4.13(q,1H),3.74(s,3H),3.03(s,3H),2.33(s ,3H),1.24-1.20(t,3H).
ESI MS m/z: 519.14 [M+1] +
実施例26. (R)-6-(2,3-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-ジメチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 26. (R)-6-(2,3-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-dimethyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:519.14[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 519.14 [M+1] +
実施例27. (S)-6-(2,5-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 27. (S)-6-(2,5-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.53(s,1H),7.78(s,1H),7.69-7.67(q,1H),7.42-7.24(m,2H),6.85-6.83(q,1H),6.09-6.06(q,1H),4.64-4.58(q,1H),4.27-4.18(m,2H),4.15-4.13(m,1H),4.04-4.03(d,1H),3.75(s,3H),3.08(s,3H),2.16(d,3H),1.29-1.16(m,3H).
ESI MS m/z:519.14[M+1]+
Synthesized by referring to the method of Example 2.
1 HNMR(400MHz,DMSO-D6)δ11.53(s,1H),7.78(s,1H),7.69-7.67(q,1H),7.42-7.24(m,2H),6.85-6.83(q,1H),6.09-6.06(q,1H),4.64-4.58(q,1H),4.27-4.18(m,2H),4.15-4.13(m,1H),4.04-4.03(d,1H),3.75(s,3H),3.08(s,3H),2.16(d,3H),1.29-1.16(m,3H).
ESI MS m/z: 519.14 [M+1] +
実施例28. (S)-6-(2,4-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 28. (S)-6-(2,4-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.51(s,1H),7.74(s,1H),7.46-7.36(m,2H),7.26-7.18(m,2H),6.84(d,1H),6.06(q,1H),4.61(q,1H),4.34-4.18(m,3H),3.75(s,3H),3.07(s,3H),2.13(s,3H),1.21(t,3H)
ESI MS m/z:519.14[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.51 (s, 1H), 7.74 (s, 1H), 7.46-7.36 (m, 2H), 7.26-7.18 (m, 2H), 6.84 (d, 1H), 6.06 (q, 1H), 4.61 (q, 1H), 4.34-4.18 (m, 3 H), 3.75 (s, 3H), 3.07 (s, 3H), 2.13 (s, 3H), 1.21 (t, 3H)
ESI MS m/z: 519.14 [M+1] +
実施例29. (S)-6-(2,4,5-トリフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 29. (S)-6-(2,4,5-trifluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:537.13[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 537.13 [M+1] +
実施例30. (R)-6-(2,5-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 30. (R)-6-(2,5-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:519.14[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 519.14 [M+1] +
実施例31. (S)-6-(2,4-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 31. (S)-6-(2,4-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.41(s,1H),7.59(d,1H),7.27-7.24(q,1H),7.13(s,1H),7.07-7.05(d,1H),7.00-6.97(q,1H),6.89-6.85(d,1H),6.08-6.04(m,1H),4.64-4.59(q,1H),4.33-4.29(t,1H),4.23-4.16(m,2H),3.75(s,3H),3.06(s,3H),2.32(s,3H),2.01-1.97(q,6H),1.22-1.17(m,3H).
ESI MS m/z:511.19[M+1]+
Synthesized by referring to the method of Example 2.
1 HNMR(400MHz,DMSO-D6)δ11.41(s,1H),7.59(d,1H),7.27-7.24(q,1H),7.13(s,1H),7.07-7.05(d,1H),7.00-6.97(q,1H),6.89-6.85(d,1H),6.08-6.04(m,1H),4.64-4.59(q,1H),4.33-4.29(t,1H),4.23-4.16(m,2H),3.75(s,3H),3.06(s,3H),2.32(s,3H),2.01-1.97(q,6H),1.22-1.17(m,3H).
ESI MS m/z: 511.19 [M+1]+
実施例32. (S)-6-(2,5-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 32. (S)-6-(2,5-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.42(s,1H),7.61(s,1H),7.60-7.13(m,2H),7.11(t,1H),6.93-6.85(m,2H),6.09-6.05(m,1H),4.66-4.59(m,1H),4.33-4.23(m,1H),4.22-4.15(m,2H),3.75(s,3H),3.06(s,3H),2.29(s,3H),2.00(d,3H),1.96(d,3H),1.40-1.18(m,3H).
ESI MS m/z:511.19[M+1]+
Synthesized by referring to the method of Example 2.
1 HNMR(400MHz,DMSO-D6)δ11.42(s,1H),7.61(s,1H),7.60-7.13(m,2H),7.11(t,1H),6.93-6.85(m,2H),6.09-6.05(m,1H),4.66-4.59(m,1H),4.33-4.23(m,1H),4.22-4.15(m,2H),3.75(s,3H),3.06(s,3H),2.29(s,3H),2.00(d,3H),1.96(d,3H),1.40-1.18(m,3H).
ESI MS m/z: 511.19 [M+1] +
実施例33. (S)-6-(2,3-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 33. (S)-6-(2,3-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.42(s,1H),7.60(s,1H),7.27-7.12(m,3H),6.96-6.85(m,2H),6.09-6.04(m,1H),4.66-4.62(t,1H),4.33-4.30(m,1H),4.23-4.17(m,2H),3.75(s,3H),3.07(s,3H),2.31(d,3H),1.99(s,3H),1.91(d,3H),1.26-1.18(m,3H).
ESI MS m/z:511.19[M+1]+
Synthesized by referring to the method of Example 2.
1 HNMR(400MHz,DMSO-D6)δ11.42(s,1H),7.60(s,1H),7.27-7.12(m,3H),6.96-6.85(m,2H),6.09-6.04(m,1H),4.66-4.62(t,1H),4.33-4.30(m,1H),4.23-4.17(m,2H),3.75(s,3H),3.07(s,3H),2.31(d,3H),1.99(s,3H),1.91(d,3H),1.26-1.18(m,3H).
ESI MS m/z: 511.19 [M+1] +
実施例34. (S)-6-(2,6-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 34. (S)-6-(2,6-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:511.19[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 511.19 [M+1] +
実施例35. (S)-6-(4-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 35. (S)-6-(4-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.45(s,1H),7.62(d,1H),7.27-7.06(m,4H),6.89-6.85(d,1H),6.08-6.04(m,1H),4.64-4.59(q,1H),4.33-4.29(t,1H),4.23-4.15(m,2H),3.75(s,3H),3.06(s,3H)2.02-1.99(q,6H),1.22-1.18(m,3H).
ESI MS m/z:515.17[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.45 (s, 1H), 7.62 (d, 1H), 7.27-7.06 (m, 4H), 6.89-6.85 (d, 1H), 6.08-6.04 (m, 1H), 4.64-4.59 (q, 1H), 4.33-4.29 (t, 1H) ), 4.23-4.15 (m, 2H), 3.75 (s, 3H), 3.06 (s, 3H) 2.02-1.99 (q, 6H), 1.22-1.18 (m, 3H).
ESI MS m/z: 515.17 [M+1] +
実施例36. (S)-6-(5-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 36. (S)-6-(5-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.47(d,1H),7.65(s,1H),7.64-7.35(m,1H),7.34-7.24(m,1H),7.18-7.13(m,1H),7.02-6.99(m,1H),6.98-6.85(m,1H),6.09-6.05(m,1H),4.60(d,1H),4.34-4.23(m,1H),4.22-4.16(m,2H),3.75(s,3H),3.07(d,3H),2.03(d,3H),1.98(t,3H),1.40-1.17(m,3H)
ESI MS m/z:515.17[M+1]+
Synthesized by referring to the method of Example 2.
1 HNMR(400MHz,DMSO-D6)δ11.47(d,1H),7.65(s,1H),7.64-7.35(m,1H),7.34-7.24(m,1H),7.18-7.13(m,1H),7.02-6.99(m,1H),6.98-6.85(m,1H),6.09-6.05(m,1H),4.60(d,1H),4.34-4.23(m,1H),4.22-4.16(m,2H),3.75(s,3H),3.07(d,3H),2.03(d,3H),1.98(t,3H),1.40-1.17(m,3H)
ESI MS m/z: 515.17 [M+1] +
実施例37. (S)-6-(3-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 37. (S)-6-(3-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.49(s,1H),7.65(s,1H),7.33-7.19(m,3H),7.02-6.99(q,1H),6.89-6.85(q,1H),6.09-6.04(m,1H),4.65-4.59(m,1H),4.34-4.30(m,1H),4.23-4.18(m,2H),3.75(s,3H),3.08(s,3H),2.03(s,3H),1.93(s,3H),1.21-1.19(t,3H).
ESI MS m/z:515.17[M+1]+
Synthesized by referring to the method of Example 2.
1 HNMR(400MHz,DMSO-D6)δ11.49(s,1H),7.65(s,1H),7.33-7.19(m,3H),7.02-6.99(q,1H),6.89-6.85(q,1H),6.09-6.04(m,1H),4.65-4.59(m,1H),4.34-4.30(m,1H),4.23-4.18(m,2H),3.75(s,3H),3.08(s,3H),2.03(s,3H),1.93(s,3H),1.21-1.19(t,3H).
ESI MS m/z: 515.17 [M+1] +
実施例38. (S)-6-(2-フルオロ-5-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 38. (S)-6-(2-fluoro-5-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.51(s,1H),7.74(s,1H),7.27-7.15(m,4H),6.84-6.82(t,1H),6.08-6.05(q,1H),4.64-4.57(q,1H),4.34-4.20(m,3H),3.75(s,3H),3.08(s,3H),2.33(s,3H),2.14(s,3H),1.24-1.20(t,3H).
ESI MS m/z:515.17[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.51 (s, 1H), 7.74 (s, 1H), 7.27-7.15 (m, 4H), 6.84-6.82 (t, 1H), 6.08-6.05 (q, 1H), 4.64-4.57 (q, 1H), 4.34-4.20 (m, 3H) ), 3.75 (s, 3H), 3.08 (s, 3H), 2.33 (s, 3H), 2.14 (s, 3H), 1.24-1.20 (t, 3H).
ESI MS m/z: 515.17 [M+1] +
実施例39. (S)-6-(2-フルオロ-3-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 39. (S)-6-(2-fluoro-3-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.50(s,1H),7.73(s,1H),7.36-7.33(q,1H),7.26-7.16(m,3H),6.85-6.83(q,1H),6.08-6.05(q,1H),4.64-4.58(q,1H),4.34-4.30(m,1H),4.25-4.19(m,2H),3.75(s,3H),3.08(s,3H),2.30(s,3H),2.13(s,3H),1.24-1.19(t,3H).
ESI MS m/z:515.17[M+1]+
Synthesized by referring to the method of Example 2.
1 HNMR(400MHz,DMSO-D6)δ11.50(s,1H),7.73(s,1H),7.36-7.33(q,1H),7.26-7.16(m,3H),6.85-6.83(q,1H),6.08-6.05(q,1H),4.64-4.58(q,1H),4.34-4.30(m,1H),4.25-4.19(m,2H),3.75(s,3H),3.08(s,3H),2.30(s,3H),2.13(s,3H),1.24-1.19(t,3H).
ESI MS m/z: 515.17 [M+1]+
実施例40. (S)-6-(2-フルオロ-4-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 40. (S)-6-(2-fluoro-4-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.50(s,1H),7.72(s,1H),7.26-7.21(t,2H),7.17-7.11(q,2H),6.84-6.82(t,1H),6.08-6.05(q,1H),4.64-4.57(q,1H),4.34-4.30(q,1H),4.27-4.18(m,2H),3.75(s,3H),3.08(s,3H),2.38(s,3H),2.13(s,3H),1.23-1.18(t,3H).
ESI MS m/z:515.17[M+1]+
Synthesized by referring to the method of Example 2.
1 HNMR(400MHz,DMSO-D6)δ11.50(s,1H),7.72(s,1H),7.26-7.21(t,2H),7.17-7.11(q,2H),6.84-6.82(t,1H),6.08-6.05(q,1H),4.64-4.57(q,1H),4.34-4.30(q,1H),4.27-4.18(m,2H),3.75(s,3H),3.08(s,3H),2.38(s,3H),2.13(s,3H),1.23-1.18(t,3H).
ESI MS m/z: 515.17 [M+1] +
実施例41. (S)-6-(2-フルオロ-5-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 41. (S)-6-(2-fluoro-5-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.50(s,1H),7.77(d,1H),7.27-7.20(m,2H),7.00-6.99(m,1H),7.98-6.82(m,2H),6.07(m,1H),4.62-4.58(m,1H),4.34-4.19(m,3H),3.77(s,3H),3.73(d,3H),3.05(s,3H),2.51-2.50(m,3H),1.20-1.09(m,3H)
ESI MS m/z:531.16[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.50 (s, 1H), 7.77 (d, 1H), 7.27-7.20 (m, 2H), 7.00-6.99 (m, 1H), 7.98-6.82 (m, 2H), 6.07 (m, 1H), 4.62-4.58 (m, 1H), 4.3 4-4.19 (m, 3H), 3.77 (s, 3H), 3.73 (d, 3H), 3.05 (s, 3H), 2.51-2.50 (m, 3H), 1.20-1.09 (m, 3H)
ESI MS m/z: 531.16 [M+1] +
実施例42. (S)-6-(2-フルオロ-3-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 42. (S)-6-(2-fluoro-3-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:531.16[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 531.16 [M+1] +
実施例43. (S)-6-(2-フルオロ-4-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 43. (S)-6-(2-fluoro-4-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.49(s,1H),7.71(s,1H),7.29-7.23(m,2H),6.96(q,1H),6.88(q,1H),6.82(q,1H),6.06(q,1H),4.64-4.58(m,1H),4.34-4.18(m,3H),3.82(s,3H),3.74(d,3H),3.05(d,3H),2.14(d,3H),1.28-1.19(m,3H)
ESI MS m/z:531.16[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.49 (s, 1H), 7.71 (s, 1H), 7.29-7.23 (m, 2H), 6.96 (q, 1H), 6.88 (q, 1H), 6.82 (q, 1H), 6.06 (q, 1H), 4.64-4.58 (m, 1H), 4. 34-4.18 (m, 3H), 3.82 (s, 3H), 3.74 (d, 3H), 3.05 (d, 3H), 2.14 (d, 3H), 1.28-1.19 (m, 3H)
ESI MS m/z: 531.16 [M+1] +
実施例44. (S)-6-(5-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 44. (S)-6-(5-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.40(d,1H),7.70(d,1H),7.26-7.21(m,2H),7.20-7.11(m,1H),7.10-6.99(m,1H),6.98-6.84(m,1H),6.07(t,1H),4.62-4.59(m,1H),4.33-4.03(m,3H),3.76(d,3H),3.72(d,3H),3.05(d,3H),2.07(s,3H),1.40-1.21(m,3H)
ESI MS m/z:531.16[M+1]+
Synthesized by referring to the method of Example 2.
1 HNMR(400MHz,DMSO-D6)δ11.40(d,1H),7.70(d,1H),7.26-7.21(m,2H),7.20-7.11(m,1H),7.10-6.99(m,1H),6.98-6.84(m,1H),6.07(t,1H),4.62-4.59(m,1H),4.33-4.03(m,3H),3.76(d,3H),3.72(d,3H),3.05(d,3H),2.07(s,3H),1.40-1.21(m,3H)
ESI MS m/z: 531.16 [M+1] +
実施例45. (S)-6-(4-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 45. (S)-6-(4-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.40(s,1H),7.70(d,1H),7.26-7.16(m,2H),7.15-7.01(m,1H),6.87-6.81(m,2H),6.05(q,1H),4.65-4.59(m,1H),4.33-4.21(m,3H),4.74(s,3H),3.73(s,3H),3.03(s,3H),2.01(d,3H),1.28-1.16(m,3H)
ESI MS m/z:531.16[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.40 (s, 1H), 7.70 (d, 1H), 7.26-7.16 (m, 2H), 7.15-7.01 (m, 1H), 6.87-6.81 (m, 2H), 6.05 (q, 1H), 4.65-4.59 (m, 1H), 4.3 3-4.21 (m, 3H), 4.74 (s, 3H), 3.73 (s, 3H), 3.03 (s, 3H), 2.01 (d, 3H), 1.28-1.16 (m, 3H)
ESI MS m/z: 531.16 [M+1] +
実施例46. (S)-6-(6-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 46. (S)-6-(6-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.36(s,1H),7.78(d,1H),7.21(d,1H),6.87-6.85(q,2H),6.77-6.75(q,1H),6.04-6.01(q,1H),4.62-4.55(m,1H),4.30-4.19(m,3H),3.74(d,3H),3.06(t,3H),2.32(s,3H),1.28-1.19(m,3H).
ESI MS m/z:531.16[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.36 (s, 1H), 7.78 (d, 1H), 7.21 (d, 1H), 6.87-6.85 (q, 2H), 6.77-6.75 (q, 1H), 6.04-6.01 (q, 1H), 4.62-4.55 (m, 1H), 4.3 0-4.19 (m, 3H), 3.74 (d, 3H), 3.06 (t, 3H), 2.32 (s, 3H), 1.28-1.19 (m, 3H).
ESI MS m/z: 531.16 [M+1] +
実施例47. (R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-エチル-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 47. (R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-ethyl-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:511.19[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 511.19 [M+1] +
実施例48. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-エチル-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 48. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-ethyl-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:529.18[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 529.18 [M+1] +
実施例49. (R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-エチル-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 49. (R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-ethyl-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:529.18[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 529.18 [M+1] +
実施例50. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-エチル-7-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 50. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-ethyl-7-methyl-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:525.21[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 525.21 [M+1] +
実施例51. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1-(2,2,2-トリフルオロエチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 51. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:583.16[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 583.16 [M+1] +
実施例52. (R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1-(2,2,2-トリフルオロエチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 52. (R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:583.16[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 583.16 [M+1] +
実施例53. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1-(2,2,2-トリフルオロエチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 53. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
SI MS m/z:565.17[M+1]+
Synthesized by referring to the method of Example 19.
SIMS m/z: 565.17 [M+1] +
実施例54. (R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1-(2,2,2-トリフルオロエチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 54. (R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
SI MS m/z:565.17[M+1]+
Synthesized by referring to the method of Example 19.
SIMS m/z: 565.17 [M+1] +
実施例55. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(o-メチルフェニル)-1-(2,2,2-トリフルオロエチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 55. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(o-methylphenyl)-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:579.18[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 579.18 [M+1] +
実施例56. (S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 56. (S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:565.17[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 565.17 [M+1] +
実施例57. (S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 57. (S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:547.17[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 547.17 [M+1] +
実施例58. (S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 58. (S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:565.17[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 565.17 [M+1] +
実施例59. (S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 59. (S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:561.19[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 561.19 [M+1] +
実施例60. (S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 60. (S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:537.13[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 537.13 [M+1] +
実施例61. (S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 61. (S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:519.14[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 519.14 [M+1] +
実施例62. (R)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 62. (R)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:519.14[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 519.14 [M+1] +
実施例63. (S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 63. (S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:537.13[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 537.13 [M+1] +
実施例64. (S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 64. (S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:533.16[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 533.16 [M+1] +
実施例65. (S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-1,7-ジメチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 65. (S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-1,7-dimethyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:551.15[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 551.15 [M+1] +
実施例66. (S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1,7-ジメチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 66. (S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1,7-dimethyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:533.16[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 533.16 [M+1] +
実施例67. (S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-1,7-ジメチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 67. (S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-1,7-dimethyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:551.15[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 551.15 [M+1] +
実施例68. (S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1,7-ジメチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 68. (S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1,7-dimethyl-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:547.17[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 547.17 [M+1] +
実施例69. (S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-イソプロポキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 69. (S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-isopropoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:593.20[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 593.20 [M+1] +
実施例70. (S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-イソプロポキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 70. (S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-isopropoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:575.21[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 575.21 [M+1] +
実施例71. (S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-イソプロポキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 71. (S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-isopropoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:593.20[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 593.20 [M+1] +
実施例72. (S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-イソプロポキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 72. (S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-isopropoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:589.22[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 589.22 [M+1] +
実施例73. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-ブロモ-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 73. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:485.04[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 485.04 [M+1] +
実施例74. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 74. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.39(s,1H),8.06(t,1H),7.57-7.59(m,1H),7.41-7.55(m,2H),7.31-7.36(m,2H),7.23-7.31(m,1H),6.86(d,1H),6.07(q,1H),4.36-4.62(m,1H),4.21-4.32(m,1H),4.17-4.21(m,2H),3.74(s,3H),3.07(s,3H),1.15-1.23(m,3H).
ESI MS m/z:487.14[M+1]+
Synthesized by referring to the method of Example 2.
1 HNMR(400MHz,DMSO-D6)δ11.39(s,1H),8.06(t,1H),7.57-7.59(m,1H),7.41-7.55(m,2H),7.31-7.36(m,2H),7.23-7.31(m,1H),6.86(d,1H),6.07(q,1H),4.36-4.62(m,1H),4.21-4.32(m,1H),4.17-4.21(m,2H),3.74(s,3H),3.07(s,3H),1.15-1.23(m,3H).
ESI MS m/z: 487.14 [M+1] +
実施例75. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 75. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ8.11(m,1H),7.77(t,1H),7.58-7.62(m,1H),7.43-7.47(m,1H),7.32--7.38(m,2H),6.12(dd,1H),4.58-4.64(m,1H),4.16-4.22(m,2H),4.32-437(m,1H),3.74(s,3H),3.43(s,3H),2.96(s,3H),1.21(t,3H).
ESI MS m/z:501.15[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 8.11 (m, 1H), 7.77 (t, 1H), 7.58-7.62 (m, 1H), 7.43-7.47 (m, 1H), 7.32--7.38 (m, 2H), 6.12 (dd, 1H), 4.58-4.64 (m, 1H), 4. 16-4.22 (m, 2H), 4.32-437 (m, 1H), 3.74 (s, 3H), 3.43 (s, 3H), 2.96 (s, 3H), 1.21 (t, 3H).
ESI MS m/z: 501.15 [M+1] +
実施例76. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 76. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.39(s,1H),8.19(d,1H),7.66(d,2H),7.55(d,1H),7.47(t,2H),7.37(t,1H),7.24(d,1H),7.84(d,1H),6.07(q,1H),4.60(q,1H),4.32(q,1H),4.25-4.20(m,2H),3.74(s,3H),3.06(s,3H),1.22(t,3H).
ESI MS m/z:469.15[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.39 (s, 1H), 8.19 (d, 1H), 7.66 (d, 2H), 7.55 (d, 1H), 7.47 (t, 2H), 7.37 (t, 1H), 7.24 (d, 1H), 7.84 (d, 1H), 6.07 (q, 1H), 4 .60 (q, 1H), 4.32 (q, 1H), 4.25-4.20 (m, 2H), 3.74 (s, 3H), 3.06 (s, 3H), 1.22 (t, 3H).
ESI MS m/z: 469.15 [M+1] +
実施例77. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-フェニル-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 77. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-phenyl-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ8.25(d,1H),7.89(d,1H),7.72(d,2H),7.49(t,2H),7.39(t,1H),7.23(d,1H),6.86(d,1H),6.10(q,1H),4.60(q,1H),4.34(q,1H),4.23-4.18(m,2H),3.74(s,3H),3.45(s,3H),3.06(s,3H),1.21(t,3H)
ESI MS m/z:483.16[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 8.25 (d, 1H), 7.89 (d, 1H), 7.72 (d, 2H), 7.49 (t, 2H), 7.39 (t, 1H), 7.23 (d, 1H), 6.86 (d, 1H), 6.10 (q, 1H), 4.60 (q, 1H), 4. 34 (q, 1H), 4.23-4.18 (m, 2H), 3.74 (s, 3H), 3.45 (s, 3H), 3.06 (s, 3H), 1.21 (t, 3H)
ESI MS m/z: 483.16 [M+1] +
実施例78. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 78. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:487.14[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 487.14 [M+1] +
実施例79. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 79. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.31(s,1H),7.71(s,1H),7.22-7.32(m,6H),6.88-6.91(m,1H),6.06-6.09(dd,1H),4.59-4.65(q,1H),4.31-4.35(m,1H),4.19(m,2H),3.75(s,3H),3.08(s,3H),2.24(s,3H),1.16-1.19(q,3H).
ESI MS m/z:483.16[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.31 (s, 1H), 7.71 (s, 1H), 7.22-7.32 (m, 6H), 6.88-6.91 (m, 1H), 6.06-6.09 (dd, 1H), 4.59-4.65 (q, 1H), 4.31-4.35 (m, 1 H), 4.19 (m, 2H), 3.75 (s, 3H), 3.08 (s, 3H), 2.24 (s, 3H), 1.16-1.19 (q, 3H).
ESI MS m/z: 483.16 [M+1] +
実施例80. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 80. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.90(d,1H),7.62(t,1H),7.24-7.35(m,5H),6.91(t,1H),6.11(q,1H),4.62(q,1H),4.20-4.37(m,1H),4.16-4.19(m,2H),3.75(s,3H)3.40(s,3H),3.07(s,3H),2.26(s,3H),1.17(t,3H).
ESI MS m/z:497.18[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 7.90 (d, 1H), 7.62 (t, 1H), 7.24-7.35 (m, 5H), 6.91 (t, 1H), 6.11 (q, 1H), 4.62 (q, 1H), 4.20-4.37 (m, 1H), 4.16-4.19 (m, 2H) ), 3.75 (s, 3H), 3.40 (s, 3H), 3.07 (s, 3H), 2.26 (s, 3H), 1.17 (t, 3H).
ESI MS m/z: 497.18 [M+1] +
実施例81. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-エチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 81. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-ethylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.28(s,1H),7.82(d,1H),7.38-7.18(m,7H),6.90(d,1H),6.07(q,1H),4.61(t,1H),4.35-4.22(m,1H),4.20-4.13(m,2H),3.76(t,3H),3.08(q,3H),1.21-1.16(m,4H),1.05(t,3H).
ESI MS m/z:497.18[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.28 (s, 1H), 7.82 (d, 1H), 7.38-7.18 (m, 7H), 6.90 (d, 1H), 6.07 (q, 1H), 4.61 (t, 1H), 4.35-4.22 (m, 1H), 4.20-4.13 (m, 2 H), 3.76 (t, 3H), 3.08 (q, 3H), 1.21-1.16 (m, 4H), 1.05 (t, 3H).
ESI MS m/z: 497.18 [M+1] +
実施例82. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-エチルフェニル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 82. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-ethylphenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.87(d,1H),7.57(d,1H),7.36(m,2H),7.29-7.27(m,2H),7.23(q,1H),6.94(d,1H),6.11(q,1H),4.63(q,1H),4.34(q,1H),4.17-4.11(m,2H),3.75(s,3H),3.39(s,3H),3.07(s,3H),2.60-2.50(m,2H),1.17(t,3H),1.05(t,3H).
ESI MS m/z:511.19[M+1]+
Synthesized by referring to the method of Example 19.
1 HNMR(400MHz,DMSO-D6)δ7.87(d,1H),7.57(d,1H),7.36(m,2H),7.29-7.27(m,2H),7.23(q,1H),6.94(d,1H),6.11(q,1H),4.63(q,1H),4.34(q,1H),4.17-4.11(m,2H),3.75(s,3H),3.39(s,3H),3.07(s,3H),2.60-2.50(m,2H),1.17(t,3H),1.05(t,3H).
ESI MS m/z: 511.19 [M+1] +
実施例83. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-メトキシフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 83. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-methoxyphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.26(s,1H),7.95(d,1H),7.41(d,1H),7.30-7.38(m,2H),7.24(d,1H),7.13(d,1H),7.03(t,1H),6.83(d,1H),6.06(q,1H),4.35-4.63(m,1H),4.19-4.34(m,3H),3.75(d,6H),3.06(s,3H),1.15-1.22(m,3H)
ESI MS m/z:499.16[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.26 (s, 1H), 7.95 (d, 1H), 7.41 (d, 1H), 7.30-7.38 (m, 2H), 7.24 (d, 1H), 7.13 (d, 1H), 7.03 (t, 1H), 6.83 (d, 1H), 6.06 (q, 1H), 4.35-4.63 (m, 1H), 4.19-4.34 (m, 3H), 3.75 (d, 6H), 3.06 (s, 3H), 1.15-1.22 (m, 3H)
ESI MS m/z: 499.16 [M+1] +
実施例84. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-メトキシフェニル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 84. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-methoxyphenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ8.01(d,1H),7.65(d,1H),7.04-7.07(m,1H),7.14-7.16(d,1H),7.33--7.40(m,2H),6.10(dd,1H),4.60-4.65(m,1H),4.32-4.36(m,1H),4.17-4.24(m,2H),3.79(s,3H),3.75(s,3H)3.40(s,3H),3.,07(s,3H),1.21(t,3H).
ESI MS m/z:513.17[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 8.01 (d, 1H), 7.65 (d, 1H), 7.04-7.07 (m, 1H), 7.14-7.16 (d, 1H), 7.33--7.40 (m, 2H), 6.10 (dd, 1H), 4.60-4.65 (m, 1H), 4. 32-4.36 (m, 1H), 4.17-4.24 (m, 2H), 3.79 (s, 3H), 3.75 (s, 3H) 3.40 (s, 3H), 3. , 07(s, 3H), 1.21(t, 3H).
ESI MS m/z: 513.17 [M+1] +
実施例85. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-(トリフルオロメチル)フェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 85. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-(trifluoromethyl)phenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.33(s,1H),7.84(q,2H),7.74(t,1H),7.64(t,1H),7.47(d,1H),7.27(t,2H),6.93(d,1H),6.07(q,1H),4.61(q,1H),4.32(q,1H),4.17-4.08(m,2H),3.75(s,3H),3.07(s,3H),1.17(t,3H)
ESI MS m/z:537.13[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.33 (s, 1H), 7.84 (q, 2H), 7.74 (t, 1H), 7.64 (t, 1H), 7.47 (d, 1H), 7.27 (t, 2H), 6.93 (d, 1H), 6.07 (q, 1H), 4.61 (q, 1H), 4 .32 (q, 1H), 4.17-4.08 (m, 2H), 3.75 (s, 3H), 3.07 (s, 3H), 1.17 (t, 3H)
ESI MS m/z: 537.13 [M+1] +
実施例86. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-(トリフルオロメチル)フェニル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 86. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-(trifluoromethyl)phenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.88(d,2H),7.76(t,1H),7.66(t,1H),7.59(s,1H),7.49(d,1H),7.27(d,1H),6.96(d,1H),6.12(q,1H),4.63(q,1H),4.35(q,1H),4.12-4.06(m,2H),3.75(s,3H),3.30(s,3H),3.07(s,3H),1.15(t,3H).
ESI MS m/z:551.15[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 7.88 (d, 2H), 7.76 (t, 1H), 7.66 (t, 1H), 7.59 (s, 1H), 7.49 (d, 1H), 7.27 (d, 1H), 6.96 (d, 1H), 6.12 (q, 1H), 4.63 (q, 1H), 4. 35 (q, 1H), 4.12-4.06 (m, 2H), 3.75 (s, 3H), 3.30 (s, 3H), 3.07 (s, 3H), 1.15 (t, 3H).
ESI MS m/z: 551.15 [M+1] +
実施例87. (S)-6-(2-シクロプロピルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 87. (S)-6-(2-cyclopropylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:509.18[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 509.18 [M+1] +
実施例88. (S)-6-(2,6-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 88. (S)-6-(2,6-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:505.13[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 505.13 [M+1] +
実施例89. (S)-6-(2,6-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 89. (S)-6-(2,6-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:519.14[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 519.14 [M+1] +
実施例90. (S)-6-(2,3-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 90. (S)-6-(2,3-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.45(s,1H),8.09(s,1H),7.52-7.38(m,3H),7.32(t,1H),7.25(d,1H),6.87(d,1H),6.08(q,1H),4.59(q,1H),4.34(q,1H),4.20(q,2H),3.75(s,3H),3.08(s,3H),1.24-1.18(m,3H).
ESI MS m/z:505.13[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.45 (s, 1H), 8.09 (s, 1H), 7.52-7.38 (m, 3H), 7.32 (t, 1H), 7.25 (d, 1H), 6.87 (d, 1H), 6.08 (q, 1H), 4.59 (q, 1H), 4.34 (q, 1H), 4.20 (q, 2H), 3.75 (s, 3H), 3.08 (s, 3H), 1.24-1.18 (m, 3H).
ESI MS m/z: 505.13 [M+1] +
実施例91. (S)-6-(2,3-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 91. (S)-6-(2,3-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ8.15(s,1H),7.82(s,1H),7.52-7.41(m,2H),7.35(t,1H),7.24(d,1H),6.90(d,1H),6.12(q,1H),4.59(q,1H),4.35(q,1H),4.21-4.15(m,2H),3.74(s,3H),3.43(s,3H),3.07(s,3H),1.19(t,3H).
ESI MS m/z:519.14[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 8.15 (s, 1H), 7.82 (s, 1H), 7.52-7.41 (m, 2H), 7.35 (t, 1H), 7.24 (d, 1H), 6.90 (d, 1H), 6.12 (q, 1H), 4.59 (q, 1H), 4.35 (q, 1 H), 4.21-4.15 (m, 2H), 3.74 (s, 3H), 3.43 (s, 3H), 3.07 (s, 3H), 1.19 (t, 3H).
ESI MS m/z: 519.14 [M+1] +
実施例92. (S)-6-(2,5-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 92. (S)-6-(2,5-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.44(s,1H),8.10(s,1H),7.52-7.47(m,2H),7.43-7.37(m,1H),7.29-7.23(m,2H),6.86(d,1H),6.07(q,1H),4.58(t,1H),4.36-4.23(m,1H),4.21-4.18(m,2H),3.75(s,3H),3.07(s,3H),1.21(t,3H).
ESI MS m/z:505.13[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.44 (s, 1H), 8.10 (s, 1H), 7.52-7.47 (m, 2H), 7.43-7.37 (m, 1H), 7.29-7.23 (m, 2H), 6.86 (d, 1H), 6.07 (q, 1H), 4.58 (t, 1 H), 4.36-4.23 (m, 1H), 4.21-4.18 (m, 2H), 3.75 (s, 3H), 3.07 (s, 3H), 1.21 (t, 3H).
ESI MS m/z: 505.13 [M+1] +
実施例93. (S)-6-(2,5-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 93. (S)-6-(2,5-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ8.15(s,1H),7.81(s,1H),7.54-7.50(m,1H),7.49-7.39(m,1H),7.32-7.23(m,2H),6.89(d,1H),6.11(q,1H),4.58(t,1H),4.35(q,1H),4.22-4.15(m,2H),3.74(s,3H),3.42(s,3H),3.07(s,3H),1.19(t,3H).
ESI MS m/z:519.14[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 8.15 (s, 1H), 7.81 (s, 1H), 7.54-7.50 (m, 1H), 7.49-7.39 (m, 1H), 7.32-7.23 (m, 2H), 6.89 (d, 1H), 6.11 (q, 1H), 4.58 (t, 1H) ), 4.35 (q, 1H), 4.22-4.15 (m, 2H), 3.74 (s, 3H), 3.42 (s, 3H), 3.07 (s, 3H), 1.19 (t, 3H).
ESI MS m/z: 519.14 [M+1] +
実施例94. (S)-6-(2,4-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 94. (S)-6-(2,4-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:505.13[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 505.13 [M+1] +
実施例95. (S)-6-(2,4-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 95. (S)-6-(2,4-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:519.14[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 519.14 [M+1] +
実施例96. (S)-6-(2,4,5-トリフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 96. (S)-6-(2,4,5-trifluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.45(s,1H),8.07(s,1H),7.82-7.67(m,2H),7.49(s,1H),7.24(d,1H),6.86(d,1H),6.07(q,1H),4.57(t,1H),4.35-4.31(m,1H),4.25-4.17(m,2H),3.75(s,3H),3.07(s,3H),1.20(q,3H).
ESI MS m/z:523.12[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.45 (s, 1H), 8.07 (s, 1H), 7.82-7.67 (m, 2H), 7.49 (s, 1H), 7.24 (d, 1H), 6.86 (d, 1H), 6.07 (q, 1H), 4.57 (t, 1H), 4.35-4. 31 (m, 1H), 4.25-4.17 (m, 2H), 3.75 (s, 3H), 3.07 (s, 3H), 1.20 (q, 3H).
ESI MS m/z: 523.12 [M+1] +
実施例97. (S)-6-(2,4,5-トリフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 97. (S)-6-(2,4,5-trifluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.55(s,1H),7.67-7.77(m,2H),7.60(q,1H),7.24(d,1H),6.83(d,1H),6.06(q,1H),4.58(q,1H),4.31(q,1H),4.23(q,2H),3.74(s,3H),3.34(s,3H),3.05(d,3H),1.15-1.22(m,3H).
ESI MS m/z:537.13[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 11.55 (s, 1H), 7.67-7.77 (m, 2H), 7.60 (q, 1H), 7.24 (d, 1H), 6.83 (d, 1H), 6.06 (q, 1H), 4.58 (q, 1H), 4.31 (q, 1H), 4.23 (q, 2H), 3.74 (s, 3H), 3.34 (s, 3H), 3.05 (d, 3H), 1.15-1.22 (m, 3H).
ESI MS m/z: 537.13 [M+1] +
実施例98. (R)-6-(2,5-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 98. (R)-6-(2,5-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:505.13[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 505.13 [M+1] +
実施例99. (S)-6-(2,4-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 99. (S)-6-(2,4-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.27(s,1H),7.82(d,1H),7.28(t,3H),7.09(m,3H),6.88(d,1H),6.07(q,1H),4.62(q,1H),4.35(q,1H),4.21(q,1H),3.75(s,3H),3.06(s,3H),2.31(s,3H),2.20(s,3H),1.19(t,3H)
ESI MS m/z:497.18[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.27 (s, 1H), 7.82 (d, 1H), 7.28 (t, 3H), 7.09 (m, 3H), 6.88 (d, 1H), 6.07 (q, 1H), 4.62 (q, 1H), 4.35 (q, 1H), 4.21 (q, 1H), 3 .75 (s, 3H), 3.06 (s, 3H), 2.31 (s, 3H), 2.20 (s, 3H), 1.19 (t, 3H)
ESI MS m/z: 497.18 [M+1] +
実施例100. (S)-6-(2,4-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 100. (S)-6-(2,4-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.87(d,1H),7.57(d,1H),7.25(d,1H),7.10(q,3H),6.91(d,1H),6.10(q,1H),4.62(q,1H),4.33(q,1H),4.19-4.13(m,2H),3.74(s,3H),3.40(s,3H),3.06(s,3H),2.32(s,3H),2.20(d,3H),1.18(t,3H).
ESI MS m/z:511.19[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 7.87 (d, 1H), 7.57 (d, 1H), 7.25 (d, 1H), 7.10 (q, 3H), 6.91 (d, 1H), 6.10 (q, 1H), 4.62 (q, 1H), 4.33 (q, 1H), 4.19-4.13 (m, 2 H), 3.74 (s, 3H), 3.40 (s, 3H), 3.06 (s, 3H), 2.32 (s, 3H), 2.20 (d, 3H), 1.18 (t, 3H).
ESI MS m/z: 511.19 [M+1] +
実施例101. (S)-6-(2,5-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 101. (S)-6-(2,5-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.29(s,1H),7.84(d,1H),7.26(t,2H),7.19(d,1H),7.10(d,1H),7.05(s,1H),6.88(d,1H),6.07(q,1H),4.62(q,1H),4.32(q,1H),4.23-4.16(m,2H),3.75(s,3H),3.07(s,3H),2.29(s,3H),2.18(s,3H),1.20(t,3H).
ESI MS m/z:497.18[M+1]+
Synthesized by referring to the method of Example 2.
1 HNMR(400MHz,DMSO-D6)δ11.29(s,1H),7.84(d,1H),7.26(t,2H),7.19(d,1H),7.10(d,1H),7.05(s,1H),6.88(d,1H),6.07(q,1H),4.62(q,1H),4.32(q,1H),4.23-4.16(m,2H),3.75(s,3H),3.07(s,3H),2.29(s,3H),2.18(s,3H),1.20(t,3H).
ESI MS m/z: 497.18 [M+1] +
実施例102. (S)-6-(2,5-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 102. (S)-6-(2,5-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.88(d,1H),7.59(d,1H),7.23(q,2H),7.10(t,2H),6.91(d,1H),6.10(q,1H),4.62(q,1H),4.32(q,1H),4.19-4.13(m,2H),3.75(s,3H),3.40(s,3H),3.06(s,3H),2.31(s,3H),2.20(s,3H),1.18(t,3H).
ESI MS m/z:511.19[M+1
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 7.88 (d, 1H), 7.59 (d, 1H), 7.23 (q, 2H), 7.10 (t, 2H), 6.91 (d, 1H), 6.10 (q, 1H), 4.62 (q, 1H), 4.32 (q, 1H), 4.19-4.13 (m, 2 H), 3.75 (s, 3H), 3.40 (s, 3H), 3.06 (s, 3H), 2.31 (s, 3H), 2.20 (s, 3H), 1.18 (t, 3H).
ESI MS m/z: 511.19 [M+1
実施例103. (S)-6-(2,3-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 103. (S)-6-(2,3-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.29(s,1H),7.81(d,1H),7.27-7.13(m,4H),7.05(d,1H),6.89(d,1H),6.07(q,1H),4.62(q,1H),4.32(q,1H),4.22-4.16(m,2H),3.75(s,3H),3.07(s,3H),2.30(s,3H),2.11(s,3H),1.20(t,3H).
ESI MS m/z:497.18[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.29 (s, 1H), 7.81 (d, 1H), 7.27-7.13 (m, 4H), 7.05 (d, 1H), 6.89 (d, 1H), 6.07 (q, 1H), 4.62 (q, 1H), 4.32 (q, 1H), 4.22-4. 16 (m, 2H), 3.75 (s, 3H), 3.07 (s, 3H), 2.30 (s, 3H), 2.11 (s, 3H), 1.20 (t, 3H).
ESI MS m/z: 497.18 [M+1] +
実施例104. (S)-6-(2,3-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 104. (S)-6-(2,3-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.85(d,1H),7.55(d,1H),7.26-7.14(m,3H),7.08(d,1H),6.92(d,1H),6.11(q,1H),4.63(q,1H),4.34(q,1H),4.19-4.12(m,2H),3.75(s,3H),3.39(s,3H),3.07(s,3H),2.31(s,3H),2.12(s,3H),1.18(t,3H).
ESI MS m/z:511.19[M+1]+
Synthesized by referring to the method of Example 19.
1 HNMR(400MHz,DMSO-D6)δ7.85(d,1H),7.55(d,1H),7.26-7.14(m,3H),7.08(d,1H),6.92(d,1H),6.11(q,1H),4.63(q,1H),4.34(q,1H),4.19-4.12(m,2H),3.75(s,3H),3.39(s,3H),3.07(s,3H),2.31(s,3H),2.12(s,3H),1.18(t,3H).
ESI MS m/z: 511.19 [M+1] +
実施例105. (S)-6-(2,6-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 105. (S)-6-(2,6-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:497.18[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 497.18 [M+1] +
実施例106. (S)-6-(2,6-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 106. (S)-6-(2,6-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:511.19[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 511.19 [M+1] +
実施例107. (S)-6-(4-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 107. (S)-6-(4-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.32(s,1H),7.84(d,1H),7.28-7.21(m, 3H),7.18(t,1H),7.12-7.07(m,1H),6.89(d,1H),6.07(q,1H),4.61(q,1H),4.35-4.22(m,1H),4.21-4.16(m,2H),3.75(s,3H),3.07(s,3H),2.24(s,3H),1.19(t,3H).
ESI MS m/z:501.15[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.32 (s, 1H), 7.84 (d, 1H), 7.28-7.21 (m, 3H), 7.18 (t, 1H), 7.12-7.07 (m, 1H), 6.89 (d, 1H), 6.07 (q, 1H), 4.61 (q, 1H), 4 .35-4.22 (m, 1H), 4.21-4.16 (m, 2H), 3.75 (s, 3H), 3.07 (s, 3H), 2.24 (s, 3H), 1.19 (t, 3H).
ESI MS m/z: 501.15 [M+1] +
実施例108. (S)-6-(4-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 108. (S)-6-(4-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.89(d,1H),7.60(d,1H),7.31-7.19(m,3H),7.13(q,1H),6.92(d,1H),6.11(q,1H),4.61(q,1H),4.34(q,1H),4.17-4.13(m,2H),3.74(s,3H),3.40(s,3H),3.07(s,3H),2.26(s,3H),1.17(t,3H).
ESI MS m/z:515.17[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 7.89 (d, 1H), 7.60 (d, 1H), 7.31-7.19 (m, 3H), 7.13 (q, 1H), 6.92 (d, 1H), 6.11 (q, 1H), 4.61 (q, 1H), 4.34 (q, 1H), 4.17-4.1 3 (m, 2H), 3.74 (s, 3H), 3.40 (s, 3H), 3.07 (s, 3H), 2.26 (s, 3H), 1.17 (t, 3H).
ESI MS m/z: 515.17 [M+1] +
実施例109. (S)-6-(5-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 109. (S)-6-(5-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:501.15[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 501.15 [M+1] +
実施例110. (S)-6-(5-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 110. (S)-6-(5-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:515.17[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 515.17 [M+1] +
実施例111. (S)-6-(3-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 111. (S)-6-(3-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:501.15[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 501.15 [M+1] +
実施例112. (S)-6-(3-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 112. (S)-6-(3-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:515.17[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 515.17 [M+1] +
実施例113. (S)-6-(2-フルオロ-5-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 113. (S)-6-(2-fluoro-5-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:501.15[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 501.15 [M+1] +
実施例114. (S)-6-(2-フルオロ-5-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 114. (S)-6-(2-fluoro-5-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:515.17[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 515.17 [M+1] +
実施例115. (S)-6-(2-フルオロ-4-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 115. (S)-6-(2-fluoro-4-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:501.15[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 501.15 [M+1] +
実施例116. (S)-6-(2-フルオロ-4-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 116. (S)-6-(2-fluoro-4-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:515.17[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 515.17 [M+1] +
実施例117. (S)-6-(5-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 117. (S)-6-(5-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:517.15[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 517.15 [M+1] +
実施例118. (S)-6-(5-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 118. (S)-6-(5-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:531.16[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 531.16 [M+1] +
実施例119. (S)-6-(4-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 119. (S)-6-(4-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:517.15[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 517.15 [M+1] +
実施例120. (S)-6-(4-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 120. (S)-6-(4-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:531.16[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 531.16 [M+1] +
実施例121. (S)-6-(6-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 121. (S)-6-(6-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:517.15[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 517.15 [M+1] +
実施例122. (S)-6-(ピリジン-2-イル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 122. (S)-6-(pyridin-2-yl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:470.14[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 470.14 [M+1] +
実施例123. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 123. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:484.16[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 484.16 [M+1] +
実施例124. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-エチル-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 124. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-ethyl-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:498.17[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 498.17 [M+1] +
実施例125. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-(2-メトキシエチル)-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 125. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-(2-methoxyethyl)-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:528.18[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 528.18 [M+1] +
実施例126. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 126. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ8.11(m,1H),7.77(t,1H),7.58-7.62(m,1H),7.43-7.47(m,1H),7.32--7.38(m,2H),6.12(dd,1H),4.58-4.64(m,1H),4.16-4.22(m,2H),4.32-437(m,1H),3.74(s,3H),3.43(s,3H),2.96(s,3H),1.21(t,3H)
ESI MS m/z:501.15[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 8.11 (m, 1H), 7.77 (t, 1H), 7.58-7.62 (m, 1H), 7.43-7.47 (m, 1H), 7.32--7.38 (m, 2H), 6.12 (dd, 1H), 4.58-4.64 (m, 1H), 4. 16-4.22 (m, 2H), 4.32-437 (m, 1H), 3.74 (s, 3H), 3.43 (s, 3H), 2.96 (s, 3H), 1.21 (t, 3H)
ESI MS m/z: 501.15 [M+1] +
実施例127. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 127. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:496.18[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 496.18 [M+1] +
実施例128. (S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 128. (S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:501.16[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 501.16 [M+1] +
実施例129. (S)-5-ブロモ-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 129. (S)-5-bromo-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:470.03[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 470.03 [M+1] +
実施例130. (S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-フェニル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 130. (S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-phenyl-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.11(s,1H),7.45-7.41(t,2H),7.33-7.31(d,2H),7.27-7.20(q,5H),6.84-6.82(d,1H),6.06-6.03(q,1H),4.40-4.35(m,3H),4.28-4.24(t,1H),3.75(s,6H),3.04(s,3H),1.33-1.30(q,3H).
ESI MS m/z:468.15[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.11 (s, 1H), 7.45-7.41 (t, 2H), 7.33-7.31 (d, 2H), 7.27-7.20 (q, 5H), 6.84-6.82 (d, 1H), 6.06-6.03 (q, 1H), 4.40-4.35 (m, 3H), 4.28-4.24 (t, 1H), 3.75 (s, 6H), 3.04 (s, 3H), 1.33-1.30 (q, 3H).
ESI MS m/z: 468.15 [M+1] +
実施例131. (S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-フェニル-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 131. (S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-phenyl-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.68-7.66(d,2H),7.48-7.43(q,3H),7.34-7.24(m,4H),6.86-6.84(d,1H),6.09-6.06(q,1H),4.40-4.30(q,3H),4.28-4.24(t,1H),3.74(s,3H),3.41(s,3H),3.04(s,3H),1.32-1.29(t,3H).
ESI MS m/z:482.17[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 7.68-7.66 (d, 2H), 7.48-7.43 (q, 3H), 7.34-7.24 (m, 4H), 6.86-6.84 (d, 1H), 6.09-6.06 (q, 1H), 4.40-4.30 (q, 3H), 4.28- 4.24 (t, 1H), 3.74 (s, 3H), 3.41 (s, 3H), 3.04 (s, 3H), 1.32-1.29 (t, 3H).
ESI MS m/z: 482.17 [M+1] +
実施例132. (S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 132. (S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.12(s,1H),7.47-7.51(m,1H),7.28-7.38(m,1H),7.24-7.27(m,4H),7.13(t,2H),6.85(d,1H),6.05(q,1H),4.33-4.41(m,3H),4.22-4.28(m,1H),3.74(s,3H),3.03(d,3H),1.29(t,3H)
ESI MS m/z:486.14[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.12 (s, 1H), 7.47-7.51 (m, 1H), 7.28-7.38 (m, 1H), 7.24-7.27 (m, 4H), 7.13 (t, 2H), 6.85 (d, 1H), 6.05 (q, 1H), 4.33-4.4 1 (m, 3H), 4.22-4.28 (m, 1H), 3.74 (s, 3H), 3.03 (d, 3H), 1.29 (t, 3H)
ESI MS m/z: 486.14 [M+1] +
実施例133. (S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロフェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 133. (S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluorophenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.40-7.54(m,1H),7.34-7.39(m,1H),7.26-7.32(m,5H),7.25(d,1H),6.85(d,1H),6.08(q,1H),4.25-4.43(m,4H),3.74(s,3H),3.38(s,3H),3.05(s,3H),1.27(q,3H).
ESI MS m/z:486.14[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 7.40-7.54 (m, 1H), 7.34-7.39 (m, 1H), 7.26-7.32 (m, 5H), 7.25 (d, 1H), 6.85 (d, 1H), 6.08 (q, 1H), 4.25-4.43 (m, 4H), 3.74 (s, 3H), 3.38 (s, 3H), 3.05 (s, 3H), 1.27 (q, 3H).
ESI MS m/z: 486.14 [M+1] +
実施例134. (R)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 134. (R)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:486.14[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 486.14 [M+1] +
実施例135. (S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(4-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 135. (S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(4-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:486.14[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 486.14 [M+1] +
実施例136. (R)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(4-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 136. (R)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(4-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:486.14[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 486.14 [M+1] +
実施例137. (S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-5-(4-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 137. (S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-5-(4-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:500.16[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 500.16 [M+1] +
実施例138. (R)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-5-(4-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 138. (R)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-5-(4-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:500.16[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 500.16 [M+1] +
実施例139. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(o-メチルフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 139. (S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(o-methylphenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.04(s,1H),7.15-7.19(m,6H),6.86-6.90(m,3H),6.04(q,1H),4.35(q,4H),4.00(q,3H),3.05(s,3H),2.21(s,3H),1.29(t,3H)
ESI MS m/z:482.17[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.04 (s, 1H), 7.15-7.19 (m, 6H), 6.86-6.90 (m, 3H), 6.04 (q, 1H), 4.35 (q, 4H), 4.00 (q, 3H), 3.05 (s, 3H), 2.21 (s, 3H), 1. 29 (t, 3H)
ESI MS m/z: 482.17 [M+1] +
実施例140. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(o-メチルフェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 140. (S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(o-methylphenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.15-7.30(m,6H),7.88-6.97(m.,1H),7.16(t.,1H),6.90(d.,1H),6.07(q.,1H),4.28-4.44(m.,4H),3.75(s,3H),3.36(s,3H),3.34(s,3H),2.50(t,3H),2.45(t,3H).
ESI MS m/z:496.18[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 7.15-7.30 (m, 6H), 7.88-6.97 (m., 1H), 7.16 (t., 1H), 6.90 (d., 1H), 6.07 (q., 1H), 4.28-4.44 (m., 4H), 3.75 (s, 3H), 3.36 (s, 3H), 3.34 (s, 3H), 2.50 (t, 3H), 2.45 (t, 3H).
ESI MS m/z: 496.18 [M+1] +
実施例141. (R)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(o-メチルフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 141. (R)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(o-methylphenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:482.17[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 482.17 [M+1] +
実施例142. (S)-5-(2-クロロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 142. (S)-5-(2-chlorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:502.11[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 502.11 [M+1] +
実施例143. (S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-メトキシフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 143. (S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-methoxyphenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.00(s,1H),7.23-7.32(m,3H),7.14 (d,1H),7.08(t,2H),6.97-7.02(m,2H),6.83(d,1H),6.03(q,1H),4.35-4.42(m,3H),4.21-4.27(m,1H),3.74(d,6H),3.05(s,3H),1.32(t,3H).
ESI MS m/z:498.16[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.00 (s, 1H), 7.23-7.32 (m, 3H), 7.14 (d, 1H), 7.08 (t, 2H), 6.97-7.02 (m, 2H), 6.83 (d, 1H), 6.03 (q, 1H), 4.35-4.42 (m, 3 H), 4.21-4.27 (m, 1H), 3.74 (d, 6H), 3.05 (s, 3H), 1.32 (t, 3H).
ESI MS m/z: 498.16 [M+1] +
実施例144. (S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-メトキシフェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 144. (S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-methoxyphenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.21-7.34(m,5H),7.07-7.10(m,2H),7.02(t,1H),6.84(d,1H),6.07(q,1H),4.24-4.43(m,4H),3.74(d,6H),3.33(t,3H),3.05(s,3H),1.29(q,3H)
ESI MS m/z:512.18[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 7.21-7.34 (m, 5H), 7.07-7.10 (m, 2H), 7.02 (t, 1H), 6.84 (d, 1H), 6.07 (q, 1H), 4.24-4.43 (m, 4H), 3.74 (d, 6H), 3.33 (t, 3H) ), 3.05 (s, 3H), 1.29 (q, 3H)
ESI MS m/z: 512.18 [M+1] +
実施例145. (R)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-メトキシフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 145. (R)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-methoxyphenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:498.16[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 498.16 [M+1] +
実施例146. (S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-(トリフルオロメチル)フェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 146. (S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.08(s,1H),7.82-7.80(d,1H),7.69-7.67(d,1H),7.60-7.58(d,1H),7.41-7.39(d,1H),7.29-7.24(q.2H),6.91-6.87(q,2H),6.05-6.02(q,1H),4.38-4.27(m,5H),3.77-3.74(t,3H),3.05(s,3H),1.28-1.25(t,3H).
ESI MS m/z:536.14[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.08 (s, 1H), 7.82-7.80 (d, 1H), 7.69-7.67 (d, 1H), 7.60-7.58 (d, 1H), 7.41-7.39 (d, 1H), 7.29-7.24 (q.2H), 6.91-6.87 (q, 2H), 6.05-6.02 (q, 1H), 4.38-4.27 (m, 5H), 3.77-3.74 (t, 3H), 3.05 (s, 3H), 1.28-1.25 (t, 3H).
ESI MS m/z: 536.14 [M+1] +
実施例147. (S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-(トリフルオロメチル)フェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 147. (S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-(trifluoromethyl)phenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
1HNM(400MHz,DMSO-D6)7.84-7.82(d,1H),7.73-7.59(m,2H),7.44-7.42(d,1H),7.33-7.27(q,2H),7.15(s,1H),6.96-6.91(t,2H),6.09-6.06(q,1H),4.45-4.37(m,1H),4.34-4.24(m,3H),3.78-3.74(t,3H),3.35(s,3H),3.05(s,3H),1.27-1.23(t,3H).
ESI MS m/z:550.15[M+1]+
Synthesized by referring to the method of Example 19.
1 HNM(400MHz,DMSO-D6)7.84-7.82(d,1H),7.73-7.59(m,2H),7.44-7.42(d,1H),7.33-7.27(q,2H),7.15(s,1H),6.96-6.91(t,2H),6.09-6.06(q,1H),4.45-4.37(m,1H),4.34-4.24(m,3H),3.78-3.74(t,3H),3.35(s,3H),3.05(s,3H),1.27-1.23(t,3H).
ESI MS m/z: 550.15 [M+1] +
実施例148. (S)-5-(2-シクロプロピルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 148. (S)-5-(2-cyclopropylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:508.18[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 508.18 [M+1] +
実施例149. (S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-イソプロピルフェニル)-4-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 149. (S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-isopropylphenyl)-4-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:524.21[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 524.21 [M+1] +
実施例150. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-エチルフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 150. (S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-ethylphenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.03(s,1H),7.28(q,3H),7.21(d,2H),7.13(d,2H),6.86(t,3H),4.33-4.42(m,4H),3.75(s,3H),3.05(s,3H),2.53(q,2H),1.27(q,3H),1.03(t,3H).
ESI MS m/z:496.18[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.03 (s, 1H), 7.28 (q, 3H), 7.21 (d, 2H), 7.13 (d, 2H), 6.86 (t, 3H), 4.33-4.42 (m, 4H), 3.75 (s, 3H), 3.05 (s, 3H), 2.53 (q, 2H), 1.27 (q, 3H), 1.03 (t, 3H).
ESI MS m/z: 496.18 [M+1] +
実施例151. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-エチルフェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 151. (S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-ethylphenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.11-7.34(m,7H),6.91(t,2H),6.07(q,1H),4.29-4.44(m,4H),3.75(s,3H),3.34(d,3H),3.05(s,3H),2.50-2.58(m,2H),1.25(q,3H),1.03(t,3H).
ESI MS m/z:510.20[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 7.11-7.34 (m, 7H), 6.91 (t, 2H), 6.07 (q, 1H), 4.29-4.44 (m, 4H), 3.75 (s, 3H), 3.34 (d, 3H), 3.05 (s, 3H), 2.50-2.58 (m, 2H) ), 1.25(q, 3H), 1.03(t, 3H).
ESI MS m/z: 510.20 [M+1] +
実施例152. (S)-5-(2,3-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 152. (S)-5-(2,3-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.18(s,1H),7.43-7.34(m,1H),7.32-7.24(m,4H),7.16-7.13(q,2H),6.86-6.84(t,1H),6.07-6.03(q,1H),4.38-4.33(m,3H),4.29-4.23(q,1H),3.75(s,3H),3.06(s,3H),1.32-1.29(t,3H).
ESI MS m/z:504.13[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.18 (s, 1H), 7.43-7.34 (m, 1H), 7.32-7.24 (m, 4H), 7.16-7.13 (q, 2H), 6.86-6.84 (t, 1H), 6.07-6.03 (q, 1H), 4.38-4.33 (m, 3H), 4.29-4.23 (q, 1H), 3.75 (s, 3H), 3.06 (s, 3H), 1.32-1.29 (t, 3H).
ESI MS m/z: 504.13 [M+1] +
実施例153. (S)-5-(2,3-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 153. (S)-5-(2,3-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.43-7.20(m,7H),6.88-6.86(d,1H),6.11-6.07(q,1H),4.42-4.26(m,4H),3.75(s,3H),3.40(s,3H),3.06(s,3H),1.31-1.28(t,3H).
ESI MS m/z:518.15[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 7.43-7.20 (m, 7H), 6.88-6.86 (d, 1H), 6.11-6.07 (q, 1H), 4.42-4.26 (m, 4H), 3.75 (s, 3H), 3.40 (s, 3H), 3.06 (s, 3H), 1.31 −1.28(t,3H).
ESI MS m/z: 518.15 [M+1] +
実施例154. (S)-5-(2,6-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 154. (S)-5-(2,6-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.14-11.00(d,1H),7.28-7.20(m,2H),7.13-7.03(t,1H),6.99-6.90(m,3H),6.81-6.79(d,1H),6.03-5.99(q,1H),4.42-4.28(m,4H),4.26-4.13(m,1H),3.74(s,3H),3.12-3.07(d,1H),3.02(s,3H),1.31-1.28(t,3H).
ESI MS m/z:504.13[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.14-11.00 (d, 1H), 7.28-7.20 (m, 2H), 7.13-7.03 (t, 1H), 6.99-6.90 (m, 3H), 6.81-6.79 (d, 1H), 6.03-5.99 (q, 1H), 4.4 2-4.28 (m, 4H), 4.26-4.13 (m, 1H), 3.74 (s, 3H), 3.12-3.07 (d, 1H), 3.02 (s, 3H), 1.31-1.28 (t, 3H).
ESI MS m/z: 504.13 [M+1] +
実施例155. (S)-5-(2,6-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 155. (S)-5-(2,6-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.27-7.15(m,4H),7.08-7.06(t,1H),7.04-7.00(t,1H),6.83-6.81(d,1H),6.07-6.03(q,1H),4.39-4.22(m,5H),3.74(s,3H),3.35(s,3H),3.02(s,3H)1.30-1.27(t,3H).
ESI MS m/z:518.15[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 7.27-7.15 (m, 4H), 7.08-7.06 (t, 1H), 7.04-7.00 (t, 1H), 6.83-6.81 (d, 1H), 6.07-6.03 (q, 1H), 4.39-4.22 (m, 5H), 3.74 ( s, 3H), 3.35 (s, 3H), 3.02 (s, 3H) 1.30-1.27 (t, 3H).
ESI MS m/z: 518.15 [M+1] +
実施例156. (S)-5-(2,4-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 156. (S)-5-(2,4-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.14(s,1H),7.57-7.51(m,1H),7.37-7.31(m,1H),7.27-7.24(q,2H),7.22-7.17(m,1H),7.16-7.07(m,2H),6.85-6.83(t,1H),6.06-6.03(q,1H),4.38-4.34(m,3H),4.33-4.22(m,1H),3.75(s,3H),3.05(s,3H),1.32-1.29(t,3H).
ESI MS m/z:504.13[M+1]+
Synthesized by referring to the method of Example 2.
1 HNMR(400MHz,DMSO-D6)δ11.14(s,1H),7.57-7.51(m,1H),7.37-7.31(m,1H),7.27-7.24(q,2H),7.22-7.17(m,1H),7.16-7.07(m,2H),6.85-6.83(t,1H),6.06-6.03(q,1H),4.38-4.34(m,3H),4.33-4.22(m,1H),3.75(s,3H),3.05(s,3H),1.32-1.29(t,3H).
ESI MS m/z: 504.13 [M+1] +
実施例157. (S)-5-(2,4-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 157. (S)-5-(2,4-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.38-7.31(m,1H),7.29-7.13(m,6H),6.87-6.85(d,1H),6.10-6.06(q,1H),4.42-4.28(m,4H),3.75(s,3H),3.38(s,3H),3.05(s,3H),1.31-1.24(q,3H).
ESI MS m/z:518.15[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 7.38-7.31 (m, 1H), 7.29-7.13 (m, 6H), 6.87-6.85 (d, 1H), 6.10-6.06 (q, 1H), 4.42-4.28 (m, 4H), 3.75 (s, 3H), 3.38 (s, 3H) , 3.05(s, 3H), 1.31-1.24(q, 3H).
ESI MS m/z: 518.15 [M+1] +
実施例158. (S)-5-(2,4,5-トリフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 158. (S)-5-(2,4,5-trifluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.17(s,1H),7.68-7.62(m,2H),7.27-7.23(t,2H)7.14-7.11(m,2H),6.85-6.83(d,1H),6.06-6.03(q,1H),4.40-4.34(m,3H),4.28-4.25(t,1H),3.75(s,3H),3.05(s,3H),1.32-1.29(t,3H).
ESI MS m/z:522.12[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.17 (s, 1H), 7.68-7.62 (m, 2H), 7.27-7.23 (t, 2H) 7.14-7.11 (m, 2H), 6.85-6.83 (d, 1H), 6.06-6.03 (q, 1H), 4.40-4.34 ( m, 3H), 4.28-4.25 (t, 1H), 3.75 (s, 3H), 3.05 (s, 3H), 1.32-1.29 (t, 3H).
ESI MS m/z: 522.12 [M+1] +
実施例159. (S)-5-(2,4,5-トリフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 159. (S)-5-(2,4,5-trifluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.75-7.63(m,2H),7.38(s,1H),7.33-7.31(d,1H),7.27-7.25(d,1H),7.20-7.18(d,1H),6.87-6.85(d,1H),6.10-6.07(q,1H),4.41-4.25(m,4H),3.75(s,3H),3.39(s,3H),3.05(s,3H),1.31-1.28(t,3H).
ESI MS m/z:536.14[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 7.75-7.63 (m, 2H), 7.38 (s, 1H), 7.33-7.31 (d, 1H), 7.27-7.25 (d, 1H), 7.20-7.18 (d, 1H), 6.87-6.85 (d, 1H), 6.10-6.07 ( q, 1H), 4.41-4.25 (m, 4H), 3.75 (s, 3H), 3.39 (s, 3H), 3.05 (s, 3H), 1.31-1.28 (t, 3H).
ESI MS m/z: 536.14 [M+1] +
実施例160. (S)-5-(2,5-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 160. (S)-5-(2,5-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.17(s,1H),7.39-7.25(m,2H),7.24-7.1(m,3H),7.16-7.14(q,2H),6.85-6.83(t,1H),6.07-6.03(q,1H),4.40-4.35(m,3H),4.33-4.22(m,1H),3.75(s,3H),3.05(s,3H),1.32-1.29(t,3H).
ESI MS m/z:504.13[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.17 (s, 1H), 7.39-7.25 (m, 2H), 7.24-7.1 (m, 3H), 7.16-7.14 (q, 2H), 6.85-6.83 (t, 1H), 6.07-6.03 (q, 1H), 4.40-4.35 ( m, 3H), 4.33-4.22 (m, 1H), 3.75 (s, 3H), 3.05 (s, 3H), 1.32-1.29 (t, 3H).
ESI MS m/z: 504.13 [M+1] +
実施例161. (S)-5-(2,5-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 161. (S)-5-(2,5-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.46-7.31(m,4H),7.26-7.21(m,3H),6.87-6.85(d,1H),6.10-6.07(q,1H),4.37-4.25(m,4H),3.74(s,3H),3.39(s,3H),3.05(s,3H),1.31-1.27(q,3H).
ESI MS m/z:518.15[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 7.46-7.31 (m, 4H), 7.26-7.21 (m, 3H), 6.87-6.85 (d, 1H), 6.10-6.07 (q, 1H), 4.37-4.25 (m, 4H), 3.74 (s, 3H), 3.39 (s, 3H) , 3.05(s, 3H), 1.31-1.27(q, 3H).
ESI MS m/z: 518.15 [M+1] +
実施例162. (S)-5-(2,4-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 162. (S)-5-(2,4-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.00(s,1H),7.36-7.26(m,1H),7.19-7.17(t,2H),7.11-7.01(m,1H),6.99-6.94(t,3H),6.87-6.85(q,1H),6.05-6.01(q,1H),4.51-4.26(m,3H),4.41-4.22(q,1H),3.77-3.74(q,3H),3.07-3.02(t,3H),2.30-2.29(d,3H),2.20-2.28(d,3H),1.31-1.25(q,3H).
ESI MS m/z:496.18[M+1]+
Synthesized by referring to the method of Example 2.
1 HNMR(400MHz,DMSO-D6)δ11.00(s,1H),7.36-7.26(m,1H),7.19-7.17(t,2H),7.11-7.01(m,1H),6.99-6.94(t,3H),6.87-6.85(q,1H),6.05-6.01(q,1H),4.51-4.26(m,3H),4.41-4.22(q,1H),3.77-3.74(q,3H),3.07-3.02(t,3H),2.30-2.29(d,3H),2.20-2.28(d,3H),1.31-1.25(q,3H).
ESI MS m/z: 496.18 [M+1] +
実施例163. (S)-5-(2,4-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 163. (S)-5-(2,4-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.27-7.24(q,2H),7.11-7.05(q,5H),6.93-6.87(q,1H),6.08-6.05(q,1H),4.42-4.31(m,4H),3.77-3.75(d,3H),3.35(s,3H),3.07-3.05(s,3H),2.30(s,3H),1.29-1.23(q,3H).
ESI MS m/z:510.20[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 7.27-7.24 (q, 2H), 7.11-7.05 (q, 5H), 6.93-6.87 (q, 1H), 6.08-6.05 (q, 1H), 4.42-4.31 (m, 4H), 3.77-3.75 (d, 3H), 3.35 ( s, 3H), 3.07-3.05 (s, 3H), 2.30 (s, 3H), 1.29-1.23 (q, 3H).
ESI MS m/z: 510.20 [M+1]+
実施例164. (S)-5-(2,5-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 164. (S)-5-(2,5-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.02(s,1H),7.28-7.26(d,1H),7.20-7.13(q,2H),7.05-7.03(d,1H),6.98(s,1H),6.88-6.86(q,3H),6.05-6.02(q,1H),4.42-4.33(m,3H),4.28-4.26(d,1H),3.78-3.75(d,3H),3.08-3.05(d,3H),2.27(s,3H),2.19-2.16(d,3H),1.31-1.26(q,3H).
ESI MS m/z:496.18[M+1]+
Synthesized by referring to the method of Example 2.
1 HNMR(400MHz,DMSO-D6)δ11.02(s,1H),7.28-7.26(d,1H),7.20-7.13(q,2H),7.05-7.03(d,1H),6.98(s,1H),6.88-6.86(q,3H),6.05-6.02(q,1H),4.42-4.33(m,3H),4.28-4.26(d,1H),3.78-3.75(d,3H),3.08-3.05(d,3H),2.27(s,3H),2.19-2.16(d,3H),1.31-1.26(q,3H).
ESI MS m/z: 496.18 [M+1] +
実施例165. (S)-5-(2,5-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 165. (S)-5-(2,5-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.27-7.25(q,2H),7.17-7.13(t,2H),7.06-7.02(t,2H),6.94-6.92(d,1H),6.89-6.87(d,1H),6.09-6.05(q,1H),4.44-4.27(m,4H),3.75(s,3H),3.36(s,3H),3.05(s,3H),2.28(s,3H),2.18(s,3H),1.30-1.26(t,3H).
ESI MS m/z:510.20[M+1]+
Synthesized by referring to the method of Example 19.
1 HNMR(400MHz,DMSO-D6)δ7.27-7.25(q,2H),7.17-7.13(t,2H),7.06-7.02(t,2H),6.94-6.92(d,1H),6.89-6.87(d,1H),6.09-6.05(q,1H),4.44-4.27(m,4H),3.75(s,3H),3.36(s,3H),3.05(s,3H),2.28(s,3H),2.18(s,3H),1.30-1.26(t,3H).
ESI MS m/z: 510.20 [M+1] +
実施例166. (S)-5-(2,3-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 166. (S)-5-(2,3-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.02(s,1H),7.28-7.26(d,1H),7.18-7.08(m,3H),7.00-6.99(d,1H),6.88-6.83(m.3H),6.05-6.02(q,1H),4.42-4.33(m,3H),4.29-4.27(d,1H),3.75(s,3H),3.05(s,3H),2.08(s,3H),2.09(s,3H),1.31-1.24(q,3H).
ESI MS m/z:496.18[M+1]+
Synthesized by referring to the method of Example 2.
1 HNMR(400MHz,DMSO-D6)δ11.02(s,1H),7.28-7.26(d,1H),7.18-7.08(m,3H),7.00-6.99(d,1H),6.88-6.83(m.3H),6.05-6.02(q,1H),4.42-4.33(m,3H),4.29-4.27(d,1H),3.75(s,3H),3.05(s,3H),2.08(s,3H),2.09(s,3H),1.31-1.24(q,3H).
ESI MS m/z: 496.18 [M+1] +
実施例167. (S)-5-(2,3-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル--1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 167. (S)-5-(2,3-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl--1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)7.28-7.26(d,2H),7.17-7.10(m,3H),7.04-7.03(d,1H),6.91-6.88(m,2H),6.10-6.06(q,1H),4.44-4.30(m,4H),3.75(s,3H),3.36(s,3H),3.05(s,3H),2.29(s,3H),2.11(s,3H),1.30-1.26(t,3H).
ESI MS m/z:510.20[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) 7.28-7.26 (d, 2H), 7.17-7.10 (m, 3H), 7.04-7.03 (d, 1H), 6.91-6.88 (m, 2H), 6.10-6.06 (q, 1H), 4.44-4.30 (m, 4H), 3.75 (s , 3H), 3.36 (s, 3H), 3.05 (s, 3H), 2.29 (s, 3H), 2.11 (s, 3H), 1.30-1.26 (t, 3H).
ESI MS m/z: 510.20 [M+1] +
実施例168. (S)-5-(2,6-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 168. (S)-5-(2,6-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:496.18[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 496.18 [M+1] +
実施例169. (S)-5-(4-フルオロ-2-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 169. (S)-5-(4-fluoro-2-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.01(s,1H),7.25-7.20(t,1H),7.12-7.10(d,2H),7.09-7.07(d,2H),6.84-6.82(d,1H),6.05-6.02(q,1H),4.40-4.33(m,3H),4.28-4.22(q,1H),3.75(s,3H),3.05-3.01(d,3H),2.34(s,3H),1.33-1.29(q,3H).
ESI MS m/z:500.16[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.01 (s, 1H), 7.25-7.20 (t, 1H), 7.12-7.10 (d, 2H), 7.09-7.07 (d, 2H), 6.84-6.82 (d, 1H), 6.05-6.02 (q, 1H), 4.40-4.33 (m, 3H), 4.28-4.22 (q, 1H), 3.75 (s, 3H), 3.05-3.01 (d, 3H), 2.34 (s, 3H), 1.33-1.29 (q, 3H).
ESI MS m/z: 500.16 [M+1] +
実施例170. (S)-5-(4-フルオロ-2-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 170. (S)-5-(4-fluoro-2-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:514.17[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 514.17 [M+1] +
実施例171. (S)-5-(5-フルオロ-2-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 171. (S)-5-(5-fluoro-2-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:500.16[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 500.16 [M+1] +
実施例172. (S)-5-(5-フルオロ-2-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 172. (S)-5-(5-fluoro-2-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.34-7.26(m,3H),7.20(s,1H),7.12-7.03(m,2 H),7.00-6.98(q,1H),6.90-6.88(d,1H),6.10-6.06(q,1H),4.44-4.26(m,4H),3.75(s,3H),3.37(s,3H),3.06(s,3H),2.21(s,3H),1.30-1.26(t,3H).
ESI MS m/z:514.17[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 7.34-7.26 (m, 3H), 7.20 (s, 1H), 7.12-7.03 (m, 2H), 7.00-6.98 (q, 1H), 6.90-6.88 (d, 1H), 6.10-6.06 (q, 1H), 4.44-4.26 (m, 4H), 3.75 (s, 3H), 3.37 (s, 3H), 3.06 (s, 3H), 2.21 (s, 3H), 1.30-1.26 (t, 3H).
ESI MS m/z: 514.17 [M+1] +
実施例173. (S)-5-(3-フルオロ-2-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 173. (S)-5-(3-fluoro-2-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.08(s,1H),7.16-7.11(t,3H),7.06-7.04(d,1H),6.91-6.90(t,1H),6.88-6.86(d,3H),6.05-6.02(q,1H),4.42-4.23(m,4H),3.75(s,3H),3.05(s,3H),2.12(s,1H),1.31-1.27(t,3H).
ESI MS m/z:500.16[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.08 (s, 1H), 7.16-7.11 (t, 3H), 7.06-7.04 (d, 1H), 6.91-6.90 (t, 1H), 6.88-6.86 (d, 3H), 6.05-6.02 (q, 1H), 4.42-4.23 (m, 4H), 3.75 (s, 3H), 3.05 (s, 3H), 2.12 (s, 1H), 1.31-1.27 (t, 3H).
ESI MS m/z: 500.16 [M+1] +
実施例174. (S)-5-(3-フルオロ-2-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル--1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 174. (S)-5-(3-fluoro-2-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl--1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.30-7.25(q,3H),7.18-7.13(t,2H),7.10-7.08( d,1H),6.98-6.96(q,1H),6.90-6.88(d,1H),6.09-6.06(q,1H),4.44-4.26(m,4H),3.75(s,3H),3.37(s,3H),3.05(s,3H),2.14(s,3H),1.29-1.26(t,3H).
ESI MS m/z:514.17[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 7.30-7.25 (q, 3H), 7.18-7.13 (t, 2H), 7.10-7.08 (d, 1H), 6.98-6.96 (q, 1H), 6.90-6.88 (d, 1H), 6.09-6.06 (q, 1H), 4.44 -4.26 (m, 4H), 3.75 (s, 3H), 3.37 (s, 3H), 3.05 (s, 3H), 2.14 (s, 3H), 1.29-1.26 (t, 3H).
ESI MS m/z: 514.17 [M+1] +
実施例175. (S)-5-(2-フルオロ-5-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 175. (S)-5-(2-fluoro-5-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.11(s,1H),7.30-7.21(m,3H),7.16-7.09(q,4H),6.85-6.83(d,1H),6.06-6.03(q,1H),4.40-4.33(m,3H),4.28-4.22(q,1H),3.75(s,3H),3.05(s,3H),2.32(s,3H),1.34-1.24(q,3H)
ESI MS m/z:500.16[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.11 (s, 1H), 7.30-7.21 (m, 3H), 7.16-7.09 (q, 4H), 6.85-6.83 (d, 1H), 6.06-6.03 (q, 1H), 4.40-4.33 (m, 3H), 4.28-4.22 (q, 1H), 3.75 (s, 3H), 3.05 (s, 3H), 2.32 (s, 3H), 1.34-1.24 (q, 3H)
ESI MS m/z: 500.16 [M+1] +
実施例176. (S)-5-(2-フルオロ-5-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 176. (S)-5-(2-fluoro-5-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.35-7.24(m,4H),7.18-7.15(q,3H),6.86-6.84(d,1H),6.10-6.06(q,1H),4.42-4.25(m,4H),3.74(s,3H),3.39(s,3H),3.05(s,3H),2.33( s,3H),1.33-1.29(t,3H)。
ESI MS m/z:514.17[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 7.35-7.24 (m, 4H), 7.18-7.15 (q, 3H), 6.86-6.84 (d, 1H), 6.10-6.06 (q, 1H), 4.42-4.25 (m, 4H), 3.74 (s, 3H), 3.39 (s, 3H) , 3.05(s, 3H), 2.33(s, 3H), 1.33-1.29(t, 3H).
ESI MS m/z: 514.17 [M+1] +
実施例177. (S)-5-(2-フルオロ-3-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 177. (S)-5-(2-fluoro-3-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.11(s,1H),7.29-7.22(m,4H),7.16-7.08(m,3H),6.85-6.83(d,1H),6.06-6.02(q,1H),4.41-4.33(m,3H),4.28-4.26(d,1H),3.75(s,3H),3.05(s,3H),2.29-2.28(d,3H),1.32-1.29(q,3H).
ESI MS m/z:500.16[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.11 (s, 1H), 7.29-7.22 (m, 4H), 7.16-7.08 (m, 3H), 6.85-6.83 (d, 1H), 6.06-6.02 (q, 1H), 4.41-4.33 (m, 3H), 4.28-4.26 (d, 1H), 3.75 (s, 3H), 3.05 (s, 3H), 2.29-2.28 (d, 3H), 1.32-1.29 (q, 3H).
ESI MS m/z: 500.16 [M+1]+
実施例178. (S)-5-(2-フルオロ-3-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 178. (S)-5-(2-fluoro-3-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.31-7.22(m,5H),7.18-7.11(q,2H),6.87-6.83(t,1H),6.10-6.06(q,1H),4.42-4.29(m,4H),3.75(s,3H),3.38(s,3H),3.05(s,3H),2.29(s,3H),1.31-1.27(t,3H).
ESI MS m/z:514.17[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 7.31-7.22 (m, 5H), 7.18-7.11 (q, 2H), 6.87-6.83 (t, 1H), 6.10-6.06 (q, 1H), 4.42-4.29 (m, 4H), 3.75 (s, 3H), 3.38 (s, 3H) , 3.05(s, 3H), 2.29(s, 3H), 1.31-1.27(t, 3H).
ESI MS m/z: 514.17 [M+1]+
実施例179. (S)-5-(2-フルオロ-4-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 179. (S)-5-(2-fluoro-4-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.01(s,1H),7.25-7.20(t,1H),7.12-7.10(d,2H),7.09-7.07(d,2H),6.84-6.82(d,1H),6.05-6.02(q,1H),4.40-4.33(m,3H),4.28-4.22(q,1H),3.75(s,3H),3.05-3.01(d,3H),2.34(s,3H),1.33-1.29(q,3H).
ESI MS m/z:500.16[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.01 (s, 1H), 7.25-7.20 (t, 1H), 7.12-7.10 (d, 2H), 7.09-7.07 (d, 2H), 6.84-6.82 (d, 1H), 6.05-6.02 (q, 1H), 4.40-4.33 (m, 3H), 4.28-4.22 (q, 1H), 3.75 (s, 3H), 3.05-3.01 (d, 3H), 2.34 (s, 3H), 1.33-1.29 (q, 3H).
ESI MS m/z: 500.16 [M+1] +
実施例180. (S)-5-(2-フルオロ-4-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 180. (S)-5-(2-fluoro-4-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.44-7.40(t,1H),7.31-7.24(m,3H),7.15-7.09(q,3H),6.86-6.84(d,1H),6.09-6.06(q,1H),4.38-4.24(m,4H),3.74(s,3H),3.38(s,3H),3.04(s,3H),2.35(s,3H),1.31-1.28(q,3H).
ESI MS m/z:514.17[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 7.44-7.40 (t, 1H), 7.31-7.24 (m, 3H), 7.15-7.09 (q, 3H), 6.86-6.84 (d, 1H), 6.09-6.06 (q, 1H), 4.38-4.24 (m, 4H), 3.74 ( s, 3H), 3.38 (s, 3H), 3.04 (s, 3H), 2.35 (s, 3H), 1.31-1.28 (q, 3H).
ESI MS m/z: 514.17 [M+1] +
実施例181. (S)-5-(2-フルオロ-5-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 181. (S)-5-(2-fluoro-5-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.11(s,1H),7.27-7.18(m,3H),7.13-7.11(d,2H),6.99-6.97(q,1H),6.06-6.03(q,1H),4.40-4.35(m,3H),4.28-4.22(q,1H),3.78-3.75(d,6H),3.05(s,3H),1.33-1.29(t,3H).
ESI MS m/z:516.15[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.11 (s, 1H), 7.27-7.18 (m, 3H), 7.13-7.11 (d, 2H), 6.99-6.97 (q, 1H), 6.06-6.03 (q, 1H), 4.40-4.35 (m, 3H), 4.28-4.22 (q, 1H), 3.78-3.75 (d, 6H), 3.05 (s, 3H), 1.33-1.29 (t, 3H).
ESI MS m/z: 516.15 [M+1] +
実施例182. (S)-5-(2-フルオロ-5-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 182. (S)-5-(2-fluoro-5-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.29-7.08(m,7H),6.86-6.84(d,1H),6.10-6.06(q,1H),4.43-4.24(m,4H),3.75-3.74(d,6H),3.37(s,3H),3.06(s,3H),1.33-1.29(t,3H).
ESI MS m/z:530.17[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 7.29-7.08 (m, 7H), 6.86-6.84 (d, 1H), 6.10-6.06 (q, 1H), 4.43-4.24 (m, 4H), 3.75-3.74 (d, 6H), 3.37 (s, 3H), 3.06 (s, 3H) , 1.33-1.29(t,3H).
ESI MS m/z: 530.17 [M+1] +
実施例183. (S)-5-(2-フルオロ-3-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 183. (S)-5-(2-fluoro-3-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:516.15[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 516.15 [M+1] +
実施例184. (S)-5-(2-フルオロ-4-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 184. (S)-5-(2-fluoro-4-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.07(s,1H),7.25-7.20(d,1H),7.18(s,1H),7.07-7.04(t,1H),6.93-6.90(t,2H),6.89-6.82(m,3H),6.05-6.02(q,1H),4.40-4.35(m,3H),4.27-4.21(q,1H),3.80-3.75(t,3H),3.05(s,3H),1.33-1.29(t,3H).
ESI MS m/z:516.15[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.07 (s, 1H), 7.25-7.20 (d, 1H), 7.18 (s, 1H), 7.07-7.04 (t, 1H), 6.93-6.90 (t, 2H), 6.89-6.82 (m, 3H), 6.05-6.02 (q, 1H) ), 4.40-4.35 (m, 3H), 4.27-4.21 (q, 1H), 3.80-3.75 (t, 3H), 3.05 (s, 3H), 1.33-1.29 (t, 3H).
ESI MS m/z: 516.15 [M+1] +
実施例185. (S)-5-(2-フルオロ-4-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 185. (S)-5-(2-fluoro-4-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)7.48-7.43(t,1H),7.28-7.24(q,3H),7.13-7.11(d,1H),6.95-6.84(m,3H),6.10-6.06(q,1H),4.42-4.33(m,3H),4.30-4.24(q,1H),3.81-3.75(t,6H),3.38(s,3H),3.05(s,3H),1.32-1.28(t,3H)..
ESI MS m/z:530.17[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) 7.48-7.43 (t, 1H), 7.28-7.24 (q, 3H), 7.13-7.11 (d, 1H), 6.95-6.84 (m, 3H), 6.10-6.06 (q, 1H), 4.42-4.33 (m, 3H), 4.30-4 .24 (q, 1H), 3.81-3.75 (t, 6H), 3.38 (s, 3H), 3.05 (s, 3H), 1.32-1.28 (t, 3H). .
ESI MS m/z: 530.17 [M+1] +
実施例186. (S)-5-(5-フルオロ-2-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 186. (S)-5-(5-fluoro-2-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.04(s,1H),7.27-7.10(m,1H),7.09-7.03(m,6H),6.84-6.82(d,1H),6.05-6.02(q,1H),4.41-4.34(m,3H),4.27-4.21(q,1H),3.75-3.73(d,6H),3.05(s,3H),1.34-1.24(q,3H)..
ESI MS m/z:516.15[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.04 (s, 1H), 7.27-7.10 (m, 1H), 7.09-7.03 (m, 6H), 6.84-6.82 (d, 1H), 6.05-6.02 (q, 1H), 4.41-4.34 (m, 3H), 4.27-4.21 (q, 1H), 3.75-3.73 (d, 6H), 3.05 (s, 3H), 1.34-1.24 (q, 3H). .
ESI MS m/z: 516.15 [M+1] +
実施例187. (S)-5-(5-フルオロ-2-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 187. (S)-5-(5-fluoro-2-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.36(s,1H),7.30-7.18(m,4H),7.06-7.03(q,1H),6.95-6.91(m,1H),6.87-6.85(d,1H),6.11-6.07(q,1H),4.39-4.25(m,4H),3.79(s,3H),3.75(s,3H),3.40-3.37(d,3H),3.05(s,3H)1.32-1.18(t,3H)..
ESI MS m/z:530.17[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 7.36 (s, 1H), 7.30-7.18 (m, 4H), 7.06-7.03 (q, 1H), 6.95-6.91 (m, 1H), 6.87-6.85 (d, 1H), 6.11-6.07 (q, 1H), 4.39-4.25 ( m, 4H), 3.79 (s, 3H), 3.75 (s, 3H), 3.40-3.37 (d, 3H), 3.05 (s, 3H) 1.32-1.18 (t, 3H). .
ESI MS m/z: 530.17 [M+1] +
実施例188. (S)-5-(4-フルオロ-2-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 188. (S)-5-(4-fluoro-2-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.11(s,1H),7.29-7.22(m,4H),7.16-7.08(m,3H),6.85-6.83(d,1H),6.06-6.02(q,1H),4.41-4.33(m,3H),4.28-4.26(d,1H),3.75(s,3H),3.05(s,3H),2.29-2.28(d,3H),1.32-1.29(q,3H).
ESI MS m/z:516.15[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.11 (s, 1H), 7.29-7.22 (m, 4H), 7.16-7.08 (m, 3H), 6.85-6.83 (d, 1H), 6.06-6.02 (q, 1H), 4.41-4.33 (m, 3H), 4.28-4.26 (d, 1H), 3.75 (s, 3H), 3.05 (s, 3H), 2.29-2.28 (d, 3H), 1.32-1.29 (q, 3H).
ESI MS m/z: 516.15 [M+1] +
実施例189. (S)-5-(4-フルオロ-2-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 189. (S)-5-(4-fluoro-2-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.20(s,4H),7.06-7.01(m,2H),6.99-6.81(m,2H),6.09-6.05(q,1H),4.42-4.24(m,4H),3.77-3.75(d,6H),3.36(s,3H),3.07-3.05(d,3H),1.32-1.29(t,3H).
ESI MS m/z:530.17[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 7.20 (s, 4H), 7.06-7.01 (m, 2H), 6.99-6.81 (m, 2H), 6.09-6.05 (q, 1H), 4.42-4.24 (m, 4H), 3.77-3.75 (d, 6H), 3.36 (s, 3H) , 3.07-3.05 (d, 3H), 1.32-1.29 (t, 3H).
ESI MS m/z: 530.17 [M+1] +
実施例190. (S)-5-(6-フルオロ-2-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 190. (S)-5-(6-fluoro-2-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.01(s,1H),7.28-7.26(d,1H),7.18-7.16(d,1H),6.89-6.85(t,5H),6.06-6.02(q,1H),4.42-4.34(m,3H),4.28-4.22(q,1H),3.76-3.72(q,6H),3.10-3.06(d,3H),1.32-1.27(q,3H).
ESI MS m/z:516.15[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.01 (s, 1H), 7.28-7.26 (d, 1H), 7.18-7.16 (d, 1H), 6.89-6.85 (t, 5H), 6.06-6.02 (q, 1H), 4.42-4.34 (m, 3H), 4.28-4.22 (q, 1H), 3.76-3.72 (q, 6H), 3.10-3.06 (d, 3H), 1.32-1.27 (q, 3H).
ESI MS m/z: 516.15 [M+1] +
実施例191. (S)-5-(6-フルオロ-2-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 191. (S)-5-(6-fluoro-2-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.39-7.34(q,1H),7.27-7.24(q,2H),7.12(s,1H),6.97-6.87(m,4H),6.10-6.07(q,1H),4.39-4.28(m,4H),3.77-3.73(q,6H),3.34(s,3H),3.07(s,3H)1.31-1.28(t,3H).
ESI MS m/z:530.17[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 7.39-7.34 (q, 1H), 7.27-7.24 (q, 2H), 7.12 (s, 1H), 6.97-6.87 (m, 4H), 6.10-6.07 (q, 1H), 4.39-4.28 (m, 4H), 3.77-3.73 ( q, 6H), 3.34 (s, 3H), 3.07 (s, 3H) 1.31-1.28 (t, 3H).
ESI MS m/z: 530.17 [M+1] +
実施例192. (S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-エトキシフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 192. (S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-ethoxyphenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:512.18[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 512.18 [M+1] +
実施例193. (R)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-エトキシフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 193. (R)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-ethoxyphenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:512.18[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 512.18 [M+1] +
実施例194. (S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(ピリジン-2-イル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 194. (S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(pyridin-2-yl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:469.15[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 469.15 [M+1] +
実施例195. (R)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(ピリジン-2-イル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 195. (R)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(pyridin-2-yl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:469.15[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 469.15 [M+1] +
実施例196. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-5-(ピリジン-2-イル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 196. (S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-5-(pyridin-2-yl)-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:483.16[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 483.16 [M+1] +
実施例197. (S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-エチル-5-(ピリジン-2-イル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 197. (S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-ethyl-5-(pyridin-2-yl)-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:497.18[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 497.18 [M+1] +
実施例198. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-(2-メトキシエチル)-5-(ピリジン-2-イル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 198. (S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-(2-methoxyethyl)-5-(pyridin-2-yl)-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:527.19[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 527.19 [M+1] +
実施例199. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(4-フルオロ-2-メチルフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 199. (S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(4-fluoro-2-methylphenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ11.05(s,1H),7.18-7.28(m,1H),7.12(t,3H),7.04(d,1H),6.86(t,3H),6.04(q,1H),4.28-4.38(m,3H),4.27(d,1H),3.75(s,3H),3.05(s,3H),2.21(s,3H),1.27(q,3H)
ESI MS m/z:500.16[M+1]+
Synthesized by referring to the method of Example 2.
1 H NMR (400 MHz, DMSO-D6) δ 11.05 (s, 1H), 7.18-7.28 (m, 1H), 7.12 (t, 3H), 7.04 (d, 1H), 6.86 (t, 3H), 6.04 (q, 1H), 4.28-4.38 (m, 3H), 4.27 (d, 1H), 3. 75 (s, 3H), 3.05 (s, 3H), 2.21 (s, 3H), 1.27 (q, 3H)
ESI MS m/z: 500.16 [M+1] +
実施例200. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(4-フルオロ-2-メチルフェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 200. (S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(4-fluoro-2-methylphenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
1HNMR(400MHz,DMSO-D6)δ7.23-7.28(m,3H),7.17(t,2H),7.04-7.09(m,1H),6.91(q,2H),6.06(q,1H),4.25-4.44(m,4H),3.74(s,3H),3.34(t,3H),3.05(s,3H),2.23(s,3H),1.26(q,3H).
ESI MS m/z:500.16[M+1]+
Synthesized by referring to the method of Example 19.
1 H NMR (400 MHz, DMSO-D6) δ 7.23-7.28 (m, 3H), 7.17 (t, 2H), 7.04-7.09 (m, 1H), 6.91 (q, 2H), 6.06 (q, 1H), 4.25-4.44 (m, 4H), 3.74 (s, 3H), 3.34 (t, 3H) ), 3.05 (s, 3H), 2.23 (s, 3H), 1.26 (q, 3H).
ESI MS m/z: 500.16 [M+1] +
実施例201. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロ-5-メチルフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 201. (S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluoro-5-methylphenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:500.16[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 500.16 [M+1] +
実施例202. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロ-5-メチルフェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 202. (S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluoro-5-methylphenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:514.17[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 514.17 [M+1] +
実施例203. (S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4-(2-メトキシフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 203. (S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4-(2-methoxyphenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:498.16[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 498.16 [M+1] +
実施例204. (S)-1-(1-(1-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4-(o-メチルフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 204. (S)-1-(1-(1-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4-(o-methylphenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:482.17[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 482.17 [M+1] +
実施例205. (S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4-(2-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 205. (S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4-(2-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:486.14[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 486.14 [M+1] +
実施例206. (S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4-フェニル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 206. (S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4-phenyl-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:468.15[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 468.15 [M+1] +
実施例207. (S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4-(2-フルオロベンジル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 207. (S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4-(2-fluorobenzyl)-1H-benzo[d]imidazol-2(3H)-one
実施例2の方法を参照して合成した。
ESI MS m/z:500.16[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 500.16 [M+1] +
実施例208. (S)-3-シクロプロピル-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 208. (S)-3-cyclopropyl-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:526.17[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 526.17 [M+1] +
実施例209. (S)-3-シクロプロピル-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 209. (S)-3-cyclopropyl-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:446.17[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 446.17 [M+1] +
実施例210. (S)-5-ブロモ-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-(2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 210. (S)-5-bromo-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-(2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:576.04[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 576.04 [M+1] +
実施例211. (S)-3-シクロプロピル-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(トリフルオロメチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 211. (S)-3-cyclopropyl-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(trifluoromethyl)-1H-benzo[d]imidazol-2(3H)-one
実施例19の方法を参照して合成した。
ESI MS m/z:500.14[M+1]+
Synthesized by referring to the method of Example 19.
ESI MS m/z: 500.14 [M+1] +
実施例212. (S)-エチル1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-2-オキソ-2,3-ジヒドロ-1H-ベンゾ[d]イミダゾール-5-カルボキシレート Example 212. (S)-ethyl 1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate
実施例2の方法を参照して合成した。
ESI MS m/z:464.14[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 464.14 [M+1] +
実施例213. (S)-イソプロピル1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-2-オキソ-2,3-ジヒドロ-1H-ベンゾ[d]イミダゾール-5-カルボキシレート Example 213. (S)-Isopropyl 1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate
実施例2の方法を参照して合成した。
ESI MS m/z:478.16[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 478.16 [M+1] +
実施例214. (S)-2,2,2-トリフルオロエチル1-(1-(1-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-2-オキソ-2,3-ジヒドロ-1H-ベンゾ[d]イミダゾール-5-カルボキシレート Example 214. (S)-2,2,2-trifluoroethyl 1-(1-(1-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate
実施例2の方法を参照して合成した。
ESI MS m/z:518.11[M+1]+
Synthesized by referring to the method of Example 2.
ESI MS m/z: 518.11 [M+1] +
実施例215. (S)-N-(2-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-オキソイソインドリン-4-イル)アセトアミド Example 215. (S)-N-(2-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-oxoisoindolin-4-yl)acetamide
工程1.(S)-2-((((1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)アミノ)メチル)-6-ニトロ安息香酸メチル Step 1. (S)-2-((((1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)amino)methyl)-6-methyl nitrobenzoate
2-(ブロモメチル)-6-ニトロ安息香酸メチル(200mg,0.73mmol)を2.0mLのアセトニトリルに溶解し、(S)-1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチルアミン(215mg,0.78mg)、炭酸カリウム(201mg,1.45mmol)を加え、80℃に加熱し、還流しながら2時間反応させた。反応系を濃縮し、酢酸エチル(50mL×3)で抽出し、有機相を合わせた後、飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥させ、濾過し、濃縮して油状物を得た。少量の酢酸エチルで溶解した後、大量の石油エーテルを添加し、固体を析出させ、濾過し、メタノールで2回洗浄して、黄色固体210mgを得た。 Methyl 2-(bromomethyl)-6-nitrobenzoate (200 mg, 0.73 mmol) was dissolved in 2.0 mL of acetonitrile, (S)-1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethylamine (215 mg, 0.78 mg) and potassium carbonate (201 mg, 1.45 mmol) were added, heated to 80° C., and reacted for 2 hours while refluxing. The reaction mass was concentrated and extracted with ethyl acetate (50 mL x 3), the organic phases were combined, then washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to give an oil. After dissolving with a small amount of ethyl acetate, a large amount of petroleum ether was added to precipitate a solid, filtered and washed with methanol twice to obtain 210 mg of a yellow solid.
工程2. (S)-(2-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-ニトロイソインドリン-1-オン)。 Step 2. (S)-(2-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-nitroisoindolin-1-one).
工程1の生成物(200mg,0.43mmol)を4.0mLの溶媒(アセトニトリル:エタノール=1:1)に溶解し、氷酢酸0.2mLを添加し、90℃に加熱し、還流しながら反応させた。反応系を濃縮し、酢酸エチル(50mL×3)で抽出し、有機相を合わせ、飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥させ、濾過し、濃縮して目的化合物150mgを得た。 The product of step 1 (200 mg, 0.43 mmol) was dissolved in 4.0 mL of solvent (acetonitrile:ethanol=1:1), 0.2 mL of glacial acetic acid was added, heated to 90° C. and reacted under reflux. The reaction mass was concentrated and extracted with ethyl acetate (50 mL×3), the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to obtain 150 mg of the desired compound.
工程3. (S)-7-アミノ-2-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)イソインドリン-1-オン Step 3. (S)-7-amino-2-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)isoindolin-1-one
還元鉄粉を125mLの溶媒エタノール/水(4:1)に加え、氷酢酸4滴を滴下し、70-80℃に加熱し、還流させ、30分間活性化した。工程2の生成物(150mg,0.345mmol)を添加し、還流しながら2時間反応させた。珪藻土で反応系を吸引濾過し、濾液を濃縮した後、酢酸エチル(50mL×3)で抽出し、有機相を合わせ、飽和食塩水で洗浄し、さらに無水硫酸ナトリウムで乾燥させ、濾過し、濃縮して目的化合物100mgを得た。 The reduced iron powder was added to 125 mL of solvent ethanol/water (4:1), 4 drops of glacial acetic acid was added dropwise, heated to 70-80° C., refluxed and activated for 30 minutes. The product of step 2 (150 mg, 0.345 mmol) was added and allowed to react at reflux for 2 hours. The reaction system was suction-filtered with diatomaceous earth, the filtrate was concentrated, extracted with ethyl acetate (50 mL×3), the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain 100 mg of the target compound.
工程4. (S)-N-(2-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-オキソイソインドリン-4-イル)アセトアミド
工程3の生成物(100mg,0.25mmol)を4.0mLのテトラヒドロフランに溶解し、塩化アセチル0.1mLを加え、加熱して還流しながら2時間反応させた。反応系を濃縮し、酢酸エチル(50mL×3)で抽出し、有機相を合わせ、飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥させ、濾過し、濃縮して目的化合物80mgを得た。
1HNMR(400MHz,DMSO-D6)δ10.23(s,1H),8.28-8.26(d,1H),7.55-7.51(t,1H),7.29-7.22(q,2H),6.94-6.92(d,1H),5.88-5.85(q,1H),4.73-4.68 (d,1H),4.41-4.31(m,3H),4.14-4.00(m,2H)3.76(s,3H),3.03(s,3H),2.17(s,3H),1.32-1.29(t,3H).
ESI MS m/z:448.15[M+1]+
Step 4. (S)-N-(2-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-oxoisoindolin-4-yl)acetamide The product of step 3 (100 mg, 0.25 mmol) was dissolved in 4.0 mL of tetrahydrofuran, 0.1 mL of acetyl chloride was added, and the reaction was allowed to proceed for 2 hours while heating to reflux. The reaction mass was concentrated and extracted with ethyl acetate (50 mL×3), the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to obtain 80 mg of the desired compound.
1 HNMR(400MHz,DMSO-D6)δ10.23(s,1H),8.28-8.26(d,1H),7.55-7.51(t,1H),7.29-7.22(q,2H),6.94-6.92(d,1H),5.88-5.85(q,1H),4.73-4.68 (d,1H),4.41-4.31(m,3H),4.14-4.00(m,2H)3.76(s,3H),3.03(s,3H),2.17(s,3H),1.32-1.29(t,3H).
ESI MS m/z: 448.15 [M+1] +
実施例216. (R)-N-(2-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-オキソイソインドリン-4-イル)アセトアミド Example 216. (R)-N-(2-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-oxoisoindolin-4-yl)acetamide
実施例215の方法を参照して合成した。
ESI MS m/z:448.15[M+1]+
Synthesized by referring to the method of Example 215.
ESI MS m/z: 448.15 [M+1] +
実施例217. (S)-N-(2-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-オキソイソインドリン-4-イル)シクロプロパンカルボキサミド Example 217. (S)-N-(2-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-oxoisoindolin-4-yl)cyclopropanecarboxamide
実施例215の方法を参照して合成した。
ESI MS m/z:474.16[M+1]+
Synthesized by referring to the method of Example 215.
ESI MS m/z: 474.16 [M+1] +
実施例218. (R)-N-(2-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-オキソイソインドリン-4-イル)シクロプロパンカルボキサミド Example 218. (R)-N-(2-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-oxoisoindolin-4-yl)cyclopropanecarboxamide
実施例215の方法を参照して合成した。
ESI MS m/z:474.16[M+1]+
Synthesized by referring to the method of Example 215.
ESI MS m/z: 474.16 [M+1] +
実施例219. (S)-N-(2-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-オキソイソインドリン-4-イル)プロピオンアミド Example 219. (S)-N-(2-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-oxoisoindolin-4-yl)propionamide
実施例215の方法を参照して合成した。
ESI MS m/z:462.16[M+1]+
Synthesized by referring to the method of Example 215.
ESI MS m/z: 462.16 [M+1] +
実施例220. (R)-N-(2-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-オキソイソインドリン-4-イル)プロピオンアミド Example 220. (R)-N-(2-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-oxoisoindolin-4-yl)propionamide
実施例215の方法を参照して合成した。
ESI MS m/z:462.16[M+1]+
Synthesized by referring to the method of Example 215.
ESI MS m/z: 462.16 [M+1] +
実施例221、5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-ニトロ-4H-チエノ[3,4-c]ピロール-4,6(5H)-ジオン Example 221, 5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-nitro-4H-thieno[3,4-c]pyrrole-4,6(5H)-dione
工程1:2-ニトロチオフェン-3,4-ジカルボン酸
マグネチックスターラーおよび乾燥チューブを備えた250mL丸底フラスコに、20mLの発煙硝酸(含量95%)を加え、氷浴で0-5℃に冷却し、5gのチエノ[3,4-c]フラン-1,3-ジオンをバッチで添加した後、その温度で30分間反応させた。反応混合物を40mLの氷水混合液に注ぎ、酢酸エチルで抽出し、すべての酢酸エチル層を合わせ、水(50mL×2)および飽和食塩水で順次に洗浄し、無水硫酸ナトリウムで乾燥させ、濾過し、溶媒を乾燥まで蒸発させ、固体3.5gを得た。
Step 1: 2-Nitrothiophene-3,4-dicarboxylic acid A 250 mL round-bottomed flask equipped with a magnetic stirrer and a drying tube was charged with 20 mL of fuming nitric acid (95% content), cooled to 0-5°C in an ice bath, 5 g of thieno[3,4-c]furan-1,3-dione was added batchwise, and then reacted at that temperature for 30 minutes. The reaction mixture was poured into 40 mL of ice-water mixture and extracted with ethyl acetate, all ethyl acetate layers were combined, washed with water (50 mL x 2) and saturated brine successively, dried over anhydrous sodium sulfate, filtered and the solvent was evaporated to dryness to give 3.5 g of solid.
工程2:4-ニトロチエノ[3,4-c]フラン-1,3-ジオン
マグネチックスターラー、還流冷却器および乾燥チューブを備えた50mL丸底フラスコに、2gの工程1の化合物および2mLの無水酢酸を加え、3時間還流し、溶媒を乾燥まで蒸発させ、目的化合物1.2gを得た。
Step 2: 4-Nitrothieno[3,4-c]furan-1,3-dione To a 50 mL round-bottomed flask equipped with a magnetic stirrer, reflux condenser and drying tube was added 2 g of the compound of step 1 and 2 mL of acetic anhydride, refluxed for 3 hours and the solvent was evaporated to dryness to give 1.2 g of the desired compound.
工程3:5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-ニトロ-4H-チエノ[3,4-c]ピロール-4,6(5H)-ジオン
マグネチックスターラーおよび乾燥チューブを備えた250mL丸底フラスコに、1.0gの工程2の化合物、1.36gの1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチルアミン(WO2018157779に開示された方法を参照して合成する)、10mLのTHFを加え、室温で一晩撹拌した。1.2gのCDIを添加し、油浴で2時間還流した。室温まで冷却し、30mLの酢酸エチルおよび150mLの水を添加して抽出し、分液を行い、有機層を100mLの0.5N塩酸で洗浄し、100mLの飽和食塩水で洗浄し、無水硫酸マグネシウムで乾燥させ、濾過し、溶媒を乾燥まで蒸発させ、カラムクロマトグラフィーにより精制して目的化合物0.52gを得た。ESI MS m/z:456.05[M+1]+
Step 3: 5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-nitro-4H-thieno[3,4-c]pyrrole-4,6(5H)-dione In a 250 mL round bottom flask equipped with a magnetic stirrer and drying tube, 1.0 g of the compound from step 2, 1.36 g of 1-(6-ethoxy-5-methoxypyridine-2 -yl)-2-(methylsulfonyl)ethylamine (synthesized by referring to the method disclosed in WO2018157779), 10 mL of THF was added and stirred overnight at room temperature. 1.2 g of CDI was added and refluxed in an oil bath for 2 hours. Cool to room temperature, add 30 mL of ethyl acetate and 150 mL of water for extraction, separate the layers, wash the organic layer with 100 mL of 0.5N hydrochloric acid, wash with 100 mL of saturated brine, dry over anhydrous magnesium sulfate, filter, evaporate the solvent to dryness, and purify by column chromatography to obtain 0.52 g of the desired compound. ESI MS m/z: 456.05 [M+1] +
実施例222. (S)-5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-ニトロ-4H-チエノ[3,4-c]ピロール-4,6(5H)-ジオン Example 222. (S)-5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-nitro-4H-thieno[3,4-c]pyrrole-4,6(5H)-dione
実施例221の方法を参照して合成した。
ESI MS m/z:456.05[M+1]+
Synthesized by referring to the method of Example 221.
ESI MS m/z: 456.05 [M+1] +
実施例223. (S)-1-アミノ-5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4H-チエノ[3,4-c]ピロール-4,6(5H)-ジオン Example 223. (S)-1-amino-5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4H-thieno[3,4-c]pyrrole-4,6(5H)-dione
マグネチックスターラー、還流冷却器および乾燥チューブを備えた250mL丸底フラスコに、2.0gの実施例134の生成物および100mLのエタノール/水(2:1)を加え、加熱して還流させ、1.8gの還元鉄粉を添加し、2時間還流させた。吸引濾過して、濾液を乾燥まで蒸発させ、200mLの酢酸エチルおよび150mLの水を添加して抽出し、分液を行い、有機層を100mLの水で洗浄し、100mLの飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥させ、濾過し、溶媒を乾燥まで蒸発させ、カラムクロマトグラフィーにより精制して黄褐色固体1.1gを得た。
ESI MS m/z:426.07[M+1]+
Into a 250 mL round bottom flask equipped with a magnetic stirrer, reflux condenser and drying tube was added 2.0 g of the product of Example 134 and 100 mL of ethanol/water (2:1) and heated to reflux, and 1.8 g of reduced iron powder was added and refluxed for 2 hours. Suction filtered, the filtrate was evaporated to dryness, 200 mL ethyl acetate and 150 mL water were added for extraction, the layers were separated, the organic layer was washed with 100 mL water, washed with 100 mL saturated brine, dried over anhydrous sodium sulfate, filtered, evaporated the solvent to dryness and purified by column chromatography to give 1.1 g of a tan solid.
ESI MS m/z: 426.07 [M+1] +
実施例224. N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)アセトアミド Example 224. N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)acetamide
実施例223の生成物をアセチル化して目的化合物を得た。
ESI MS m/z:468.08[M+1]+
Acetylation of the product of Example 223 gave the desired compound.
ESI MS m/z: 468.08 [M+1] +
実施例225. (R)-N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)アセトアミド Example 225. (R)-N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)acetamide
実施例224の方法を参照して合成した。
ESI MS m/z:468.08[M+1]+
Synthesized by referring to the method of Example 224.
ESI MS m/z: 468.08 [M+1] +
実施例226. (S)-N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)プロピオンアミド Example 226. (S)-N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)propionamide
実施例224の方法を参照して合成した。
ESI MS m/z:482.10[M+1]+
Synthesized by referring to the method of Example 224.
ESI MS m/z: 482.10 [M+1] +
実施例227. (S)-N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)シクロプロパンカルボキサミド Example 227. (S)-N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)cyclopropanecarboxamide
実施例224の方法を参照して合成した。
ESI MS m/z:494.10[M+1]+
Synthesized by referring to the method of Example 224.
ESI MS m/z: 494.10 [M+1] +
実施例228. (S)-2-(ジメチルアミノ)-N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)アセトアミド Example 228. (S)-2-(dimethylamino)-N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)acetamide
実施例224の方法を参照して合成した。
ESI MS m/z:511.12[M+1]+
Synthesized by referring to the method of Example 224.
ESI MS m/z: 511.12 [M+1] +
実施例229. (S)-2-(ジエチルアミノ)-N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)アセトアミド Example 229. (S)-2-(diethylamino)-N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)acetamide
実施例224の方法を参照して合成した。
ESI MS m/z:539.16[M+1]+
Synthesized by referring to the method of Example 224.
ESI MS m/z: 539.16 [M+1] +
実施例230. (S)-N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)-2-(ピペリジン-1-イル)アセトアミド Example 230. (S)-N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)-2-(piperidin-1-yl)acetamide
実施例224の方法を参照して合成した。
ESI MS m/z:551.16[M+1]+
Synthesized by referring to the method of Example 224.
ESI MS m/z: 551.16 [M+1] +
実施例231. (S)-N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)-2-(ピロリジン-1-イル)アセトアミド Example 231. (S)-N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)-2-(pyrrolidin-1-yl)acetamide
実施例224の方法を参照して合成した。
ESI MS m/z:537.14[M+1]+
Synthesized by referring to the method of Example 224.
ESI MS m/z: 537.14 [M+1] +
実施例232. (S)-N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)-2-モルホリノアセトアミド Example 232. (S)-N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)-2-morpholinoacetamide
実施例224の方法を参照して合成した。
ESI MS m/z:553.13[M+1]+
Synthesized by referring to the method of Example 224.
ESI MS m/z: 553.13 [M+1] +
実施例233. PDE4阻害活性の測定
本発明化合物のPDE4A1A、PDE4B1、PDE4D2に対する阻害活性のIC50値。
Example 233. Measurement of PDE4 inhibitory activity IC50 value of inhibitory activity against PDE4A1A, PDE4B1 and PDE4D2 of the compounds of the present invention.
実験材料:
酵素:PDE4A1A(BPS,CatNo.60040);PDE4B1(BPS,Cat No60041)、PDE4D2。
陽性化合物:Trequinsin(Sigma,Cat No.T20S7)。
反応プレート:384ウェルプレート(PerkiNEImer,Cat No.60077)。
実験機器:Wallac VictoRMuti-lable counter(PekiNElmer)
Experiment material:
Enzymes: PDE4A1A (BPS, Cat No. 60040); PDE4B1 (BPS, Cat No. 60041), PDE4D2.
Positive compound: Trequinsin (Sigma, Cat No. T20S7).
Reaction plate: 384 well plate (PerkiNEImer, Cat No. 60077).
Experimental equipment: Wallac VictoRMuti-lable counter (PekiNElmer)
実験手順:
I. 1×反応液および反応停止液を調製した。
II. PDE酵素反応
1)PDEを1×反応液に溶解して2×酵素溶液を調製した。
2)FAM-cAMPを1×反応液に溶解して2×基質溶液を調製した。
3)EchO550により、対応体積の化合物DMSO溶液を反応プレートに移した。
4)2×酵素溶液を反応プレートの対応するウェルに入れ、化合物溶液とともに室温で15分間インキュベートした。
5)2×基質溶液を反応プレートの対応するウェルに入れ、反応を開始した。
6)反応プレートを室温で30分間インキュベートした後、反応停止液を添加して反応を停止した。さらに、室温で60分間インキュベートした。
Experimental procedure:
I. A 1× reaction solution and a reaction stop solution were prepared.
II. PDE Enzyme Reaction 1) PDE was dissolved in 1× reaction solution to prepare 2× enzyme solution.
2) A 2x substrate solution was prepared by dissolving FAM-cAMP in a 1x reaction solution.
3) EchO550 transferred the corresponding volume of compound DMSO solution to the reaction plate.
4) 2x enzyme solution was placed in corresponding wells of the reaction plate and incubated with compound solution for 15 minutes at room temperature.
5) 2x substrate solution was added to the corresponding wells of the reaction plate to initiate the reaction.
6) After incubating the reaction plate at room temperature for 30 minutes, the reaction was stopped by adding a reaction stop solution. Furthermore, it incubated for 60 minutes at room temperature.
III. Victorによりデータを読み取った。
IV. カーブフィッティング
Excelで阻害率を算出した。Graphpad prismでIC50を算出した。
III. Data were read by Victor.
IV. Inhibition rate was calculated with curve fitting Excel. IC50 was calculated with Graphpad prism.
*WX011:WO2018036470の実施例11であり、開示された方法に従って合成された。
*WX063:WO2018036469の実施例63であり、開示された方法に従って合成された。
+:20nMで顕著な阻害作用があった。
-:20nMで顕著な阻害作用がなかった。
例*:実施例*を表す。
*WX011: Example 11 of WO2018036470, synthesized according to the disclosed method.
*WX063: Example 63 of WO2018036469, synthesized according to the disclosed method.
+: Significant inhibitory action was observed at 20 nM.
-: No significant inhibitory action at 20 nM.
Example*: Represents an example*.
結論:本発明の実施例2、8、10、12、30は、アプレミラスト(Apremilast)およびWO2018036470の実施例11(WX011)と比較して、PDE4A1A、PDE4B1、PDE4D2に対する阻害活性がいずれも著しく向上している。WO2018036469の実施例63(WX063)と比較して、本発明化合物は、PDE4D2に対する阻害活性がより低く、その嘔吐副作用がより少ないことが示唆された(Osamu Suzukiら、J.Pharmacol.Sci.2013,123:219-226)。 Conclusion: Examples 2, 8, 10, 12 and 30 of the present invention have significantly improved inhibitory activity against PDE4A1A, PDE4B1 and PDE4D2 compared to Apremilast and Example 11 (WX011) of WO2018036470. Compared to Example 63 of WO2018036469 (WX063), the compounds of the present invention have lower inhibitory activity against PDE4D2, suggesting less emetic side effects (Osamu Suzuki et al., J. Pharmacol. Sci. 2013, 123:219-226).
好ましくは、式(I)で表される構造を有する化合物、およびその異性体、溶媒和物、重水素化誘導体または薬学的に許容される塩であり、ここで、前記化合物は、以下の構造を含む。
3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-エチルフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-イソプロピルフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-メトキシフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-メトキシフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(2-(トリフルオロメチル)フェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-2-(3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-2-オキソ-2,3-ジヒドロ-1H-イミダゾ[4,5-b]ピリジン-6-イル)ベンゾニトリル;
(R)-2-(3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-2-オキソ-2,3-ジヒドロ-1H-イミダゾ[4,5-b]ピリジン-6-イル)ベンゾニトリル;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1,7-ジメチル-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-(2-メトキシエチル)-7-メチル-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-1,7-ジメチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-1,7-ジメチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,6-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-6-(2,6-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,3-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-6-(2,3-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,5-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,4-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,4,5-トリフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-6-(2,5-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,4-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,5-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,3-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,6-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(4-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(5-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-5-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-3-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-4-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-5-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-3-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-4-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(5-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(4-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(6-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-エチル-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-エチル-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-エチル-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-エチル-7-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1-(2,2,2-トリフルオロエチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1-(2,2,2-トリフルオロエチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1-(2,2,2-トリフルオロエチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1-(2,2,2-トリフルオロエチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(o-メチルフェニル)-1-(2,2,2-トリフルオロエチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-1,7-ジメチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1,7-ジメチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-1,7-ジメチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1,7-ジメチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-イソプロポキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-イソプロポキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-イソプロポキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-イソプロポキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-ブロモ-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル) -6-フェニル-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-エチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-エチルフェニル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-メトキシフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-メトキシフェニル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-(トリフルオロメチル)フェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-(トリフルオロメチル)フェニル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-シクロプロピルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,6-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,6-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,3-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,3-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,5-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,5-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,4-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,4-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,4,5-トリフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,4,5-トリフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-6-(2,5-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,4-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,4-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,5-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,5-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,3-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,3-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,6-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,6-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(4-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(4-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(5-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(5-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(3-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(3-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-5-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-5-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-4-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-4-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(5-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(5-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(4-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(4-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(6-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(ピリジン-2-イル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-エチル-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-(2-メトキシエチル)-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-5-ブロモ-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-フェニル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-フェニル-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロフェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(R)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(4-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(R)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(4-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-5-(4-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(R)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-5-(4-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(o-メチルフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(o-メチルフェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(R)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(o-メチルフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-クロロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-メトキシフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-メトキシフェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(R)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-メトキシフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-(トリフルオロメチル)フェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-(トリフルオロメチル)フェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-シクロプロピルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-イソプロピルフェニル)-4-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-エチルフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-エチルフェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,3-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,3-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,6-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,6-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,4-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,4-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,4,5-トリフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,4,5-トリフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,5-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,5-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,4-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,4-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,5-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,5-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,3-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,3-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,6-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(4-フルオロ-2-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(4-フルオロ-2-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(5-フルオロ-2-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(5-フルオロ-2-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(3-フルオロ-2-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(3-フルオロ-2-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル--1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-5-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-5-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-3-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-3-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-4-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-4-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-5-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-5-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-3-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-4-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-4-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(5-フルオロ-2-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(5-フルオロ-2-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(4-フルオロ-2-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(4-フルオロ-2-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(6-フルオロ-2-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(6-フルオロ-2-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-エトキシフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(R)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-エトキシフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(ピリジン-2-イル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(R)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(ピリジン-2-イル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-5-(ピリジン-2-イル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-エチル-5-(ピリジン-2-イル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-(2-メトキシエチル)-5-(ピリジン-2-イル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(4-フルオロ-2-メチルフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(4-フルオロ-2-メチルフェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロ-5-メチルフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロ-5-メチルフェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4-(2-メトキシフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4-(o-メチルフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4-(2-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4-フェニル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4-(2-フルオロベンジル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-3-シクロプロピル-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-3-シクロプロピル-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-ブロモ-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-(2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-3-シクロプロピル-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(トリフルオロメチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-エチル1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-2-オキソ-2,3-ジヒドロ-1H-ベンゾ[d]イミダゾール-5-カルボキシレート;
(S)-イソプロピル1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-2-オキソ-2,3-ジヒドロ-1H-ベンゾ[d]イミダゾール-5-カルボキシレート;および
(S)-2,2,2-トリフルオロエチル1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-2-オキソ-2,3-ジヒドロ-1H-ベンゾ[d]イミダゾール-5-カルボキシレート。
Preferred are compounds having the structure represented by formula (I), and isomers, solvates, deuterated derivatives or pharmaceutically acceptable salts thereof, wherein said compounds include the structures:
3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(o-methylphenyl)-1H-imidazo[4,5b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(o-methylphenyl)-1H-imidazo[4,5b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-ethylphenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-isopropylphenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-methoxyphenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-methoxyphenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(2-(trifluoromethyl)phenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-2-(3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)benzonitrile;
(R)-2-(3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)benzonitrile;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1,7-dimethyl-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-(2-methoxyethyl)-7-methyl-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-1,7-dimethyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-1,7-dimethyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,6-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R ) -6-(2,6-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,3-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-6-(2,3-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7 -methyl -1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,5-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,4-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,4,5-trifluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-6-(2,5-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,4-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,5-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,3-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,6-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(4-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(5-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-5-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-3-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-4-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-5-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-3-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-4-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(5-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(4-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(6-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-ethyl-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-ethyl-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-ethyl-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-ethyl-7-methyl-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(o-methylphenyl)-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-1,7-dimethyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1,7-dimethyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-1,7-dimethyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1,7-dimethyl-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-isopropoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-isopropoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-isopropoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-isopropoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-phenyl-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-ethylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-ethylphenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-methoxyphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-methoxyphenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-(trifluoromethyl)phenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-(trifluoromethyl)phenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-cyclopropylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,6-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,6-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,3-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,3-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,5-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,5-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,4-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,4-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,4,5-trifluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,4,5-trifluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-6-(2,5-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,4-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,4-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,5-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,5-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,3-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,3-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,6-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,6-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(4-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(4-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(5-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(5-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(3-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(3-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-5-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-5-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-4-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-4-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(5-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(5-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(4-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(4-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(6-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(pyridin-2-yl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-ethyl-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-(2-methoxyethyl)-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-5-bromo-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1 -( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-phenyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1 -( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-phenyl-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1 -( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1 -( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluorophenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(R)-1-(1 -( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1 -( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(4-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one;
(R)-1-(1 -( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(4-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1 -( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-5-(4-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one;
(R)-1-(1 -( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-5-(4-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(o-methylphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(o-methylphenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(R)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(o-methylphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-chlorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1 -( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-methoxyphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1 -( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-methoxyphenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(R)-1-(1 -( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-methoxyphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1 -( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1 -( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-(trifluoromethyl)phenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-cyclopropylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1- ( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-isopropylphenyl)-4-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-ethylphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-ethylphenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,3-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,3-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,6-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,6-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,4-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,4-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,4,5-trifluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,4,5-trifluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,5-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,5-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,4-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,4-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,5-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,5-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,3-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,3-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,6-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(4-fluoro-2-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(4-fluoro-2-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(5-fluoro-2-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(5-fluoro-2-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(3-fluoro-2-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(3-fluoro-2-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl--1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-5-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-5-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-3-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-3-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-4-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-4-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-5-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-5-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-3-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-4-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-4-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(5-fluoro-2-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(5-fluoro-2-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(4-fluoro-2-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(4-fluoro-2-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(6-fluoro-2-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(6-fluoro-2-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1 -( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-ethoxyphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(R)-1-(1 -( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-ethoxyphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1 -( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(pyridin-2-yl)-1H-benzo[d]imidazol-2(3H)-one;
(R)-1-(1 -( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(pyridin-2-yl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-5-(pyridin-2-yl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1 -( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-ethyl-5-(pyridin-2-yl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-(2-methoxyethyl)-5-(pyridin-2-yl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(4-fluoro-2-methylphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(4-fluoro-2-methylphenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluoro-5-methylphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluoro-5-methylphenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1 -( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4-(2-methoxyphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-( 6 -ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4-(o-methylphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1 -( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4-(2-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1 -( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4-phenyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1 -( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4-(2-fluorobenzyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-3-cyclopropyl-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-3-cyclopropyl-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-bromo-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-(2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-3-cyclopropyl-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(trifluoromethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-ethyl 1-(1 -( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate;
(S)-isopropyl 1-(1 -( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate; and (S)-2,2,2-trifluoroethyl 1-(1-( 6 -ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-2- Oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate.
工程2:N-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロフェニル)-4-メチル-3-ニトロピリジン-2-アミン Step 2: N-(1-( 6 -ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluorophenyl)-4-methyl-3-nitropyridin-2-amine
工程2. (S)-N-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロフェニル)-4-メチル-3-ニトロピリジン-2-アミン Step 2. (S)-N-(1-( 6 -ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluorophenyl)-4-methyl-3-nitropyridin-2-amine
実施例24. (R)-6-(2,6-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 24. (R ) -6-(2,6-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例26. (R)-6-(2,3-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン Example 26. (R)-6-(2,3-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7 -methyl -1H-imidazo[4,5-b]pyridin-2(3H)-one
実施例130. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-フェニル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 130. (S)-1-(1- ( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-phenyl-1H-benzo[d]imidazol-2(3H)-one
実施例131. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-フェニル-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 131. (S)-1-(1- ( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-phenyl-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例132. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 132. (S)-1-(1- ( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例133. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロフェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 133. (S)-1-(1- ( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluorophenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例134. (R)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 134. (R)-1-(1- ( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例135. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(4-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 135. (S)-1-(1- ( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(4-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例136. (R)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(4-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 136. (R)-1-(1- ( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(4-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例137. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-5-(4-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 137. (S)-1-(1- ( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-5-(4-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例138. (R)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-5-(4-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 138. (R)-1-(1- ( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-5-(4-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例143. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-メトキシフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 143. (S)-1-(1- ( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-methoxyphenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例144. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-メトキシフェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 144. (S)-1-(1- ( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-methoxyphenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例145. (R)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-メトキシフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 145. (R)-1-(1- ( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-methoxyphenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例146. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-(トリフルオロメチル)フェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 146. (S)-1-(1- ( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例147. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-(トリフルオロメチル)フェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 147. (S)-1-(1- ( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-(trifluoromethyl)phenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例149. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-イソプロピルフェニル)-4-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 149. (S)-1-(1- ( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-isopropylphenyl)-4-methyl-1H-benzo[d]imidazol-2(3H)-one
実施例192. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-エトキシフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 192. (S)-1-(1- ( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-ethoxyphenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例193. (R)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-エトキシフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 193. (R)-1-(1- ( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-ethoxyphenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例194. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(ピリジン-2-イル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 194. (S)-1-(1- ( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(pyridin-2-yl)-1H-benzo[d]imidazol-2(3H)-one
実施例195. (R)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(ピリジン-2-イル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 195. (R)-1-(1- ( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(pyridin-2-yl)-1H-benzo[d]imidazol-2(3H)-one
実施例197. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-エチル-5-(ピリジン-2-イル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 197. (S)-1-(1- ( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-ethyl-5-(pyridin-2-yl)-1H-benzo[d]imidazol-2(3H)-one
実施例203. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4-(2-メトキシフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 203. (S)-1-(1- ( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4-(2-methoxyphenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例204. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4-(o-メチルフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 204. (S)-1-(1-( 6 -ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4-(o-methylphenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例205. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4-(2-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 205. (S)-1-(1- ( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4-(2-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one
実施例206. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4-フェニル-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 206. (S)-1-(1- ( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4-phenyl-1H-benzo[d]imidazol-2(3H)-one
実施例207. (S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4-(2-フルオロベンジル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン Example 207. (S)-1-(1- ( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4-(2-fluorobenzyl)-1H-benzo[d]imidazol-2(3H)-one
実施例212. (S)-エチル1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-2-オキソ-2,3-ジヒドロ-1H-ベンゾ[d]イミダゾール-5-カルボキシレート Example 212. (S)-ethyl 1-(1- ( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate
実施例213. (S)-イソプロピル1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-2-オキソ-2,3-ジヒドロ-1H-ベンゾ[d]イミダゾール-5-カルボキシレート Example 213. (S)-Isopropyl 1-(1 -( 6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate
実施例214. (S)-2,2,2-トリフルオロエチル1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-2-オキソ-2,3-ジヒドロ-1H-ベンゾ[d]イミダゾール-5-カルボキシレート Example 214. (S)-2,2,2-trifluoroethyl 1-(1-( 6 -ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate
Claims (10)
ただし、
X1は、NまたはCHから選択され;
X2、X3、X4のうちの1つはNから選択され、その他はCHであり;
Xは、O、-N(R6)、-CH(R6)-から選択され;
Rは、水素、C1-C3アルキル、C3-C6シクロアルキルからなる群から選択され、Rはハロゲンで置換されていてもよく;
R1、R2、R3は、それぞれ独立して、水素、ハロゲン、ヒドロキシル、-CN、-NH2、C1-C6アルキル、C1-6アルコキシ、C1-C6アルキルアミノ、C2-6アルケニル、C3-6シクロアルケニル、3-6員ヘテロシクロアルケニル、C3-C6シクロアルキル、3-6員ヘテロシクロアルキル、フェニル、5-6員ヘテロアリール、-COOR8からなる群から選択され、これらの基は、ハロゲン、C1-C6アルキル、ハロゲン化されていてもよいC1-C6アルキル、C3-C6シクロアルキル、ハロゲン化されていてもよいC3-C6シクロアルキルで置換されていてもよく;
R4、R5は、それぞれ独立して、C1-C6アルキル、C3-C6シクロアルキルからなる群から選択され、R4、R5は、重水素、トリチウム又はハロゲンで置換されていてもよく;
R6は、H、ハロゲン、ヒドロキシル、CN、-NH2、COOH、R7-L1-からなる群から選択され、或いは、C1-6アルキル、C1-C6ヘテロアルキル、C3-C6シクロアルキル、3-6員ヘテロシクロアルキル、フェニル、5-6員ヘテロアリール、-COOR9、-SO2R10、-SO2NHR11、-NHCONHR12からなる群から選択され、これらの基は、ハロゲン、C1-C6アルキル、ハロゲン化されていてもよいC1-C6アルキル、C3-C6シクロアルキル、ハロゲン化されていてもよいC3-C6シクロアルキルで置換されていてもよく;
R7は、C3-C6シクロアルキル、3-6員ヘテロシクロアルキル、3-6員ヘテロシクロアルケニル、フェニル、5-6員ヘテロアリール、-COOR8からなる群から選択され、R7は、ハロゲン、C1-C6アルキル、C3-C6シクロアルキルで置換されていてもよく;
L1は、-CH2-、-CH2CH2-、O、S、NHからなる群から選択され;
R8、R9、R10、R11、R12は、C1-C6アルキル、ハロゲン化C1-C6アルキル、C3-C6シクロアルキルである、
式(I)で表される構造を有する化合物、およびその異性体、溶媒和物、重水素化誘導体または薬学的に許容される塩。 A compound having the structure represented by formula (I), and isomers, solvates, deuterated derivatives or pharmaceutically acceptable salts thereof, wherein
however,
X 1 is selected from N or CH;
one of X 2 , X 3 , X 4 is selected from N and the others are CH;
X is selected from O, -N(R 6 ), -CH(R 6 )-;
R is selected from the group consisting of hydrogen, C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl, and R is optionally substituted with halogen;
R 1 、R 2 、R 3は、それぞれ独立して、水素、ハロゲン、ヒドロキシル、-CN、-NH 2 、C1-C6アルキル、C1-6アルコキシ、C1-C6アルキルアミノ、C2-6アルケニル、C3-6シクロアルケニル、3-6員ヘテロシクロアルケニル、C3-C6シクロアルキル、3-6員ヘテロシクロアルキル、フェニル、5-6員ヘテロアリール、-COOR 8からなる群から選択され、これらの基は、ハロゲン、C1-C6アルキル、ハロゲン化されていてもよいC1-C6アルキル、C3-C6シクロアルキル、ハロゲン化されていてもよいC3-C6シクロアルキルで置換されていてもよく;
R 4 and R 5 are each independently selected from the group consisting of C1-C6 alkyl and C3-C6 cycloalkyl, and R 4 and R 5 are optionally substituted with deuterium, tritium or halogen;
R 6は、H、ハロゲン、ヒドロキシル、CN、-NH 2 、COOH、R 7 -L 1 -からなる群から選択され、或いは、C1-6アルキル、C1-C6ヘテロアルキル、C3-C6シクロアルキル、3-6員ヘテロシクロアルキル、フェニル、5-6員ヘテロアリール、-COOR 9 、-SO 2 R 10 、-SO 2 NHR 11 、-NHCONHR 12からなる群から選択され、これらの基は、ハロゲン、C1-C6アルキル、ハロゲン化されていてもよいC1-C6アルキル、C3-C6シクロアルキル、ハロゲン化されていてもよいC3-C6シクロアルキルで置換されていてもよく;
R 7 is selected from the group consisting of C3-C6 cycloalkyl, 3-6 membered heterocycloalkyl, 3-6 membered heterocycloalkenyl, phenyl, 5-6 membered heteroaryl, —COOR 8 , R 7 is optionally substituted with halogen, C1-C6 alkyl, C3-C6 cycloalkyl;
L 1 is selected from the group consisting of -CH 2 -, -CH 2 CH 2 -, O, S, NH;
R 8 , R 9 , R 10 , R 11 , R 12 are C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C6 cycloalkyl;
A compound having the structure represented by formula (I) and its isomers, solvates, deuterated derivatives or pharmaceutically acceptable salts.
からなる群から選択される、
請求項1に記載の化合物、およびその異性体、溶媒和物、重水素化誘導体または薬学的に許容される塩。 X is
selected from the group consisting of
3. A compound of claim 1, and isomers, solvates, deuterated derivatives or pharmaceutically acceptable salts thereof.
からなる群から選択され、
これらの基が、ハロゲン、-OH、-NH2、-CN、C1-C6アルキル、ハロゲン化されていてもよいC1-C6アルキル、C3-C6シクロアルキル、ハロゲン化されていてもよいC3-C6シクロアルキルで置換されていてもよい、
請求項1または2に記載の化合物、およびその異性体、溶媒和物、重水素化誘導体または薬学的に許容される塩。 R 1 , R 2 and R 3 are each independently
is selected from the group consisting of
These groups are optionally substituted with halogen, —OH, —NH 2 , —CN, C1-C6 alkyl, optionally halogenated C1-C6 alkyl, C3-C6 cycloalkyl, optionally halogenated C3-C6 cycloalkyl,
3. A compound according to claim 1 or 2, and isomers, solvates, deuterated derivatives or pharmaceutically acceptable salts thereof.
3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-エチルフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-イソプロピルフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-メトキシフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-メトキシフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(2-(トリフルオロメチル)フェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-2-(3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-2-オキソ-2,3-ジヒドロ-1H-イミダゾ[4,5-b]ピリジン-6-イル)ベンゾニトリル;
(R)-2-(3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-2-オキソ-2,3-ジヒドロ-1H-イミダゾ[4,5-b]ピリジン-6-イル)ベンゾニトリル;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1,7-ジメチル-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-(2-メトキシエチル)-7-メチル-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-1,7-ジメチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-1,7-ジメチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,6-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)(S)-6-(2,6-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,3-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-6-(2,3-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-ジメチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,5-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,4-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,4,5-トリフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-6-(2,5-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,4-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,5-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,3-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,6-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(4-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(5-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-5-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-3-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-4-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-5-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-3-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-4-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(5-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(4-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(6-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-エチル-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-エチル-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-エチル-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-エチル-7-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1-(2,2,2-トリフルオロエチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1-(2,2,2-トリフルオロエチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1-(2,2,2-トリフルオロエチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1-(2,2,2-トリフルオロエチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(o-メチルフェニル)-1-(2,2,2-トリフルオロエチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-1,7-ジメチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1,7-ジメチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-1,7-ジメチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(5-(ジフルオロメトキシ)-6-エトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1,7-ジメチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-イソプロポキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-イソプロポキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-イソプロポキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-1-(2,2-ジフルオロエチル)-3-(1-(6-エトキシ-5-イソプロポキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-7-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-ブロモ-7-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル) -6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-フェニル-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(4-フルオロフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-6-(o-メチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-エチルフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-エチルフェニル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-メトキシフェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-メトキシフェニル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-(トリフルオロメチル)フェニル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-(トリフルオロメチル)フェニル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-シクロプロピルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,6-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,6-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2- (メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,3-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,3-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,5-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,5-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,4-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,4-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,4,5-トリフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,4,5-トリフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(R)-6-(2,5-ジフルオロフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,4-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,4-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,5-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,5-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,3-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,3-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,6-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2,6-ジメチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(4-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(4-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(5-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(5-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(3-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(3-フルオロ-2-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-5-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-5-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-4-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2- (メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(2-フルオロ-4-メチルフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(5-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(5-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(4-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(4-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(6-フルオロ-2-メトキシフェニル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-6-(ピリジン-2-イル)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-エチル-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-(2-メトキシエチル)-6-(ピリジン-2-イル)-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-6-(2-フルオロフェニル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-メチル-6-フェニル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-3-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル) -6-(4-フルオロフェニル)-1-メチル-1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン;
(S)-5-ブロモ-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-フェニル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-フェニル-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロフェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(R)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(4-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(R)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(4-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-5-(4-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(R)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-5-(4-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(o-メチルフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(o-メチルフェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(R)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(o-メチルフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-クロロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-メトキシフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-メトキシフェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(R)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-メトキシフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-(トリフルオロメチル)フェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-(トリフルオロメチル)フェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-シクロプロピルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-イソプロピルフェニル)-4-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-エチルフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-エチルフェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,3-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,3-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,6-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,6-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,4-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,4-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,4,5-トリフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,4,5-トリフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,5-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,5-ジフルオロフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,4-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,4-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,5-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,5-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,3-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,3-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2- (メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2,6-ジメチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(4-フルオロ-2-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(4-フルオロ-2-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(5-フルオロ-2-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(5-フルオロ-2-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(3-フルオロ-2-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(3-フルオロ-2-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル--1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-5-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-5-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-3-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-3-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-4-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-4-メチルフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル) -2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-5-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-5-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-3-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-4-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(2-フルオロ-4-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(5-フルオロ-2-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(5-フルオロ-2-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(4-フルオロ-2-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(4-フルオロ-2-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(6-フルオロ-2-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-(6-フルオロ-2-メトキシフェニル)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-エトキシフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(R)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-エトキシフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(ピリジン-2-イル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(R)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(ピリジン-2-イル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-メチル-5-(ピリジン-2-イル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-エチル-5-(ピリジン-2-イル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-(2-メトキシエチル)-5-(ピリジン-2-イル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(4-フルオロ-2-メチルフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(4-フルオロ-2-メチルフェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロ-5-メチルフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロ-5-メチルフェニル)-3-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4-(2-メトキシフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4-(o-メチルフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4-(2-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4-フェニル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4-(2-フルオロベンジル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-3-シクロプロピル-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(2-フルオロフェニル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-3-シクロプロピル-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-メチル-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-5-ブロモ-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-(2-(メチルスルホニル)エチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-3-シクロプロピル-1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-5-(トリフルオロメチル)-1H-ベンゾ[d]イミダゾール-2(3H)-オン;
(S)-エチル1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-2-オキソ-2,3-ジヒドロ-1H-ベンゾ[d]イミダゾール-5-カルボキシレート;
(S)-イソプロピル1-(1-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-2-オキソ-2,3-ジヒドロ-1H-ベンゾ[d]イミダゾール-5-カルボキシレート;および
(S)-2,2,2-トリフルオロエチル1-(1-(1-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-2-オキソ-2,3-ジヒドロ-1H-ベンゾ[d]イミダゾール-5-カルボキシレート
を含む、
請求項1~3のいずれか1項に記載の化合物、およびその異性体、溶媒和物、重水素化誘導体または薬学的に許容される塩。 The compound has the following structure:
3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(o-methylphenyl)-1H-imidazo[4,5b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(o-methylphenyl)-1H-imidazo[4,5b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-ethylphenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-isopropylphenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-methoxyphenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-methoxyphenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(2-(trifluoromethyl)phenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-2-(3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)benzonitrile;
(R)-2-(3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)benzonitrile;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1,7-dimethyl-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-(2-methoxyethyl)-7-methyl-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-1,7-dimethyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-1,7-dimethyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,6-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)(S)-6-(2,6-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,3-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-6-(2,3-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-dimethyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,5-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,4-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,4,5-trifluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-6-(2,5-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,4-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,5-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,3-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,6-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(4-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(5-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-5-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-3-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-4-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-5-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-3-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-4-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(5-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(4-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(6-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-ethyl-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-ethyl-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-ethyl-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-ethyl-7-methyl-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(o-methylphenyl)-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-1,7-dimethyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1,7-dimethyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-1,7-dimethyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(5-(difluoromethoxy)-6-ethoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1,7-dimethyl-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-isopropoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-isopropoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-isopropoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-1-(2,2-difluoroethyl)-3-(1-(6-ethoxy-5-isopropoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-7-methyl-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-bromo-7-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-phenyl-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-6-(o-methylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-ethylphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-ethylphenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-methoxyphenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-methoxyphenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-(trifluoromethyl)phenyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-(trifluoromethyl)phenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-cyclopropylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,6-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,6-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,3-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,3-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,5-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,5-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,4-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,4-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,4,5-trifluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,4,5-trifluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(R)-6-(2,5-difluorophenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,4-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,4-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,5-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,5-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,3-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,3-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,6-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2,6-dimethylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(4-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(4-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(5-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(5-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(3-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(3-fluoro-2-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-5-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-5-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-4-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(2-fluoro-4-methylphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(5-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(5-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(4-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(4-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(6-fluoro-2-methoxyphenyl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-6-(pyridin-2-yl)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-ethyl-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-(2-methoxyethyl)-6-(pyridin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(2-fluorophenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-3-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-6-(4-fluorophenyl)-1-methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one;
(S)-5-bromo-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-phenyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-phenyl-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluorophenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(R)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(4-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one;
(R)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(4-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-5-(4-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one;
(R)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-5-(4-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(o-methylphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(o-methylphenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(R)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(o-methylphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-chlorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-methoxyphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-methoxyphenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(R)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-methoxyphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-(trifluoromethyl)phenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-cyclopropylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-isopropylphenyl)-4-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-ethylphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-ethylphenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,3-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,3-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,6-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,6-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,4-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,4-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,4,5-trifluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,4,5-trifluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,5-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,5-difluorophenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,4-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,4-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,5-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,5-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,3-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,3-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2,6-dimethylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(4-fluoro-2-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(4-fluoro-2-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(5-fluoro-2-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(5-fluoro-2-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(3-fluoro-2-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(3-fluoro-2-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl--1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-5-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-5-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-3-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-3-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-4-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-4-methylphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-5-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-5-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-3-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-4-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(2-fluoro-4-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(5-fluoro-2-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(5-fluoro-2-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(4-fluoro-2-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(4-fluoro-2-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(6-fluoro-2-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-(6-fluoro-2-methoxyphenyl)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-ethoxyphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(R)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-ethoxyphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(pyridin-2-yl)-1H-benzo[d]imidazol-2(3H)-one;
(R)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(pyridin-2-yl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-methyl-5-(pyridin-2-yl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-ethyl-5-(pyridin-2-yl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-(2-methoxyethyl)-5-(pyridin-2-yl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(4-fluoro-2-methylphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(4-fluoro-2-methylphenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluoro-5-methylphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluoro-5-methylphenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4-(2-methoxyphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4-(o-methylphenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4-(2-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4-phenyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4-(2-fluorobenzyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-3-cyclopropyl-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(2-fluorophenyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-3-cyclopropyl-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-methyl-1H-benzo[d]imidazol-2(3H)-one;
(S)-5-bromo-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-(2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-3-cyclopropyl-1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-5-(trifluoromethyl)-1H-benzo[d]imidazol-2(3H)-one;
(S)-ethyl 1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate;
(S)-isopropyl 1-(1-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate; and (S)-2,2,2-trifluoroethyl 1-(1-(1-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-2 - oxo-2,3-dihydro-1H-benzo[d]imidazole-5-carboxylate,
A compound according to any one of claims 1 to 3, and isomers, solvates, deuterated derivatives or pharmaceutically acceptable salts thereof.
ただし、
Y1は、NまたはCHから選択され;
Y2、Y3、Y4のうちの1つはNから選択され、その他はCHであり;
R13は、C1-C3アルキル、C1-C6シクロアルキルからなる群から選択され、R13はハロゲンで置換されていてもよく;
R14、R15、R16は、それぞれ独立して、水素、ハロゲン、ヒドロキシル、CN、-NO2、-NH2、C1-C6アルキル、C1-C6アルコキシ、C1-C6アルキルアミノ、C1-C6アルキルアミド、C3-C6シクロアルキルアミド、C2-C6アルケニル、C3-C6シクロアルケニル、3-6員ヘテロシクロアルケニル、C3-C6シクロアルキル、3-6員ヘテロシクリル、フェニル、5-6員ヘテロアリールからなる群から選択され、これらの基は、ハロゲン、C3-C6シクロアルキル、C1-C8アルコキシ、C3-C8シクロアルコキシ、3-12員ヘテロシクリル、C1-C8アルキルアミノ、ジ(C1-C8アルキル)置換アミノ、フェニル、5-6員ヘテロアリールで置換されていてもよく;
R17、R18は、それぞれ独立して、C1-C6アルキル、C3-C6シクロアルキルからなる群から選択され、R17、R18は、重水素、トリチウム又はハロゲンで置換されていてもよい、
式(II)で表される構造を有する化合物、およびその異性体、溶媒和物、重水素化誘導体または薬学的に許容される塩。 A compound having the structure represented by formula (II), and isomers, solvates, deuterated derivatives or pharmaceutically acceptable salts thereof,
however,
Y 1 is selected from N or CH;
one of Y 2 , Y 3 , Y 4 is selected from N and the others are CH;
R 13 is selected from the group consisting of C1-C3 alkyl, C1-C6 cycloalkyl, and R 13 is optionally substituted with halogen;
R 14 、R 15 、R 16は、それぞれ独立して、水素、ハロゲン、ヒドロキシル、CN、-NO 2 、-NH 2 、C1-C6アルキル、C1-C6アルコキシ、C1-C6アルキルアミノ、C1-C6アルキルアミド、C3-C6シクロアルキルアミド、C2-C6アルケニル、C3-C6シクロアルケニル、3-6員ヘテロシクロアルケニル、C3-C6シクロアルキル、3-6員ヘテロシクリル、フェニル、5-6員ヘテロアリールからなる群から選択され、これらの基は、ハロゲン、C3-C6シクロアルキル、C1-C8アルコキシ、C3-C8シクロアルコキシ、3-12員ヘテロシクリル、C1-C8アルキルアミノ、ジ(C1-C8アルキル)置換アミノ、フェニル、5-6員ヘテロアリールで置換されていてもよく;
R 17 and R 18 are each independently selected from the group consisting of C1-C6 alkyl and C3-C6 cycloalkyl, R 17 and R 18 are optionally substituted with deuterium, tritium or halogen;
A compound having the structure represented by formula (II) and its isomers, solvates, deuterated derivatives or pharmaceutically acceptable salts.
(S)-N-(2-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-オキソイソインドリン-4-イル)アセトアミド;
(R)-N-(2-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-オキソイソインドリン-4-イル)アセトアミド;
(S)-N-(2-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-オキソイソインドリン-4-イル)シクロプロパンカルボキサミド;
(R)-N-(2-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-オキソイソインドリン-4-イル)シクロプロパンカルボキサミド;
(S)-N-(2-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-オキソイソインドリン-4-イル)プロピオンアミド;または
(R)-N-(2-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-3-オキソイソインドリン-4-イル)プロピオンアミド
を含む、
請求項5に記載の化合物、およびその異性体、溶媒和物、重水素化誘導体または薬学的に許容される塩。 The compound has the following structure:
(S)-N-(2-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-oxoisoindolin-4-yl)acetamide;
(R)-N-(2-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-oxoisoindolin-4-yl)acetamide;
(S)-N-(2-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-oxoisoindolin-4-yl)cyclopropanecarboxamide;
(R)-N-(2-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-oxoisoindolin-4-yl)cyclopropanecarboxamide;
(S)-N-(2-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-oxoisoindolin-4-yl)propionamide; or (R)-N-(2-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-3-oxoisoindolin-4-yl)propionamide,
6. A compound according to claim 5, and isomers, solvates, deuterated derivatives or pharmaceutically acceptable salts thereof.
ただし、
R19は、C1-C3アルキル、C3-C6シクロアルキルからなる群から選択され、R19はハロゲンで置換されていてもよく;
R20、R21は、水素、ハロゲン、C1-C8アルキル、C1-C8アルコキシ、ヒドロキシル、シアノ、ニトロ、-NHC(O)R26、-NHSO2R26または-NR24R25からなる群からそれぞれ選択され;
R22、R23は、それぞれ独立して、C1-C6アルキルからなる群から選択され、R22、R23は、重水素、トリチウム又はハロゲンで置換されていてもよく;
R24、R25は、水素、C1-C8アルキル、C6-C12アリール、C(O)R26、SO2R26からなる群からそれぞれ選択され、或いは、R24、R25は、それらが結合されたNとともに4-8員環または-CH2CH2ZCH2CH2-を形成し;
Zは、O、S、NR26からなる群から選択され;
R26は、水素、C1-C6アルキル、C3-C6シクロアルキル、C1-C8アルキルアミノであり、R26は、ハロゲン、C1-C8アルコキシ、C3-C8シクロアルコキシ、3-12員ヘテロシクリル、C1-C8アルキルアミノ、ジ(C1-C8アルキル)置換アミノで置換されていてもよい、
式(III)で表される構造を有する化合物、およびその異性体、溶媒和物、重水素化誘導体、ならびにそれらの薬学的に許容される塩。 A compound having the structure represented by formula (III), and its isomers, solvates, deuterated derivatives, and pharmaceutically acceptable salts thereof,
however,
R 19 is selected from the group consisting of C1-C3 alkyl, C3-C6 cycloalkyl, and R 19 is optionally substituted with halogen;
R 20 , R 21 are each selected from the group consisting of hydrogen, halogen, C1-C8 alkyl, C1-C8 alkoxy, hydroxyl, cyano, nitro, —NHC(O)R 26 , —NHSO 2 R 26 or —NR 24 R 25 ;
R 22 , R 23 are each independently selected from the group consisting of C1-C6 alkyl, and R 22 , R 23 are optionally substituted with deuterium, tritium or halogen;
R 24 , R 25 are each selected from the group consisting of hydrogen, C1-C8 alkyl, C6-C12 aryl, C(O)R 26 , SO 2 R 26 , or R 24 , R 25 together with the N to which they are attached form a 4-8 membered ring or -CH 2 CH 2 ZCH 2 CH 2 -;
Z is selected from the group consisting of O, S, NR26 ;
R 26 is hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C8 alkylamino, R 26 is optionally substituted with halogen, C1-C8 alkoxy, C3-C8 cycloalkoxy, 3-12 membered heterocyclyl, C1-C8 alkylamino, di(C1-C8 alkyl) substituted amino;
A compound having the structure represented by Formula (III), and its isomers, solvates, deuterated derivatives, and pharmaceutically acceptable salts thereof.
5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-ニトロ-4H-チエノ[3,4-c]ピロール-4,6(5H)-ジオン;
(S)-5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-1-ニトロ-4H-チエノ[3,4-c]ピロール-4,6(5H)-ジオン;
(S)-1-アミノ-5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4H-チエノ[3,4-c]ピロール-4,6(5H)-ジオン;
N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)アセトアミド;
(S)-N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)アセトアミド;
(R)-N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)アセトアミド;
(S)-N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)プロピオンアミド;
(S)-N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)シクロプロパンカルボキサミド;
(S)-2-(ジメチルアミノ)-N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)アセトアミド;
(S)-2-(ジエチルアミノ)-N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)アセトアミド;
(S)-N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)-2-(ピペリジン-1-イル)アセトアミド;
(S)-N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)-2-(ピロリジン-1-イル)アセトアミド;または
(S)-N-(5-(1-(6-エトキシ-5-メトキシピリジン-2-イル)-2-(メチルスルホニル)エチル)-4,6-ジオキソ-5,6-ジヒドロ-4H-チエノ[3,4-c]ピロール-1-イル)-2-モルホリノアセトアミド
を含む、
請求項7に記載の化合物、およびその異性体、溶媒和物、重水素化誘導体または薬学的に許容される塩。 The compound has the following structure:
5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-nitro-4H-thieno[3,4-c]pyrrole-4,6(5H)-dione;
(S)-5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-1-nitro-4H-thieno[3,4-c]pyrrole-4,6(5H)-dione;
(S)-1-amino-5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4H-thieno[3,4-c]pyrrole-4,6(5H)-dione;
N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)acetamide;
(S)-N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)acetamide;
(R)-N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)acetamide;
(S)-N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)propionamide;
(S)-N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)cyclopropanecarboxamide;
(S)-2-(dimethylamino)-N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)acetamide;
(S)-2-(diethylamino)-N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)acetamide;
(S)-N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)-2-(piperidin-1-yl)acetamide;
(S)-N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)-2-(pyrrolidin-1-yl)acetamide; or (S)-N-(5-(1-(6-ethoxy-5-methoxypyridin-2-yl)- 2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)-2-morpholinoacetamide,
8. A compound according to claim 7, and isomers, solvates, deuterated derivatives or pharmaceutically acceptable salts thereof.
請求項9に記載の使用。 said PDE4-related disease is an immune inflammatory and autoimmune disease or condition, including systemic lupus erythematosus (SLE), lupus nephritis, psoriasis, cutaneous lupus, Crohn's disease, ulcerative colitis, type 1 diabetes, rheumatoid arthritis, systemic juvenile idiopathic arthritis, atopic dermatitis, ankylosing spondylitis and multiple sclerosis;
Use according to claim 9.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010114076.2 | 2020-02-24 | ||
CN202010114076 | 2020-02-24 | ||
CN202010748673.0 | 2020-07-28 | ||
CN202010748673 | 2020-07-28 | ||
CN202010881875.2 | 2020-08-28 | ||
CN202010881875 | 2020-08-28 | ||
PCT/CN2021/077232 WO2021169913A1 (en) | 2020-02-24 | 2021-02-22 | Pde4 inhibitor compound and medical use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023531113A true JP2023531113A (en) | 2023-07-21 |
Family
ID=77490688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022551055A Pending JP2023531113A (en) | 2020-02-24 | 2021-02-22 | PDE4 INHIBITOR COMPOUNDS AND MEDICINE USES THEREOF |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230141101A1 (en) |
EP (1) | EP4101848A4 (en) |
JP (1) | JP2023531113A (en) |
KR (1) | KR20220145853A (en) |
CN (1) | CN115397819A (en) |
WO (1) | WO2021169913A1 (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101514866B1 (en) * | 2009-05-14 | 2015-04-24 | 티안진 헤메이 바이오-텍 컴퍼니 리미티드 | Thiophene derivatives |
RU2743126C9 (en) * | 2016-08-22 | 2021-04-27 | Шицзячжуан Сагесити Нью Драг Дивелопмент Ко., Лтд. | Pde4 inhibitor |
ES2852098T3 (en) * | 2016-08-22 | 2021-09-13 | Medshine Discovery Inc | Cyclic compound that acts as a PDE4 inhibitor |
CA3052516C (en) * | 2017-02-28 | 2022-08-16 | Kangpu Biopharmaceuticals, Ltd. | An isoindoline derivative, a pharmaceutical composition and use thereof |
US10570147B2 (en) * | 2017-06-13 | 2020-02-25 | Biotheryx, Inc. | Bicyclic compounds and methods of use |
-
2021
- 2021-02-22 EP EP21759622.0A patent/EP4101848A4/en not_active Withdrawn
- 2021-02-22 JP JP2022551055A patent/JP2023531113A/en active Pending
- 2021-02-22 CN CN202180016637.8A patent/CN115397819A/en active Pending
- 2021-02-22 WO PCT/CN2021/077232 patent/WO2021169913A1/en unknown
- 2021-02-22 US US17/904,497 patent/US20230141101A1/en active Pending
- 2021-02-22 KR KR1020227032037A patent/KR20220145853A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN115397819A (en) | 2022-11-25 |
EP4101848A4 (en) | 2023-07-26 |
EP4101848A1 (en) | 2022-12-14 |
WO2021169913A1 (en) | 2021-09-02 |
US20230141101A1 (en) | 2023-05-11 |
KR20220145853A (en) | 2022-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2683566C1 (en) | Derivative with articulated rings and method for preparation thereof, intermediate compound, pharmaceutical composition and application thereof | |
US20230227464A1 (en) | Pyrazine derivative and application thereof in inhibiting shp2 | |
EP3131897B1 (en) | Factor ixa inhibitors | |
JP5123949B2 (en) | Non-nucleoside reverse transcriptase inhibitors | |
JP2022546520A (en) | RIP1 INHIBITOR COMPOUNDS AND METHODS FOR MAKING AND USING SAME | |
SK19542000A3 (en) | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives, process for producing thereof, pharmaceutical composition them containing, their use and intermediates | |
BR112020001299A2 (en) | heteroaryl piperazine derivatives, method of preparing them and their use in medicine | |
BR112015010102B1 (en) | HETEROCYCLIC COMPOUND SUBSTITUTED BY amide AND PHARMACEUTICAL COMPOSITION COMPRISING IT | |
EP3131896B1 (en) | Factor ixa inhibitors | |
BG66141B1 (en) | B-carboline derivatives useful as inhibitors of phosphodiesterase | |
BRPI0720525A2 (en) | MAPK / ERK KINASE INHIBITORS | |
AU2020378407B2 (en) | Heterocyclic RIP1 inhibitory compounds | |
BR112020018983A2 (en) | OXADIAZOLE TRANSITORY POTENTIAL RECEPTOR CHANNEL INHIBITORS | |
US20110015200A1 (en) | Nitrogen-containing bycyclic compounds active on chronic pain conditions | |
WO2015195880A1 (en) | Imidazo-pyridazne derivatives as casein kinase 1 delta/epsilon inhibitors | |
HU210764B (en) | Process for producing pyrazolo- and triazolotriazine derivatives and pharmaceutical compositions containing them | |
US7985754B2 (en) | Selective antagonists of A2A adenosine receptors | |
WO2018005192A9 (en) | Compounds and their use for reducing uric acid levels | |
JP2023531113A (en) | PDE4 INHIBITOR COMPOUNDS AND MEDICINE USES THEREOF | |
US5380714A (en) | 2-furyl-triazalo [1,5-a]-[1,3,5]triazines and pyrazolo [2,3-a][1,3,5]triazines | |
FI101072B (en) | Process for the Preparation of Therapeutically Useful 4-Amino-3-Oxidized iazolyl-imidazo £ 1,5-a | quinoxaline and 5-amino-3-oxadiazolyl-imidazo | |
US5246932A (en) | Heterocyclic compounds | |
KR20230096965A (en) | Arylamide compound, pharmaceutical composition containing the same, and preparation method and use thereof | |
SI9300674A (en) | 2-(2-furyl)-5-(2-(morpholino)etylamino) (1,2,4)triazolo(1,5-a) (1,3,5)triazine-7-amin for use as an adenosinic antagonist | |
CN111925313A (en) | Compound with PDE4 inhibitory activity, preparation method, composition and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221031 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230707 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240222 |